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CHAPTER 1
Introduction and Outline of the Thesis
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Introduction and outline of the thesis
CANCER  is a very important public health problem. Bladder cancer is one 
of the most common malignancies occurring worldwide. For example, 
approximately 50,000 new patients are diagnosed with bladder cancer each 
year, resulting in about 11,000 deaths annually in the United States (U.S.) 
only [1]. In general there is a marked male preponderance of bladder cancer; 
not only in transitional cell carcinoma (TCC), but also in squamous cell 
carcinomas and adenocarcinomas [2]. Bladder cancer is two to five times 
more frequent in males than females, a difference that is not entirely 
explained by differences in cigarette smoking or occupational exposure [3]. 
Ninety-eight percent of all the bladder cancers are epithelial malignancies, 
with approximately 90% being TCC. TCC is generally divided into 
superficial and invasive disease, because the natural history and treatment of 
the two forms are different. Seventy percent of the TCC are superficial 
[carcinoma in-situ (CIS), Ta, T1] at initial presentation [4,5]. CIS comprises 
a neoplasm that undermines or replaces the normal urothelium and extends 
along the urothelial lining. Stage Ta tumors are lesions confined to the 
urothelial mucosa that extend papillary fronds surrounding a central 
fibrovascular stalk into the lumen of the bladder. Stage T1 tumors are also 
papillary lesions that are occasionally more nodular and that penetrate into 
the lamina propria [6]. Depending on the characteristics of the population 
included and the length of the follow-up, 60%-80% of superficial bladder
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cancers will recur with 2-50% showing stage progression [7]. Multivariate 
analyses have indicated that multiplicity, grade, prior recurrences and the 
findings at first cystoscopy 3 months after TUR are the most important 
variables commonly available to the clinician to identify patients at greatest 
risk for recurrence. Meanwhile, again grade, tumor size, T category and 
prior recurrences are predictive for the risk to develop muscle-invasive 
cancer [8]. The early diagnosis of superficial bladder cancer is still a 
dilemma. Exophytic tumors are reliably diagnosed but flat TCC, particularly 
carcinoma in-situ (CIS), remains an endoscopic problem. Therefore, voided 
urine cytology and bladder wash cytology are routinely performed to 
complement cystoscopy, but its sensitivity is poor, especially in low grade 
TCC [9,10]. Recently, tumor markers and computer assisted image analysis 
systems have been described for early diagnosis of bladder cancer. A 
subject as problematic as early diagnosis is treatment. The standard initial 
therapy for superficial bladder cancer is transurethral resection of all visible 
tumor, and many patients with high grade or recurrent tumors are 
subsequently given adjuvant intravesical immunotherapy or chemotherapy. 
There are basically three applications of intravesical therapy: adjuvant, 
prophylactic and therapeutic. Adjuvant therapy implies that the agent is used 
as a single treatment after apparently complete tumor resection in order to 
prevent tumor cell implantation and subsequent recurrence by that 
mechanism. Prophylactic use implies the repeated administration of drugs
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after the apparently complete resection of the tumor in order to prevent de 
novo recurrence. Finally, therapeutic use implies repeated drug 
administration in order to remove residual un-resected disease, either CIS or 
papillary tumor [11]. Because of the heterogeneous nature of superficial 
bladder cancer and the various therapeutic options available, it is advisable 
to individualize therapy for patients with superficial bladder cancer. 
Incidence and mortality rates of bladder cancer vary with age, race, lifestyle 
and gender [12]. However, variations in stage distribution and survival of 
bladder cancer in both sexes have not been well documented. There are 
some suggestions that the prognosis of females with bladder cancer is worse 
than that of males [13,14]. Hence, the question was raised whether females 
are being diagnosed in more advanced disease stages. The answer to this 
question is important as it might lead to significant changes in our 
diagnostic approaches in both sexes. In our first study concerning this 
subject, the stage distribution in different genders was studied at first 
presentation. The results of this study raised a second question; are females 
being diagnosed with bladder cancer at more advanced stages or is there 
even a prognostic difference between genders in case of diagnosis at the 
same stage of the disease? Therefore, we have undertaken a second study 
based on two large series of U.S. and the Netherlands cancer registries 
where the stages have been properly adjusted. In C hapter 2, besides giving 
the results of the two studies already mentioned, a review article that
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summarizes the general properties of the bladder cancer in women is 
discussed.
The need for the early diagnosis of the bladder cancer cannot be 
overemphasized and the delay in diagnosing the tumor is clearly associated 
with poor prognosis. Although cystoscopy and cytology are considered as 
the gold standards in this respect, they have a number of important 
disadvantages. For example; cystoscopy, even with flexible instruments, 
remains invasive and bothersome for the patient. On the other hand, even 
though urine cytology has been an integral part of bladder cancer screening 
since 1945 [15], it is undeniably inadequate as a gold standard. It is plagued 
with low sensitivity and remains a subjective diagnostic criterion for the 
majority of the lesions. This means that we presently do not have an ideal 
diagnostic method for bladder cancer. Given these shortcomings, we will 
have either to try to increase the diagnostic value of the existing tests or to 
develop new tests to replace them. With regard to the first, we have 
concentrated our efforts particularly on urine cytology as one of the most 
important diagnostic tests. Cytological interpretation of urine samples can 
be problematic, as low cellular yields, subtle atypia in low-grade 
malignancies, the presence of reactive atypia, degenerative changes, 
therapeutic alterations, and low inter- and intra-observer reproducibility may 
result in low sensitivity in urine cytology [16]. Moreover, negative findings 
on cytology do not rule out bladder cancer. A major part of the cytologies
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are being reported as either acellular or suspicious in terms of bladder 
tumors. This is because, in the majority of the cases, it is quite difficult to 
obtain cells appropriate for a proper cytological evaluation or in sufficient 
quantities. This, in turn, constitutes one of the most important causes of low 
sensitivity in the cytologies mentioned above. This is the reason why the 
present section of the thesis took up this problem, where we carried out 
study to obtain better cellular yields of urine for cytology. The ultimate goal 
of this investigation was to improve the sensitivity of urine cytology by 
using different urinary samples. In C hapter 3, the results of this study are 
described. In the second part of our research relating to cytology, on the 
other hand, we have concentrated on new tests and methods available to the 
urological community. Today, in an attempt to refine the early diagnosis of 
bladder cancer, in particular, superficial bladder cancer, and to improve 
disease monitoring, research efforts have been focused on developing tests 
to augment, and perhaps replace, the standard methods such as urine 
cytology and cystoscopy. Rapid staining techniques and quantitative 
measurement of tumor antigens have been developed in parallel with 
attempts towards decreasing the processing time, reducing the cystoscopy 
procedure frequency and eliminating cytological errors. Indeed, 
technological advances have provided significant improvements in 
diagnostic skills, but the search still continues for more sensitive and 
specific non-invasive bladder tumor markers to replace urine cytology. In
Introduction and outline of the thesis 15
order to see the stage that was reached in this process of technological 
development, first we reviewed several new techniques and markers that 
have been developed for the monitoring and diagnosis of superficial bladder 
cancer, and compared them with the results of cytology in C hapter 4. Then, 
we prospectively assessed the diagnostic value of the Bladder Tumor 
Antigen stat test (BTA stat test) and the Urinary Bladder Cancer test (UBC 
test) in C hapters 5 and 6, respectively. The main objectives of this research 
was to compare these new techniques with cytology in order to pinpoint 
their respective advantages and disadvantages, to find out whether they can 
replace cytology or be used in combination, and to see whether or not with 
their use the need for cystoscopy could be reduced.
Mortality rates from bladder cancer in the U.S. fell from 28% to 22% 
between 1980 and 1999 [23]. The improved survival rate is thought to be 
associated with the advent and increased use of intravesical immunotherapy 
and intravesical chemotherapy, cisplatinum based systemic chemotherapy 
in addition to general advances in diagnosis, surgery and medical 
management of malignancies. In this part of the thesis we have concentrated 
on intravesical immunotherapy and intravesical chemotherapy that are being 
extensively used in the clinic. The best-investigated form of intravesical 
immunotherapy for superficial bladder cancer is treatment with bacillus 
Calmette-Guérin (BCG) from Mycobacterium bovis. Presently, BCG 
immunotherapy is considered as the most effective treatment and
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prophylaxis for superficial bladder cancer in high-risk patients, but several 
aspects of the BCG treatment are still controversial [24,25], such as the 
effector mechanism, the optimal dosage, the appropriate strain and the best 
clinical schedules. Satisfactory answers to these questions will have to be 
found as soon as possible in order to render treatment more effective. 
Hence, we particularly focused on these aspects of intravesical BCG in 
superficial bladder cancer. Moreover, we aimed to give several informed 
guidelines on this treatment modality in this part of thesis.
An antitumor effect may be potentiated when two separately effective 
treatment modalities are combined because their mechanisms of action are 
different. One of these treatment modalities is intravesical chemo- 
immunotherapy for superficial bladder cancer. Hence, we carried out a 
study to compare sequential intravesical therapy with mitomycin C and 
BCG versus mytomicine C alone in a randomized trial. Our ultimate goal 
was to achieve a maximum antitumor effect with a minimum of side effects 
in this phase III study. In C hapter 7, an overview of the intravesical BCG 
immunotherapy and the results of our intravesical chemo-immunotherapy 
study are presented.
One other treatment modality of superficial bladder cancer is intravesical 
chemotherapy. Intravesical chemotherapy is indicated as a first choice for 
low and intermediate risk superficial bladder cancer patients and as an 
alternative treatment when BCG is not effective or when the side effects of
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BCG are intolerable [26]. The use of intravesical chemotherapy for 
superficial bladder cancer has become one of the important treatment 
modalities. The mechanism of action and the principles of intravesical 
chemotherapy are distinctly different from intravesical BCG 
immunotherapy. Despite this, as in BCG, the controversy, in this treatment 
modality, is still continuing, and the profession is facing many questions 
where there is no unanimity on the possible answers. Believing that all the 
alternative modalities of treatment will have to be considered together for an 
effective therapy, in C hapter 8, we have tried to evaluate the real place of 
intravesical chemotherapy in the treatment of superficial bladder tumors by 
comparatively identifying widely used drugs, the new drugs, additional 
measurements, improvements in the efficacy of intravesical therapy and 
sequential chemo/immunotherapy.
In C hapter 9, a summary and discussion of the present thesis are presented 
in English and in Dutch.
We can summarize the main aims of this thesis as follows:
1. To present new approaches to the diagnosis of bladder cancer by 
comparing bladder cancer prognosis in different genders,
2. To help increase the diagnostic value of cytology, as a gold standard, 
which in its present form leads to problems in diagnosis due low 
sensitivity,
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3. To assess whether the place of cytology in the diagnostic spectrum has 
changed or not and to evaluate the diagnostic capabilities of the two 
recently developed urinary tests
4. To define the optimal principles of treatment of superficial bladder 
cancer.
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I- GENDER DIFFERENCES IN STAGE 
DISTRIBUTION OF BLADDER CANCER 
Introduction
Bladder cancer is a heterogeneous disease with an unpredictable clinical 
course. The heterogeneity makes bladder tumors complex but interesting to 
investigate. Although reports about gender differences and stage 
distribution of bladder cancer are limited [1-3], a few reports on gender and 
survival in patients with bladder cancer are avaliable [4-7]. Although stage 
and survival are in some way related, this is not the subject of this study.
We investigated the gender differences in stage distribution of bladder 
cancer and upper urinary tract tumors (UUT). The aim of this study was to 
compare the stage distribution at the first presentation in male and female 
patients with bladder cancer and UUT tumors, using a nation-wide 
population-based Cancer Registry in the Netherlands.
Materials and Methods
The Netherlands Cancer Registry is a population-based cancer registry. All 
bladder malignancies including carcinoma in situ (CIS) and non-invasive 
bladder cancer, diagnosed from 1989 to 1994 in people living in The 
Netherlands were registered nation-wide. The cancer registry collects the 
data according to a minimum data set, which includes identification data
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(e.g. name, date of birth, gender, postal code) and tumor data (e.g. 
topography, morphology, stage, date of incidence). The minimum data set is 
based on the item list of the World Health Organization, the International 
Agency for Research on Cancer and International Association of Cancer 
Registries, which was drawn up to facilitate international exchange of 
cancer data. The topography and morphology were coded according to the 
International Classification of Diseases for Oncology. Tumors were 
classified as transitional cell carcinoma (TCC) (pure or mixed with another 
morphology), squamous cell carcinoma, adenocarcinoma and sarcoma. 
Recurrences are not registered in the cancer registry if they occur in the 
same site as the primary tumor. New primary tumors are only possible if 
they occur in another site (eg, pyelum after first primary in the bladder) or 
with another morphology (eg, pure squamous carcinoma after primary 
TCC). For the staging of tumors, the TNM classification was used [8]. The 
diagnosis of N+ was based on the histological evaluation of resected lymph 
nodes during radical cystectomy or computed tomography scans. Because 
the cancer registry adheres strictly to the TNM classification rules, many 
tumors are classified as Nx and Mx. Therefore, all Nx and Mx were 
considered to be N0 and M0. In cases which no differentiation between T3a 
and T3b was given, the tumor was classified as T3. For ureter and pyelum, 
the same TNM staging was used as for the bladder. All stage percentages 
and UUT involvement were calculated in both males and females for all
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types of bladder cancer. The differences in percentages were tested for 
statistical significance with the chi-square test; the statistical significance 
was assumed when the p value was less than 0.05.
Results
The study population consisted of 21,795 patients with bladder cancer who 
were reported to The Netherlands Cancer Registry between 1989 and 1994. 
O f these 21,795 tumors, 20,541 (94.3%) were TCC, of which 16,415 were 
in male patients (79.9%) and 4126 were in female patients (20.1%), giving a 
male/female ratio of 4:1. The 1254 non-TCC bladder tumors accounted for 
5.7% of which 800 were in male patients (63.8%) and 454 in female patients 
(36.2%). Male patients had more superficial TCC (pTa, pT1 and CIS) at 
first presentation than female patients (71.4% and 62.5% respectively). 
Because of the large numbers, this difference is highly significant 
(p<0.0001). The largest differences were seen between pT1 and pT4 TCC 
(24.9% and 2.8% respectively, for men versus 20.6% and 3.9% respectively, 
for women). The stage distribution of these patients is presented in Table I. 
In total, 1982 TCC of the UUT were registered, 1328 in men, 654 in 
women. Also, superficial TCCs of the UUT (pTa and pT1) were more 
frequent in men (48.7% versus 37.3%, p<0.0001, table I). The nonlocalized 
bladder tumors were slightly more frequent in women for both N+ (2.2% in 
men versus 2.7% in women, p=0.07) and M+ (2.0% in men versus 2.8%
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Table I: Stage distribution of bladder and UUT TCC by gender
BLADDER URETER AND PYELUM
STAGE MALE FEMALE MALE FEMALE
N % N % N % N %
PTa 6540 39.8 1587 38.5 358 27.0 121 18.5
CIS 1100 6.7 253 6.1 58 4.4 28 4.3
pT1 4087 24.9 852 20.6 288 21.7 123 18.8
pT2 1984 12.1 522 12.7 161 2.1 70 10.7
pT3 251 1.5 86 2.1 216 16.3 142 21.7
pT3a 554 3.4 180 4.4 1 0.1 - -
pT3b 347 2.1 121 2.9 1 0.1 1 0.2
pT4 455 2.8 159 3.9 31 2.3 27 4.1
N+ 359 2.2 110 2.7 56 4.2 61 9.3
M+ 331 2.0 117 2.8 69 5.2 43 6.6
Unknown 407 2.5 139 3.4 89 6.7 38 5.8
Total 16415 100 4126 100 1328 100 654 100
in women, p=0.001). In patients with UUT tumors, N+ tumors were twice as 
frequent in female patients (9.3%) than male patients (4.2%) (p<0.0001). A 
small difference in the same direction was also seen in M+ UUT tumors: 
5.2% in men and 6.6% in women (p=0.21).
Stage differences were more clear in the other types of bladder cancer 
(combined group of squamous cell carcinoma, adenocarcinoma and 
sarcoma, n=1254) (Figure I).
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Figure I: stage differences between males and females with non- 
TCC bladder cancer
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O f all tumors 26.4% were superficial in men (3.1% pTa, 7,3% pT1 and 
16.3% CIS) compared with 12.1% in women (0.9%, 5.3% and 5.9% 
respectively). Except for pT2 tumors (13.9% in male patients versus 13.4% 
in female patients), invasive non-TCC tumors were more frequently 
diagnosed in female patients: 21.7% pT3 and 11.0% pT4 tumors in women 
and 14.5% and 8.4% in men. Although more female patients with N+ 
tumors were found (7.3% in women versus 5.6% in men), fewer M+
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patients were seen (5.1% in women versus 6.3% in men).
Discussion
Trends in stage distribution between two sexes have been described using 
several statistical methods and different staging systems. The use of 
different staging systems makes it difficult to compare various population 
groups. Moreover, whether gender differences in bladder cancer exist 
remains controversial at the present time because of some contradictory 
reports [1-3].
In a retrospective Spanish study on TCC of the bladder between 1975 and 
1991, 440 superficial and 117 invasive bladder cancer patients were 
included [1]. The relative risk for muscle invasive tumors for men compared 
with women was 1.05 (95% CI=0.65-1.08). The investigators concluded that 
gender differences had no influence on the risk of developing muscle 
invasive bladder cancer.
On the other hand, other studies suggest that female patients fare worse. 
Kiemeney et al, for example, studied bladder cancer incidence in the 
southeastern part of the Netherlands between 1975 and 1989 [2]. On 
average, male patients were diagnosed with lower staged disease than 
female patients: 28% of male patients with invasive disease had stage III or 
IV tumors at diagnosis compared to 43% of female patients.
Fleshner et al presented the National Cancer Data Base Report on bladder
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carcinoma from the United States [3]. A total of 3.700.000 cases were 
documented between 1985 and 1993. Cases of unknown stage were 
excluded from the study. In this study also, women were slightly more 
likely to be diagnosed with advanced stage diseases (stage II, III, and IV) 
than men (33.1% and 27.7%, respectively). Regardless of the stage at 
diagnosis, survival rates for women were not as good as for the men. The 
investigators concluded that women tend to fare worse than men, regardless 
of stage, and that the reasons for these findings were unclear and deserved 
further investigation. However, this worse prognosis in female patients with 
bladder cancer has not been confirmed by other investigators [4-7]. In these 
studies, the survival rates of the men were worse or similar to those of 
women.
In the present study female patients were found to have a higher percentage 
of invasive TCCs of the bladder and UUT at first presentation than male 
patients. This outcome was highly statistically significant because of the 
large patient numbers. It appears that men with bladder cancer have a 32% 
higher chance to be diagnosed with superficial disease than women with 
bladder cancer (95% CI:22% to 42%). The stage differences for squamous 
cell carcinoma, adenocarcinoma and sarcoma of the bladder were even 
larger. A statistically significant (p<0.0001) worse stage distribution was 
observed in women with these types of bladder cancer.
An explanation for higher stages in female patients with bladder cancer at
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first presentation is difficult. Studies attempting to evaluate the causes for 
the observed gender differences have not been conclusive. Cultural and 
social differences between women and men in some non-western 
communities may result in delayed access to care for women. This, 
however, cannot be an explanation for The Netherlands, since all people 
have equal access to medical care. The initial symptom in more than 80% of 
men and more than 70% of women with bladder cancer is painless 
macroscopic hematuria [9,10], probably the main reason a patient seeks 
medical care. It is possible, however, that there may be some delay in the 
diagnosis of bladder cancer in patients with cystitis with or without 
hematuria as the presenting symptom [9]. Because cystitis is more common 
in women, this might explain a delayed care seeking behavior in women. 
Although TCC is 4 times more frequent in men than in women, the sex ratio 
in patients with squamous cell carcinomas is significantly lower, and in 10 
series of squamous cell carcinoma comprising 915 patients, the sex ratio 
was 1.4:1 [11]. It is unclear why squamous cell carcinoma is almost as 
common in females as in males, but it may be related to its association with 
inflammatory processes. Epidemiological studies have demonstrated an 
increased risk of bladder cancer in individuals with chronic urinary tract 
infection [11], and urinary tract infection enhances experimental bladder 
cancer carcinogenesis [12]. The correlation between chronic inflammation 
and squamous cell carcinoma may be an explanation for the differences in
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disease stage distribution between men and women in this particular tumor. 
Another hypothesis for gender difference in bladder cancer risk is that men 
and women metabolize carcinogens differently [13]. Laboratory studies 
suggest that some androgenic hormones stimulate or do not inhibit 
oncogenesis in bladder tissue and that estrogenic hormones have the 
opposite effect [14]. The oncogenesis in transitional cell tissue of the human 
bladder is influenced by sex hormones, and hormonal changes related to 
pregnancy [13,14]. These observations suggest that bladder cancer risk in 
women may be modified by sex hormones, which undergo profound 
changes during and after pregnancy. A modulating role in the risk of bladder 
cancer associated with exposure to aromatic amines is played by metabolic 
polymorphism’s [15]. The observation of gender differences in bladder 
cancer, along with possible risk factors, suggests the consideration of 
gender-related biological determinants for future investigation.
Female patients had a higher percentage of N+ tumors than did male 
patients for all types of bladder cancer and UUT tumors. Another distinct 
gender difference in patients with TCC is urethral involvement [16]. 
Maralani et al., in a small study, showed that tumor was found in the 
lymphatic channels and vasculature of periurethral tissue and submucosa of 
the urethra without mucosal involvement in the most female patients with 
TCC [16]. This occurred despite a palpable normal urethra at the time of 
cystectomy. They explained this gender difference by the replacement of
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periurethral tissue by the prostate in men. They pointed out that the prostate 
capsule and intimate involvement of the prostatic urethra by glandular 
prostatic tissue may block the angiolymphatic extension of the tumor that is 
seen in women. This may be another explanation of higher stages found in 
women and the presence of more N+ tumors, although further studies are 
necessary to make definite conclusions.
Other factors to explain different risks for bladder cancer or a different stage 
distribution remain questionable. Ethnicity, for example, failed to account 
for the male/female difference in bladder cancer incidence [17,18]. p53 
tumor suppresser gene polymorphism, or pre-existing genotypic differences 
in the susceptibility for bladder cancer that results in different bladder 
cancer biology in women remains to be confirmed [3,19].
Conclusions
Stage distribution differences were observed between men and women with 
bladder cancer and TCC of the UUT in this large series. These differences 
were more significantly evident in non-TCC bladder tumors. Despite the 
explanations mentioned, bladder cancer still remains a challenge for further 
studies. However, female patients should be investigated carefully, and 
physicians should be aware of the possibility of higher stages of bladder 
cancer in women in whom bladder cancer is diagnosed.
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II- GENDER DIFFERENCES IN STAGE-ADJUSTED 
BLADDER CANCER SURVIVAL 
Introduction
Women in the United States and Europe have a considerable longer life 
expectancy at birth than men. The same appears to be true after a diagnosis 
of cancer. In a study by the EUROCARE Working Group [1], relative 
survival was studied among 1,188,469 adult patients derived from 
population-based cancer registries in 17 European countries between 1985 
and 1989. Overall, a survival advantage appeared to exist for women, 
significantly so for cancer of the head and neck, oesophagus, stomach, liver 
and pancreas. This led the investigators to suggest that women may be 
intrinsically more robust than men in coping with cancer. However, for 
bladder cancer, only women were found to have a significantly worse 
survival rate after adjustment for age and expected mortality: the 5-year 
relative survival rate was 60% in females versus 65% in men. The same 
finding was reported earlier in large studies from the Netherlands, Italy, 
Finland, and the US, [2-5] but not in smaller studies from Canada, 
Switzerland, and Estonia [6-8]. It has been suggested that the survival 
disadvantage for women with bladder cancer can be explained by a worse 
stage distribution at diagnosis [9].
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Our objective with this study was to evaluate possible gender differences in 
bladder cancer prognosis after adjustment for disease stage at presentation.
Materials and Methods
Data on survival of patients with bladder cancer diagnosed in the U.S. were 
obtained from the public-domain computer package Surveillance, 
Epidemiology, and End Results (SEER)* Stat 2.0 (National Cancer 
Institute, 1999; see http://www-seer.ims.nci.nih.gov/). This package 
contains data on cancer incidence and survival of nine population-based 
cancer registries belonging to the SEER program. The SEER Program of the 
NCI collects and publishes cancer incidence and survival data from 
population-based cancer registries covering approximately 10 percent of the 
U.S. population. The selected database was the August 1998 submission 
with data on 2,325,346 patients diagnosed between 1973 and 1996. For this 
study, we selected patients with urinary bladder cancer who were actively 
followed, had a tumor with malignant behavior (no pTa or pTis), had no 
second primary cancer, and were not registered by death certificate or 
autopsy only (n=94,771). Furthermore, patients with an unknown race, age, 
or sex were excluded.
Similar data on patients with bladder cancer diagnosed between 1987 and 
1994 and registered by two population-based registries in the Netherlands 
were obtained through the Comprehensive Cancer Centers in the cities of
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Amsterdam and Eindhoven. The Comprehensive Cancer Center in 
Amsterdam has registered patients with cancer in the north-western part of 
the Netherlands since 1987. Information on vital status was available for 
patients diagnosed between 1988 and 1994 and living in the metropolitan 
area of Amsterdam. The Comprehensive Cancer Center in Eindhoven has 
registered patients in the south-eastern part of the Netherlands since 1970. 
Vital status information is routinely collected for all of these patients. For 
this study, data were available for all patients in the catchment area of the 
Comprehensive Cancer Center in Eindhoven who were diagnosed between 
1987 and 1992. From both centers combined, 1,722 patients with bladder 
cancer were available for analyses (pTis and pTa excluded).
In both the U.S. and the Netherlands data bases, no information is provided 
on the cause of death. Instead, observed survival can be adjusted for the 
expected probability of survival. For the U.S., the expected probability of 
survival was generated from age, race, and gender-specific population 
statistics from 1970, 1980, and 1990 from the U.S. Bureau of the Census. 
These data are also available in the SEER*Stat 2.0 package. In the 
Netherlands, expected survival rates were calculated using all-cause age, 
gender, and calendar-year specific mortality tables from Statistics 
Netherlands. Subsequently, the relative survival was calculated as the ratio 
between the crude and expected survival [10]. For the Netherlands data, 
relative survival rates with standard errors were calculated with a computer
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program from the Finnish Cancer Registry [11]. The analysis of the U.S. 
data was performed with the SEER*Stat 2.0 computer package, which uses 
the same algorithm from the Finnish Cancer Registry. The survival analyses 
on the data from the Netherlands were stratified by disease stage according 
to the TNM staging system [12] (3 rd revised edition for diagnosis from 
1987 to 1988, 4th edition from1989 to1992, and 4th revised edition 
from1993 to 1994). The analyses of the SEER data were stratified by 
disease stage according to the 4th edition of the American Joint Committee 
on Cancer (AJCC) stage grouping [13].
Results
In the U.S. data, 59,625 men and 20,680 women with bladder cancer had 
complete information for the calculation of relative survival rates. Men had 
a significantly better 5-year relative survival rate than women: 79.5% (95% 
CI: 79.0 -  80.0%) and 73.1% (95% CI: 72.2 -  74.0%), respectively. In each 
AJCC stage category, the prognosis was found to be better for men than for 
women (Table I). After stratification by race and calendar period of 
diagnosis (data not shown), the differences in relative survival between men 
and women remained. A large number of patients with bladder cancer had 
an “unknown” (8,496 men and 3,030 women) or “blank” (34,973 men and 
12,114 women) disease stage. Again, in these groups’ men, had a 10% and 
6% better 5-year relative survival, respectively, compared with women.
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Gender differences were less striking in the Netherlands (Table II). The 
overall 5-year relative survival rate of men was found to be 58.3% (95% CI:
54.5 -  62.1%). Survival rate in women was 47.5% (95% CI: 40.8 -  54.2%). 
Women seemed to have a similar prognosis as men in disease Stage III and 
even a (non-significant) better prognosis in Stage I. In Stages II and IV, 
women fared worse than men. Because of the much smaller numbers in 
comparison with the U.S. data, the differences in prognosis in the 
Netherlands were not statistically significant.
Discussion
Female bladder cancer patients are known to present with somewhat more 
advanced disease than male patients [2,5,9]. This difference in stage 
distribution has been considered the most important reason for the worse 
survival among women with bladder cancer [1,2]. In this study, we found 
that the relatively poor survival for females remained after stratification by 
stage. According to the SEER data, women with bladder cancer appear to 
have a 3% (Stage I) to 12% (Stage IV) 5-year survival disadvantage. The 
survival difference among patients with Stage I was small. In the 
Netherlands, women with Stage I disease even seemed to have a survival 
advantage of 5% although the confidence interval of this estimate was wide. 
Stage-adjusted gender differences in survival from bladder cancer have been 
previously published. In the largest study until now, Fleshner et al. [5]
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reported on The National Cancer Data Base (NCDB), in which data are 
combined from more than 2,000 hospital cancer registries across the U.S. 
Five-year follow-up information was available for 18,525 males and 6,672 
female patients with bladder cancer. Female patients were slightly more 
likely to be diagnosed with advanced stage disease (pT2-pT4) than male 
patients: 33.1% and 27.7%, respectively. After stratification by stage, 
women still fared worse than men: the 5-year relative survival rate for men 
and women was 94.7 versus. 90.7% for AJCC stage 0, 87.8 versus 84.7% 
for Stage I, 68.3 versus 59.3% for Stage II, 48.0 versus 47.7% for Stage III, 
and 26.8 versus. 15.4% for Stage IV, respectively. These figures resemble 
our findings very closely. However, this is not surprising considering that 
both the NCDB and SEER achieve considerable coverage of the U.S. cancer 
incidence (approximately 40% and 10%, respectively) and may therefore 
even overlap to some extent.
A survival disadvantage for women with bladder cancer was also reported in 
a large European study of 17 population-based cancer registries [1]. 
Unfortunately, that study did not stratify the results by disease stage, 
although it was suggested that the longer survival for men with bladder 
cancer could be explained by a higher frequency of non-invasive cancer in 
men than in women. One of the participating countries to this study 
(Finland), however, recently presented stage and gender-specific survival 
among patients diagnosed between 1985 and 1994 [4,14]. However, because
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stage was only crudely stratified (localized, regional, or distant metastasis), 
residual confounding by stage cannot be ruled out. The 5-year relative 
survival rate for men with bladder cancer was calculated to be 72%; the rate 
for women was only 63%. After stratification by stage, the difference only 
remained among patients with localized disease; the 5-year rate among men 
(n=3,423) was 83% versus 76% among women (n=1,015). The estimate for 
men and women with regional metastases was 24% (n=71) and 28% (n=22), 
respectively, and for men and women with distant metastases it was 9% 
(n=337) and 6% (n=157), respectively.
A higher risk of death for women with bladder cancer, after adjustment for 
disease stage at presentation, is difficult to explain. Although patient delay 
may be the most important factor in explaining the relatively worse disease 
stage distribution at presentation among women, it is not likely that patient 
delay exists in the diagnosis of disease progression. Gender differences in 
genetic or hormonal defence mechanisms against disease progression are 
also unlikely considering the apparent survival advantage for women with 
other types of cancer. However, anatomic differences exist between men 
and women, which may cause differences in the risk of disease progression 
within each stage category. Men void with a higher intravesical pressure 
because of the presence of the prostate gland and along urethra. Therefore, a 
somewhat thicker detrusor muscle is expected in men. Indeed, in an animal 
study, bladders from female rats weighed significantly less than bladders
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from male rats [15]. The thicker detrusor muscle in men may also have an 
effect on blood perfusion [16], and subsequently on the possibility of 
metastases. Moreover, anatomic studies in humans showed that at the 
female bladder neck, the middle circular muscle layer does not appear to be 
as robust as that of the male, which may have an influence on lymphatic 
drainage patterns of this portion of the bladder [17]. It has also been 
suggested that the prostatic capsule and the intimate involvement of the 
prostatic urethra by glanduler prostatic tissue may block the angiolymphatic 
extension of a tumor [18].
On the other hand, one may wonder whether gender differences in stage- 
adjusted survival are artefactual. The relative survival rate is the ratio of the 
observed (crude) survival to the expected survival. The expected survival 
rate is calculated using age, gender, race, and calendar-year specific 
mortality rates for the total population. It is assumed that the presence of 
cancer is the only factor that distinguishes the cancer patient cohort from the 
general population, so that the relative survival is assumed to reflect bladder 
cancer survival adjusted for other mortality. However, in the case of bladder 
cancer, smoking is an important risk factor. Therefore, bladder cancer 
patients will consist of a higher proportion of smokers than the general 
population. Smoking is, however, also related to the risk of dying of causes 
other than bladder cancer. The expected survival rate for patients with 
bladder cancer based on the general population will thus be too optimistic.
Gender differences 42
Consequently, the relative rates will be lower than they should be [19]. 
However, because the etiologic fraction of smoking for bladder cancer is 
probably higher for men than for women [20], this theoretical bias works in 
favor of women when analyzing gender differences in survival. Another 
point of concern is the possibility of residual confounding by stage. A lower 
level of suspicion for bladder cancer in women in the case of hematuria may 
lead to subtle stage differences within each stage category.
Although it is not the focus of this study, there seems to be an enormous 
difference between survival from bladder cancer among patients from the 
USA and the Netherlands (Table I and Table II). Other European countries 
appear to exhibit fairly similar relative survival rates as the Netherlands 
[3,4]. Compared with patients in Europe, patients in the U.S. seem to have a 
better survival from several cancer sites [3,4,19,21,22]. It is hard to imagine 
that these differences are real. In theory, a better relative survival in the U.S. 
may be caused by a lower life-expectancy for people living in the U.S., 
which would lead to a smaller difference between observed survival and 
expected survival and, consequently, to a higher relative survival.
Another possibility is that follow-up of vital status among patients with 
cancer in the U.S. is not complete. However, life expectancy for U.S. whites 
is only 1 year less than that for western Europeans and the NCI reports that 
follow-up of the SEER cancer registries is complete in more than 97% [19].
Table I: Relative survival of => pT1 bladder cancer in the U.S. according to stage and gender
Stage Gender N 0 1 2
Years after diagnosis 
3 4 5
CR 2*se CR 2*se CR 2*se CR 2*se CR 2*se
1 Male
Female
12,418
3,926
100%
100%
99.4%
99.0%
0.4%
0.7%
99.1%
97.8%
0.6%
1.0%
98.3%
96.0%
0.8%
1.4%
97.8%
95.2%
1.0%
1.7%
96.5%
93.7%
1.2%
2.1%
2 Males
Female
995
402
100%
100%
87.9%
80.5%
2.5%
4.5%
78.2%
72.4%
3.4%
5.5%
73.2%
66.3%
3.9%
6.3%
70.9%
61.9%
4.3%
6.9%
65.5%
59.6%
5.0%
7.6%
3 Males
Female
883
356
100%
100%
83.9%
76.5%
3.0%
4.9%
68.7%
61.5%
4.0%
6.0%
61.5%
54.4%
4.4%
6.5%
59.1%
53.4%
4.8%
6.9%
58.8%
49.6%
5.3%
7.5%
4 Males
Female
1,905
852
100%
100%
56.1%
40.1%
2.5%
3.5%
38.4%
23.6%
2.6%
3.2%
32.9%
18.1%
2.6%
3.1%
29.1%
16.9%
2.7%
3.1%
27.1%
15.2%
2.9%
3.2%
Total Males
Female
59,625
20,680
100%
100%
91.0%
84.7%
0.3%
0.6%
86.1%
78.8%
0.4%
0,7%
83.3%
76.1%
0.4%
0.8%
81.2%
74.3%
0.5%
0.8%
79.5%
73.1%
0.5%
0.9%
Source: SEER*Stat 2.0 (NCI, 1999)
CR = relative survival se = standard error
Table II: Relative survival of => pT1 bladder cancer in the Netherlands according to stage and gender
Stage Gender N 0 1 2
Years after diagnosis 
3 4 5
CR 2*se CR 2*se CR 2*se CR 2*se CR 2*se
1 Male
Female
646
122
100%
100%
96.5%
95.8%
2.2%
4.9%
94.6%
94.0%
3.1%
6.5%
91.0%
93.9%
3.9%
7.6%
87.0%
90.0%
4.6%
9.3%
80.8%
85.7%
5.4%
11.0%
2 Males
Female
300
76
100%
100%
76.2%
76.3%
5.5%
10.8%
59.5%
56.3%
6.5%
12.9%
54.5%
44.1%
6.9%
13.5%
51.3%
42.8%
7.4%
14.1%
48.7%
38.5%
7.9%
14.7%
3 Males
Female
172
68
100%
100%
66.1%
51.6%
7.8%
12.7%
43.8%
45.4%
8.4%
13.1%
36.5%
39.5%
8.6%
13.6%
34.4%
36.3%
8.9%
14.2%
35.6%
35.0%
9.5%
14.9%
4 Males
Female
165
80
100%
100%
42.3%
28.3%
8.1%
10.4%
24.4%
14.1%
7.2%
8.3%
16.4%
10.3%
6.5%
7.4%
11.0%
9.2%
5.8%
7.2%
11.7%
9.6%
6.2%
7.5%
Total Males
Female
1350
377
100%
100%
80.1%
64.9%
2.4%
5.2%
70.0%
55.9%
2.9%
5.7%
65.2%
51.6%
3.2%
6.0%
61.5%
49.6%
3.5%
6.3%
58.3%
47.5%
3.8%
6.7%
Source: Amsterdam Cancer Registry 1988-1994 and Eindhoven Cancer Registry 1987-1992 
CR = relative survival se = standard error
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Whatever the reason for these differences, it is unlikely that it has biased the 
stage-adjusted gender comparison in our study.
Conclusions
It is unlikely that the worse prognosis for female patients with bladder 
cancer can be entirely explained by the more frequent diagnoses of higher 
stages at first presentation among women. It is not clear which additional 
factor causes a worse prognosis for women.
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III. BLADDER CANCER IN WOMEN 
Introduction
The incidence of bladder cancer in women is three to four times lower than 
in men. In this paper several differences between male and female bladder 
cancer will be highlighted with respect to risk factors, prognosis, and 
treatment.
Symptoms and Diagnosis
Hematuria is the first symptom in men in 80% of cases. In women, 70% of 
patients present with hematuria [1,2]. Often voiding complaints similar to 
those found with cystitis occur. Moreover, in women with cystitis-like 
symptoms, bladder cancer is more often found (see below). Irritative 
symptoms should therefore always be analyzed by urinary sediment and 
cytology. When a urinary tract infection is present this should be treated 
prior to further evaluation. Urethrocystoscopy should be considered in 
women with frequent cystitis or persistant erythrocyturia or leucocyturia 
after adequate treatment of cystitis.
Urine cytology showed lower sensitivity for cancer in women than in men. 
This may be caused by the frequent presence of other cell types (squamous 
cells, leucocytes) in the urine of women [3]. Quantitative cytology may 
improve reproducibility of urine cytology [4]. We developed a karyometric 
system for bladder wash cytology (Quanticyt) [5] and since 1990 we
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sampled 9172 bladder washings in 3187 patients. Earlier studies showed the 
use of karyometry using image analysis for grade bladder washing samples 
based on nuclear DNA content and nuclear shape for the prediction of tumor 
[4-7]. Our study population included 2596 men and 591 women (ratio 
4.39:1). Based on nuclear DNA content and nuclear shape the samples were 
scored as low, intermediate, or high risk for bladder cancer. Interestingly, 
high risk samples were found in 19.4% of male and only 10.4% of female 
patients (p<0.05). A high risk score is based on the presence of polyploid or 
aneuploid cells. Although aneuploidy seemed more frequent in men, when 
follow up data were compared, gender was not predictive of either 
recurrence or progression [5].
New tests for the detection of malignant cells in urine are the NMP22 
(nuclear matrix protein, ELISA test) [6,8] and BARD BTA, STAT (latex 
agglutination dipstick), and TRAK tests (ELISA) [7,9,10]. All proved 
superior to routine cytology for the detection of low grade papillary lesions. 
However, for high-grade lesions, and in particular for carcinoma in situ, 
routine cytology shows significantly higher sensitivity [6,7]. Urinary tract 
infections resulted in false positive test results, so that in women with 
urinary tract infections these tests will be less useful for discrimination 
between infection and cancer. No data are currently available suggesting 
different sensitivity for the tests between male and female patients.
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The ‘gold standard’ in the diagnosis of bladder cancer is cystoscopy. Both 
rigid and flexible cystoscopy can be performed with minimal discomfort, in 
particular in the female patient. No currently available test can replace 
cystoscopy for the initial diagnosis of bladder cancer.
Incidence
In the Netherlands between 1989 and 1994, 21,795 primary bladder cancers 
were diagnosed: 20,541 (94.25%) were transitional cell cancers (TCC), of 
which 16,415 were in male patients (80%) and 4,126 were in female 
patients (20%), a male: female ratio of 4:1. The non-TCC accounted for 
5.75% of all tumors: 800 were found in male patients (64%) and 454 in 
female patients (36%) (ratio 1.8:1). Similar gender-related incidence figures 
for TCC and non-TCC were found in most western countries [11]. In 
general the incidence of bladder cancer is two to five times higher in men 
than in women [12].
Risk factors
F ood and Environment: Even when correcting for risk factors such as 
cigarette smoking, occupational hazards, and urinary tract infection, the 
male and female ratio was estimated to be 2.7 [12]. Several factors are 
correlated with the incidence of bladder cancer, such as the consumption of 
coffee and alcohol [13]. Interestingly, the odds ratio for coffee drinking was 
found to be twice as high for women (5.2) as for men (2.6) [14,15]. As for
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men, a dose-dependent relationship between cigarette smoking and bladder 
cancer was found in women [16]. Cultural changes in smoking habits 
among women will influence bladder cancer incidence [17,18], as do 
environmental factors. In a study on the influence of living environments it 
was shown that farm residents showed a relative risk of 0.33 compared to 
the general population [19]. Dry-cleaning workers were found to have an 
increased bladder cancer mortality ratio of 2.54 [20]. Overall, the 
occupational risk factors for bladder cancer seemed similar for both men 
and women [11,12]. It was estimated that cancers attributed to occupational 
exposure in the United States are 11% in female compared to 21% in male 
patients [21]. The increasing number of working women will be likely to 
change this ratio in the future.
O f interest is also the difference between men and women with regard to 
second primary tumors. Salminen et al.[22] found an increased risk of lung 
(adeno and squamous cell carcinoma) and non-TCC kidney cancers in 
10,014 bladder cancer patients in Finland. The incidence ratio for second 
primary lung cancer as 1.3 in men and 2.6 in women compared to the 
general population. For non-TCC kidney cancer in women this ratio was 
3.6. Other studies reported an increased risk of colon carcinoma in patients 
with bladder cancer compared to the general population or patients suffering 
from melanomas [23]. Environmental factors probably play an important 
role in this increased cancer risk among bladder cancer patients. Differences
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between men and women do, however, suggest other etiological aspects, 
that remain to be explored.
Occupational and smoking habits may only partly explain the difference in 
incidence of bladder cancer between men and women. Hormonal influence 
was suggested by some, considering the lower incidence of bladder cancer 
in parous compared to nulliparous women [24]. Moreover, mucosal changes 
during the menstrual cycle have been reported [25], suggesting an influence 
on cell proliferation and differentiation.
Iatrogenic factors: As with men, there are several iatrogenic causes of 
bladder cancer in women. Special attention should be paid to patients 
receiving cyclophosphamide, e.g., for rheumatoid arthritis. Bladder cancer 
occurred in 9 out of 119 rheumatoid arthritis patients receiving 
cyclophosphamide, whereas none of the control patients not treated with 
cyclophosphamide developed cancer [26]. In 3 out of the 9 the bladder 
cancer developed more than 14 years after discontinuation of the 
medication. Intermittent (self) catheterisation potentiates the carcinogenic 
effects of cyclophosphamide [27].
Pelvic radiotherapy also carries a risk for bladder cancer development [28]. 
Most tumors after radiotherapy are of high grade and often invade through 
the bladder wall [29]. The interval between irradiation and tumor 
presentation was found to be dependent on the dose of radiotherapy: high 
doses were correlated with shorter intervals [29]. Intervals ranging from
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16.5 to 30 years were reported. The overall risk of bladder cancer after 
radiation for cervical cancer was twofold compared to the general 
population [28].
Bladder Cancer and Urinary tract infections: The similarity in symptoms 
for bladder cancer and cystitis often delays the correct diagnosis of cancer in 
women [1,30]. An increased risk for bladder cancer was found in patients 
with nephrolithiasis [31,32]. Other studies found an increase of urinary tract 
infections in patients with bladder cancer [33,34]. Particularly in 
combination with smoking, bladder cancer was 10 times more frequent in 
patients with urinary tract infections than the general population [34]. 
Urinary tract infections seem to be particularly correlated with squamous 
cell carcinoma [35].
Death from bladder cancer was found to be 12 times more common in 
paraplegic women [33]. Moreover, squamous cell carcinomas were found in 
the majority of 25-44 year-old paraplegic women with bladder cancer. The 
higher frequency of urinary tract infections in these women may partly 
account for the increased risk on squamous cell carcinoma [33,35]. Whether 
intermittent or continuous catheterization plays a role in this increased risk 
remains to be established.
Human papilloma virus infections have been reported to be correlated to 
cervical cancers. In bladder cancer different infection rates were found, 
varying from 3% [36,37] to 33% [38] by either in situ hybridization or
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polymerase chain reaction methods. In the majority of studies HPV subtypes 
16 and 18 were found. HPV 16/18 infection was found to be correlated with 
more aggressive bladder cancer [38]. Although low infection rates found in 
most studies suggested no correlation between HPV infection and bladder 
cancer [36,37,39,40], bladder cancer was more frequently found in women 
earlier treated for cervical cancer [41,42]. No data are available on HPV 
infection in women with both cervical and bladder cancer, the important 
role of HPV infections in cervical cancer may play a role in bladder cancer 
in these patients as well. Whether factors other then HPV infection such as 
smoking are responsible for this relationship remains to be established. As 
HPV infection was more frequently found in advanced stage and grade it is 
unlikely that the infection plays a role in initial tumor development [37]. 
Surprisingly, Tenti et al. [38] found higher HPV infection rates in low 
grade, papillary lesions. Data on HPV infection and bladder cancer are 
therefore conflicting. Patient population and detection methods probably a 
count partly for the differences between studies. The high incidence of this 
infection in the general population, however, warrant further analysis. 
Schistosomiasis infections are correlated with bladder cancer. Both 
transitional cell and squamous cell carcinomas may develop in the bladder 
after Schistosomiasis infection [43]. In endemic areas such as Egypt and 
eastern-Africa the majority of bladder cancer cases are Schistomiasis 
related. N-Nitroso compounds and other carcinogenes secreted in the
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bladder during infection are putatively responsible for tumor development 
[44]. In women the infection can extend to the internal genital organs 
(Female Genital Schistosomiasis, FGS), most commonly due to 
Schistosoma haematobium [45]. Probably as a result of changes in exposure 
to infection, the male to female ratio, which was 7.8:1 between 1962 and 
1967, changed to 4.9:1 in the period 1987-1992 in Egypt [43].
The higher frequency of urinary tract infections in women may account for 
the 1.4:1, male:female ratio of squamous cell carcinoma incidence, as 
opposed to the almost 4:1 ratio of urothelial cell carcinoma [46].
Tum or Stage
Recent data from the Netherlands Cancer Registry from 1989 to 1994 
showed higher tumor stages at initial diagnosis for both transitional cell 
(TCC) and non-transitional cell cancers (non-TCC) of the bladder in women 
than in men. Male patients had slightly more frequent superficial TCC (pTa, 
pT1 and CIS) than females: 71.4% and 62.5% respectively (p<0.0001). In 
particular pT4 TCC tumors were more frequent in women (3.9% versus 
2.8%). As for TCC, invasive non-TCC was more frequent in female than in 
male patients. Except for pT2 tumors, the stage difference was also seen for 
invasive non-TCC: 14.5% and 8.4% pT3 and pT4 were found in men, and 
21.7% and 11.0% were observed in women, respectively. Other studies 
confirmed the worse prognosis of bladder cancer in women: the percentage 
of invasive tumors was 27-28% in men and 33-43% in women [47,48].
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Prognosis
The higher incidence of invasive tumors in women is accompanied by a 
shorter 5-year disease specific survival in women (47%) than in men (69%) 
[47,49]. The more aggressive behavior of bladder cancer in women also 
seems reflected by the fact that the incidence of invasive tumors after an 
initial superficial lesion (tumor progression) is higher for women than for 
men [50]. No difference in tumor recurrence between men and women was 
found for superficial cancer [51].
Superficial explanations for the seemingly more aggressive behavior of 
bladder cancer in women have been postulated. The more frequent 
incidence of urinary tract infections in women may reduce suspicion on 
bladder cancer in cases of hematuria or voiding problems, resulting in a 
delay in detection [1,30].
Cell proliferation is an important aspect of tumor development. The p53 
gene product functions as a cell-cycle regulator [52]. Mutations in the p53 
gene have been reported to result in uncontrolled cell proliferation. 
Mutations result in accumulation of the non-functional gene product. 
Immunohistochemical staining studies showed increased recurrence and 
progression rates in tumors with increased p53 staining [53]. No difference 
in p53 mutations between men and women have been reported, suggesting 
that differences in progression are not caused by different mutation rates.
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The E6 oncoprotein from the HPV binds p53 resulting in increased protein 
degradation. Recently, a polymorphism in exon 4 of the p53 gene was 
correlated with an increase in tumorigenesis caused by HPV induced 
cervical cancers [54]. In prostate cancer both HPV infection and p53 
mutations seem to play a limited role in different phases of tumor 
development [55]. Similar findings were reported for bladder cancer: low 
grade and low stage lesions were more frequently HPV infected, whereas 
p53 mutations were more often found in high-grade lesions [38]. As was 
discussed above, however, data between studies vary with respect to the 
incidence of HPV infection and tumor stage. Further studies are necessary 
to elucidate the role of these prognostic parameters in women. The high 
incidence of HPV 16 and 18 infections in cervical cancer urge for careful 
analysis of HPV in different stages of bladder cancer and the role of p53 
mutations and polymorphism.
No data on prognostic markers such DNA ploidy and Ki-67 show gender 
differences accounting for the worse prognosis reported in women.
In conclusion, women seem to be diagnosed at a later stage of disease. With 
current prognostic markers no explanation can be found for the decreased 
survival for women.
T reatm ent
Superficial cancers are managed by transurethral resection. Additional 
intravesical instillations with either mitomycin-C and bacillus Calmette
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Guerin (BCG) are optional in multiple, recurrent, or high grade lesions [56]. 
Although recurrence rate may be reduced by intravesical instillation 
therapy, the chance on tumor progression from superficial to invasive cancer 
remains unchanged [56]. Overall 50-60% of superficial tumors recur after 
initial treatment, and 10-15% progress to invasive disease [2,57].
For invasive tumors radical surgery remains the cornerstone of treatment. 
Cystectomy is performed after pelvic lymph node resection; hysterectomy 
may be performed simultaneously. In case of an incontinent diversion 
(Bricker ileal stoma) or catheterisable pouches (Indiana, Kock etc.), 
urethrectomy and resection of the anterior wall of the vagina is commonly 
performed.
Orthotopic bladder replacement, initially used mainly in male patients, 
proved useful in a selected group of female bladder cancer patients [58,59]. 
Orthotopic methods use small bowel [60,61] or large bowel/coecum to 
construct a pouched connected to the urethra that remains in place and 
allows for voiding, in general without the need for self-catheterisation. 
Because the urethra is left in place, there is a risk of tumor recurrence. 
Urethral recurrence after cystectomy in women with invasive bladder cancer 
is seen in 2-13% of cases, particularly where there is bladder neck and 
trigonal involvement [59,62,63]. Vaginal involvement is found in 3% of 
women with invasive bladder cancer [64]. In cases of tumor on the bladder 
neck, urethrectomy is advocated [62] and these patients are no candidates
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for orthotopic bladder replacement [64]. With carcinoma in situ the 
incidence of urethral localisation was found to be as high as 29%, 
suggesting that in these patients urethral recurrence is more likely [65] and 
urethrectomy should be considered.
Up to 90% daytime continence and spontaneous residual-free micturition is 
reported after orthotopic bladder replacement in women [58]. Retention, the 
main complication can be avoided by resection of the bladder neck and 
proximal urethra [58].
In conclusion, the trend toward orthotopic bladder replacement instead of 
continent urinary stomata for the treatment of invasive bladder cancer in 
men will also be seen in women.
Conclusions
Bladder cancer in women shows some aspects different from the disease in 
men. TCC is 4 times more common in men than in women. In squamous 
cell carcinoma the male: female ratio is 1.4:1. Urinary tract infections are 
related to bladder cancer in women and urine cytology and cystoscopy 
should be performed in case of recurrent infections. The role of HPV 
infection is unclear. At initial presentation, invasive tumors are more 
common in women than in men. Patients with cervical cancer are at 
increased risk of bladder tumors. Orthotopic bladder replacement gives
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good results but should not be performed in patients with tumors located to 
the bladder neck, considering the increased risk for urethral recurrences.
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CHAPTER 3
Can sensitivity of voided urinary or bladder 
wash cytology be improved by the use of 
different urinary portions?
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Introduction
Urinary cytology is often a useful adjunct to cystoscopy and biopsies in the 
diagnosis of urethelial cancer of the bladder and prostatic urethra. It is more 
useful, however, in the monitoring of patients with a history of transitional 
cell carcinomas (TCCs) [1,2] and if consistently used, it can actually 
decrease the frequency with which patients need to be subjected to 
cystoscopy [3]. However, in daily practice the value of cytology is not 
sufficient to replace cystoscopies. Visual microscopic interpretation of 
material has been subject to low inter- and intraobserver reproducibility [4] 
and the sensitivities of cytopathological analysis of urine specimens are not 
high enough to detect the majority of recurrences, particularly those that are 
well or moderately differentiated [5]. Low cellular yields, subtle atypia in 
low-grade malignancies, the presence of reactive atypia, degenerative 
changes, and therapeutic alterations decrease sensitivity of cytology [6]. A 
relevant issue, therefore, is whether we can increase the sensitivity of urine 
cytology, for example by modification of the sampling technique.
In the present study, we examined the sensitivity of different portions of 
bladder wash material and voided urine for cytology to detect superficial 
TCC of the bladder.
Sensitivities of different portions of cytology 69
Materials and methods
Fifty-two patients (44 men and 8 women) were entered prospectively into 
this study. Age ranged from 18 to 76 years (mean 59.5 years). The 
diagnostic work-up consisted of cystoscopy and a transurethral biopsy, 
complete urine and blood tests, intravenous pyelography, transabdominal 
ultrasonogrphy, chest X-ray and computerize tomography in all.
All had biopsy proven superficial TCC of the bladder (pTa, pT1, pTis). 
There were 20 patients (38.5 %) with grade I, 20 patients (38.5 %) with 
grade II and 12 patients (23 %) with grade III tumors. The cystoscopies 
were done by one of two urologists (NAM, MB). Any recent history of 
genitourinary trauma, urinary tract infection, intravesical chemo- or 
immunotherapy within 3 months were recorded and these patients were not 
enrolled into this study.
A voided urine specimen was obtained pre-operatively as a first stream, mid 
stream and terminal stream in 48 patients. Then, just before the operation, 
we rinsed the bladder with 50 ml 0.09% NaCl in 46 patients. The bladder 
was emptied and the first portion, mid-portion and last portion of this wash 
material was used for cytology. All samples were cultured to exclude 
infection and dipstick test were used to exclude hematuria.
Of every cytology sample at least two slides were prepared and the samples 
were examined twice by a pathologist experienced in cytology. The
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pathologist was blinded towards clinical findings. Cytology samples were 
centrifuged and stained with May Grunwald Giemsa and Hematoxylin 
Eosin. Cytological diagnoses were subdivided into four groups: (1) no sings 
of malignancy (negative), (2) malignant cells present (positive), (3) atypia 
suspicious for malignancy (suspicious), (4) no cells were found for cytology 
(acellular).
For statistically analysis, binomial distribution was assumed and 95% 
confidence intervals (CIs) were calculated. The Mc-Nemar test was used for 
comparison of detection rates. Suspicious and cellular results were accepted 
as a negative result when calculating the sensitivity results. Statistical 
significance was assumed when the P value was less then 0.05. The 
statistical package for social sciences (SPSS) computer software was used 
for data documentation and analysis.
Results
The distribution of cytological findings is presented in Table I. The 
sensitivities of the first stream, mid stream and terminal stream of VUC 
were 34.6%, 38.5% and 38.5%, respectively. The sensitivities of the first 
portion, mid portion and last portion of BWC were 34.6%, 38.5%, 34.6%, 
respectively. Comparing the results, there was no statistical significant 
difference between the sensitivities of the portions of VUC and BWC 
(p=0.3).
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Table I. B ladder wash and voided urine cytology with histologic 
findings (n=52)
B ladder wash cytology Voided urine cy tology
Histology pI pII pIII sI sII sIII
negative 22 18 18 16 16 16
Positive 18 20 18 18 20 20
suspicious 2 4 4 8 6 6
Acellular 4 4 6 6 6 4
not done 6 6 6 4 4 4
key: pI= first portion, pII= mid portion, pIII= last portion 
sI=first stream, sII=mid-stream, sIII=terminal stream
Correlating the results with grades of the tumor, sensitivity of the first 
stream of VUC was 20%, 40% and 50% for grade I, II and III tumors, 
respectively. For the mid stream these figures are 25%, 40% and 58.3, and 
for the terminal stream of VUC the sensitivities are 25%, 30% and 75%, 
respectively. We also investigated these grade sensitivity rates for every 
portion of BWC. Sensitivities are 25%, 45% and 33.3% for the first part of 
BWC, 25%, 45% and 50% for the mid portion and 25%, 35% and 50% for 
the last BWC portion for grade I, II and III tumors, respectively. When the 
sensitivities correlated to the grade of the tumor were compared, no 
significant difference between the portions and grades (p= 0.06) was found.
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Discussion
Urinary cytology has an important role in the diagnosis and follow-up of 
patients with bladder cancer. In spite of the introduction of flow cytometry, 
most cytopathologist rely on visual cytologic examination of the exfoliated 
urethelial cells [1]. Exfoliated malignant cells are readily recognized in 
urinary specimens from patients with bladder carcinoma. These cells have 
characteristic nuclear hyperchromasia, an irregular nuclear configuration 
and altered chromatin structure [7,8]. These criteria are valuable for 
diagnosis of human bladder cancer when the lesions are of high histologic 
grade. The criteria are, however, of limited value for the detection of 
relatively common, superficial low-grade tumors [9-11].
Exfoliated cells can be obtained by two primary methods, voided urine and 
bladder-wash material [7,9]. The primary advantage of voided urine is that 
it is noninvasive [7,9], but the advantage of bladder irrigation techniques is 
more and better preserved cells [12,13]. Indeed, bladder wash material 
proved to be superior to voided urine cytology [1,9,14-16]. However, 
Badalament et al. concluded that voided urinary cytology continues to be 
the procedure of choice for detection and monitoring urothelial cancer, 
because of its proven high specificity, noninvasiveness and wide availability 
[13]. In 1981 Murphy et al., reported their experience with cystoscopic 
urine and bladder washing material. They concluded that although bladder
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washing alone has a greater diagnostic yield than cystoscopic urine, 
cystoscopic urine remains a valuable source of diagnostic information [17]. 
They found that in 20 to 30 percent of the cases, tumor cells were identified 
in cystoscopic urine and not in bladder washings. They advised, therefore, 
that both techniques should be performed. In conclusion; there is still no 
agreement which procedure is best, predominantly because of an overall low 
sensitivity.
The overall sensitivity of VUC is ranging from 17 to 60%, the specificity is 
100% [5,18-20]. The sensitivity of VUC is ranging from 3 to 8% for grade I, 
10 to 18% for grade II, 32 to 38% for grade III superficial TCC of the 
bladder. [18,19]. The sensitivity of VUC was studied extensively by 
Sarosdy et al. [18,19]. Sensitivity was determined using frozen voided urine 
samples [19] or the unspun urine allocated to cytology testing was processed 
as usual with cyto-spin or filtration method in patients undergoing 
surveillance cystoscopy for recurrent bladder cancer [18]. In these 
prospective and multicenter trails, they found cytology less sensitive than 
reported in the literature [5,7,18-20]. They pointed out that these findings 
were surprising them and data were reviewed to determine if this low 
sensitivity of VUC was caused by some centers only. However, this low 
sensitivity was consistent. They found that overall sensitivity was 17-23%, 
3-8 % for grade I, 10-18% for grade II and 32-38% for grade III superficial 
TCC of the bladder. Our overall and per grade sensitivity results for every
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part of VUC were superior to Sarosdy et al. results. Overall sensitivity 
results were between 34.6 and 38.5% for every stream of voided urine in our 
study. And, our results also were higher for each grade; 20-25% for grade I, 
30-40% for grade II and 50-75% for grade III superficial TCC of the 
bladder. The explanation could be that we studied a selective group of 
patients which all had biopsy proven superficial TCC of the bladder. 
Moreover, of every portion of cytology at least two slides were prepared and 
the samples were examined twice by one pathologist experienced in 
cytology in the same center. Another explanation may be differences in 
cytological methods and preservation of urine. For example; in this study 
urine was not frozen, but fresh morning urine was used.
A lot of studies have been done with BWC and the overall sensitive for 
detection of tumor by BWC is ranging from 23.0 to 44.8%, the specificity is 
92.5% [21-24]. The sensitivity of BWC is ranging from 0 to 28.6% for 
grade I, 21.0 to 50% for grade II and 33.0 to 83.3% for grade III superficial 
TCC of the bladder [21-24]. D ’Hallewin et al. evaluated BWC in 60 patients 
with superficial bladder cancer at stage Ta and CIS and they reported 32% 
overall sensitivity and 0%, 21% and 60% for grade I, II, III, respectively 
[24]. Ianari et al. investigated the sensitivity of BWC in 75 patients with a 
history of superficial TCC of the bladder undergoing routine follow up 
cystoscopy [23]. They found a 23% overall sensitivity for BWC and 0%, 
50% and 33% for grade I, II and III, respectively. van der Poel et al. studied
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sensitivity for BWC in 138 patients with superficial TCC of the bladder 
[21]. In this study, cells were scored with an automated image analysis 
system. An overall sensitivity rate was 44.8% and 28.6%, 29.6% and 83.3% 
for grade I, II and III, respectively. In this study, a 34.6 to 38.5% overall 
sensitivity and 25%, 35 to 45% and 33 to 50% sensitivity rates for grade I, II 
and III were found for BWC, respectively. Another approach of this study is 
the investigation of different portions of bladder wash material. Our results 
are comparable to the results from the literature with regard to overall 
sensitivity of BWC. The influence of the use of different portions of BWC 
was expected to be minimal. After installations of saline and rinsing, the 
whole urinary volume is homogeneous, and the content of different portions 
should by the same. The cellular composition of voided urine, on the 
otherhand, can have close relation with detrussor activity. Detrussor activity 
reaches a maximum at the terminal part of micturation, possibly increasing 
the amount of cells in the last portion of micturation. Indeed, we got lowest 
acellular rates for the terminal stream of voided urine. In this study, highest 
sensitivity rate for grade III tumors was found as expected. Divided VUC 
and BWC did not effect detection rates in grade I or II tumors. However, 
sensitivity for grade III tumors was highest (75%) in the terminal portion of 
voided urine and this was better than the other parts of VUC and BWC. The 
other sensitivity rates for grade I and II were comparable for every part of 
VUC and BWC.
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Conclusions
Although this study was performed in a selective and small group of 
patients, we can conclude that the terminal stream of voided urine may be 
more sensitive to detect malignant cells, especially in grade III tumors, than 
the other parts of VUC and BWC. We believe that further studies are 
necessary to evaluate this strategy to improve the sensitivity of VUC.
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Introduction
The early diagnosis of bladder cancer is a first step to effective treatment of 
the disease. Nowadays, cystoscopy is considered the gold standard in 
diagnosing tumours in the bladder, although it is invasive and costly. 
Cytopathological analysis of urine specimens copes with these 
disadvantages. Efforts to replace cystoscopy by examining voided urine for 
tumor cells have included cytopathology and flow cytometry but the 
sensitivities are not high enough to detect the majority of recurrences, 
particularly those that are well or moderately differentiated [1,2]. Hence, 
tests are needed for a careful patient fallow up and monitoring of tumor 
recurrence and mucosal changes in an early stage. The test should be quick, 
have a high sensivity, in particular for high-grade lesions, and also a high 
specificity to prevent too many unnecessary cytoscopies. Investigation of a 
variety of markers to aid in monitoring and diagnosis of bladder carcinoma 
is underway. The development of a simple, office-based test to detect 
urinary shed proteins, such as the bladder tumor antigen test, represents a 
significant step in bringing research laboratory efforts into the practical 
clinical arena.
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BARD-Bladder Tum or Antigen Test
The epithelial layer of the bladder is attached to the called basement 
membrane, primarily composed of collagen IV, laminin and proteoglycans 
[3]. During the attachment phase the tumor secretes endogenous basement 
membrane proteins, which bind to the surface receptors on the basement 
membrane. One attached, bladder tumours secrete proteolytic enzymes 
(collegenase or laminin) that disrupt the basement membrane into fragments 
of its basic compounds [4]. These fragmants are discharged into the bladder 
lumen and aggregate into high molecular weight complexes [5]. The Bard 
(Bard Diagnostic Sciences, Redmond, Wash) bladder tumor antigen (BTA) 
test is a latex agglutination test for the qualitative detection of basement 
membrane degradation complexes composed of specific polypeptides with 
molecular weight ranging from 16-165 kDa in voided urine [6-18]. The 
detection of presence of transitional cell carcinoma (TCC) by the BTA test 
is a result of basal membrane disruption. This might explain the often 
negative test results in carcinoma insitu (CiS), since in CiS basal membrane 
disruption is absent. The degree (focal, severe) of basal membrane 
interruption and number of tumours per patient associated with basal 
membrane interruption may affect the outcome of BTA test considerably 
[9]. The BTA test is easy to use and provides rapid results. It requires 
minimal technical expertise to perform or interpret [7]. Additionally, the 
BTA test results may be available to the urologist before cystoscopy, being
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performed upon initial voided urine used for pre-cystoscopy urinalysis. It 
can be done within several minutes, rendering it suitable for quick decision­
making for the performance of cytoscopy. Cytology, on the other hand, is 
relatively expensive and a few days are required for the results [7,8].
The specificity of the BTA test was investigated in healthy individuals and 
subjects without genitourinary complaints, and appeared to be 96% [10]. 
The high specificity has also been found in other large clinical series, 
ranging from 82% to 91% [6-8,11]. The specificity of cytology was 100% in 
these studies [7,11]. However, the sensitivity of BTA test was better than 
cytology, mainly because cytology was found much less sensitive than 
reported in the literature [7,8,10,11]. Large multicenter series have 
confirmed that the sensitivity of the BTA test is higher than that of cytology. 
Depending on stage and grade, the sensitivity of the BTA test ranges from 
40% to 70% while the sensitivity of cytology is between 17% and 32% 
[7,8,10,11]. The reported specificity and sensitivity of both cytology and 
BTA test are shown in Table I.
Many of the false-negative BTA test results were in low-grade lesions. It is 
unlikely that the delay in cystoscopy would affect patients adversely [6,12]. 
As with cytology, certain conditions may cause false-positive BTA test 
results and should be considered limitations to test.
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Table I: Com parison of sensitivity and specificity of the B ard BTA 
tests and cytology
SENSITIVITY SPECIFICITY
BTA test Cytology BTA test Cytology
Ianari et al 54% 23% 91% 100%
Sarosdy et al 40% 17% 96% NI
D ’Hallewin et al 65% 32% NI NI
Leyh et al 70% 25% 90% 100%
The UK and Erie 
Ag Study Group
58% NI 86% NI
NI: not indicated
These include prostatic biopsy or resection within 14 days, renal or bladder 
calculi, symptomatic sexually transmitted disease and some other 
genitourinary cancers, such as penile, ovarian, endometrial or cervical 
carcinoma [10,12]. Also previous radiotherapy may give false-positive 
results and further studies are needed to determine the sensitivity and 
specificity in such patients. Most of the false-positive BTA results can be 
explained by the inflammation, since the test is unreliable in the presence of 
urinary tract infection [6].
The BTA stat is new and simplified test. The BTA stat is technically more 
simple to use (one step, no sample preparation) than the BTA test and tests a 
different antigen. The BTA test is a four step, latex agglutination assay
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performed on buffered urine [10,11]. The BTA stat test is a single-step, 5- 
min immunochromatographic assay performed by placing five drops of 
untreated voided urine into a well on a small disposable test device [13,14]. 
The BTA stat test is more sensitive than and has equal specificity to the 
BTA test. Overall sensitivities for the BTA stat is 66%. The sensitivitiy of 
the BTA stat for tumor grades I-III is 39%, 65, and 83%, respectively, 
versus 43%, 59%, and 70% for BTA test. The sensitivity of the BTA stat 
test by tumor stage for pTa, pTis, T1 and T2-4 is 45%, 53%, 85% and 75%, 
respectively, versus 33%,50%, 64% and 55% for the BTA stat test. In 
conclusion, the BTA stat test is not only simpler and faster than the first 
generation BTA test, it also more sensitive [14].
The BTA trak test is a quantitative enzyme immunoassay utilising 
monoclonal antibodies to bind to bladder tumor antigen in the urine. This 
test can be performed on fresh or frozen single voided urine samples. Both 
sensitivity and specificity of the BTA trak test are better than those of the 
BTA test The sensitivity of BTA trak test for tumor grades I, II, and III is 
55%, 67%, and 85% respectively. Concentrations of bladder tumor antigen 
(U/ml) in urine correlated with tumor grade. The mean concentrations by 
tumor grades I, II, and III are 210 U/ml, 543 U/ml, and 914 U/ml, 
respectively [15].
These results indicate that The BTA stat and trak tests are superior to the 
BTA test and possibly will soon replace the BTA test.
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N uclear m atrix protein 22 (NMP 22)
Nuclear matrix proteins are part of the internal structural framework of the 
nucleus, which may have an important role in DNA replication, 
transcription and processing of RNA, and regulation of gene expression 
[16,17]. The NMP22 test kit (Matritech, Inc., Newton, Massachusetts) 
detects complexed (greater than 1000 kDa) and fragmented (approximately 
30 kDa) forms of nuclear mitotic apparatus protein in voided urine [17,18]. 
The function of nuclear mitotic apparatus protein appears to be a proper 
distribution of chromatids to daughter cells [19,20]. This role of the nuclear 
mitotic apparatus proteins make it a potential marker for malignant cells in 
which abnormal distribution of genetic material is found [17,21]. It has been 
shown that intracellular nuclear mitotic apparatus protein concentration is at 
least 25-fold greater in bladder cancer cell lines compared to the mean level 
in urethelial cells isolated from normal bladders. Similar studies have shown 
that intracellular nuclear mitotic apparatus protein concentration is at least 
10-fold greater in other cancer tissues and transformed cell lines compared 
to normal tissues and normal phenotype cell lines, respectively [17,21,22]. 
Normal subjects have been shown to have low levels of NMP22 in their 
urine, while patients with TCC of the urinary tract have high urinary levels. 
In normal healthy volunteers and in subjects with benign conditions median 
NMP22 levels are 2.9 and 3.3 U/ml, respectively. In patients with active 
TCC the median NMP22 level is 6.04 U/ml, while in those with a history of
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TCC but no evidence of disease the median value is 4.11 U/ml. [17]. In 
another study the median NMP22 values for urethelial cancer (including 
bladder cancer, renal pelvic, ureteric and urethral cancer) was 26.5 U/ ml 
[23].
Soloway et al. [24] evaluated the use of NMP22 in the detection of occult or 
rapidly recurring TCC of the urinary tract following surgical treatment and 
showed, the best cut off level for NMP 22 to differentiate recurrence from 
non-recurrence to be 10 U/ml. A reference value of 10 U/ml yields a 
sensitivity of 70%, specificity 79%, accuracy 76%, positive predictive value 
58%, and a negative predictive value 86%. With a reference value of 20 
U/ml, the positive predictive value increases to 71%, specificity 91% and 
accuracy 80%. Witjes et al. [25] found a sensitivity of 75%, a specificity of 
81.6%, a negative predictive value of 91.2%, and a positive predictive value 
of 56.3% using 10U/ml cut off level. Stampfer et al. [26] showed that the 
overall sensitivity for detection of bladder tumours was 68%, for screening 
low-risk tumours 59%, and for screening high-risk and invasive tumours 
was 80-90%, using cut a off level of 6.4 U/ml. The sensitivity of urinary 
NMP22 for urethelial cancer (including bladder cancer, renal pelvic, ureteric 
and urethral cancer) was 85.7% which compares favourably with that of 
voided urine cytology, which was 50% [23].
Higher NMP 22 levels are found in healthy women and blacks [17]. But, 
there is no difference in urinary NMP22 values between men and women
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with TCC [17,18]. Patients receiving intravesical therapy have greater 
NMP22 values than those not receiving it [24]. Patients with an ileal 
neobladder have very high levels of NMP22. These high levels could be 
caused by the higher cellular turn over in ileal tissue compared to normal 
bladder tissue. This might indicate that the nuclear matrix proteins, used for 
NMP22 test are not cancer- or tissue-specific, as already suggested by 
earlier laboratory tests [25,27]. It seems probably that in such patients this 
test is not useful.
Urinary NMP22 examination is a simple and highly sensitive method for 
detecting of bladder carcinoma and has many advantages over conventional 
methods such as cystoscopy and voided urine cytology. If NMP22 is <10 
U/ml the risk of malignant disease at subsequent cystoscopy is low, and a 
planned cystoscopy could be postponed. NMP22 > 20U/ml indicates a high 
probability that there will be malignant disease on a subsequent cystoscopic 
examination, which may prompt the urologist to intensively follow up the 
patient, perhaps not waiting as long to perform cystoscopy, or perhaps 
skipping follow-up cystoscopy and performing a procedure that would allow 
tissue to be collected for pathological analysis [24,28].
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Q uantitative urinary  cytology (quanticyt)
The reason why the value of urinary cytology is so low in the detection of 
malignant cells is probably due to the fact that visual microscopic 
interpretation of material is subject to low inter- and intraobserver 
reproducibility [29]. Light microscopic image analysis of cytologic material 
allows ploidy analysis as well as objective interpretation of cellular and 
nuclear features reflecting malignant deformation. Recently the quanticyt 
karyometry system was introduced for the quantitative grading of bladder- 
wash cytology [30]. It combines cell nuclear shape and DNA content to 
determine potential malignant differentiation. The graphic representation of 
several samples makes this method particularly suitable for close monitoring 
of changes in the bladder-wash cytology profile of the patients in daily 
practise [31]. In fact it objectivetes cytological features already applied by 
the cytopathologist in reaching the diagnosis. The disadvantages of the 
technique are that it is more elaborative than routine cytology and that it has 
proved to be of value only in bladder-wash material. However, good 
reproducibility of objective score enables comparison of subsequent 
samples to be made [30,31]. The entire test takes two days including 
sample fixation, staining, image processing and analysis.
Bladder-wash material has been proved to be superior to voided urine for 
routine cytology as well as for quantitative analysis [32-34]. Flow 
cytometric studies showed that ploidy analysis of bladder-wash material is a 
sensitive method of tumor detection [33-35], but it does not enable
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simultaneous visual interpretation and selection of cells. Moreover, flow 
cytometry is not suitable for morphometric analysis. Quantitative light 
microscopic techniques can be used for DNA content analysis, as well as for 
morphometric analysis [36,37].
The quanticyt score correlates with tumor recurrences and progression in the 
patient with superficial bladder cancer [31,37]. Based on nuclear shape and 
DNA content, samples can be categorized as low, intermediate and high risk 
for the recurrence of a bladder tumor. Overall recurrences rates at 1 year for 
quanticyt scores are 5.5% for low-risk samples, 12.55 for intermediate-risk, 
and 20.5% for high-risk. Progression rates are 0.5%, 1.3%, and 6.3%, 
respectively [37]. In a multivariate analysis, karyometric data provided 
significant additional information for the prediction of tumor recurrence and 
progression [36,37]. The overall sensitivity for detection of tumor by 
bladder-wash cytology is 44.8%; the specificity is 92.5%. Quanticyt’s 
overall sensitivity for the detection of tumor is 69%, and the specificity is 
85.0 % [38]. The sensitivity for tumor detection is highest for the quanticyt 
method as compared to the BTA test and cytology. Detection of low-grade 
lesions is low for quanticyt, cytology and also the BTA test. Compared to 
cytology the specificity of the quanticyt method is lower (92.5% vs 85%). 
This is probably linked to the somewhat higher sensitivity and predictive 
value of the quanticity score [36,38]. The specificity and sensitivity of both 
cytology and quanticity are detailed in Table II.
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Table II: The specificity and sensitivity of cytology and quanticyt
CYTOLOGY QUANTICYT
Overall sensitive 44.8% 69.0%
Sensitivity Gr 1 28.6% 57.1%
Sensitivity Gr 2 29.6% 55.6%
Sensitivity Gr 3 83.3% 82.6%
Sensitivity Ta 35.0% 60.0%
Sensitivity T1 85.7% 85.7%
Sensitivity T2 75.0% 100%
Sensitivity T3 66.7% 100%
Specificity 92.5% 85.0%
When the BTA test, bladder-wash cytology, and quantcyt are compared in a 
multivariate analysis, the quanticyt shows the best predicton of tumor 
recurrence. Furthermore, the quantitative representation of the quanticyt 
score may provide a more practical follow-up in daily practise. Multivariate 
analysis for the diagnosis of a tumor showed no additional value of a 
combination of the different tests [38]. The quanticyt system enables 
monitoring of bladder mucosal changes in quantitative and easy-to-read 
format. Selecting patients based on risk analysis may reduce the number of 
cystoscopies [37].
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Tumor-specific antigens
Using monoclonal antibodies, we can identity tumor-associated antigens 
selectively expressed on tumor subtypes with distinct clinical behaviours 
[39,40]. Glycoprotein 200 kDa surface antigen 19A211 and the mucinous 
antigen M344 are preferentially expressed on papillary superficial tumors 
and CIS lesions of the bladder [40,41]. Monoclonal antibodies (mAb) 
against both antigens have been developed. MAb 19A211 identifies a series 
of cytoplasmic glycoproteins ranging from 90 to 140 kDa present in tumor 
cells and, at lower level, in normal urothelial cells, and of a membrane 
glycoprotein of 200kDa observed tumor cells only [42,43]. MAb M344 
identifies a high molecular weight determinant which is not detected in any 
normal tissue [39,41], althought some investigators have shown that tumor- 
associated antigens can be found in normal mucosa near superficial and 
invasive bladder tumours [44].
M344 is positive in 74.5% of Ta-T1 tumors and 11% of T3-4 tumors. 
19A211 is also express preferentially on low-grade superficial bladder 
tumors (77% in Ta-T1) and less frequently on deeply infiltrating tumors (10 
% in T3-T4) [41,45]. The specificity of these antigens is 83.3% [45]. The 
combination of these two antigenic markers in immunocytology and flow 
cytometry studies of exfloitedcells has improved the sensitivity of detection 
for bladder tumors [40]. When M344 is combined with cytology and DNA
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ploidy measurements, the sensitivity for low- grade and high- grade tumors 
is 88% and 95%, respectively [46].
Either one or both of these tumor- associated antigens are detected in 
approximately 80% of low-grade papillary superficial tumors and CIS of the 
urinary bladder. The expression of these antigens on a large subset of low- 
grade bladder tumors, known to progress in a minority of cases, suggests 
that phenotypic differences may reflect biological potential. Beyond their 
possible significance, antibodies M344 and 19A211 may provide clinically 
useful probes for the early detection and stratification of bladder tumors 
[41,47,48]. These antibodies are currently commercially available as an 
immunofluorescent assay (Immunocyt, Diagnocure; Quebec, Canada).
F u tu re  developments
Telomerase expression and microsatellite techniques are potentially new 
diagnostic tools, though a clinically applicable test is not yet available for 
routine use.
Telomerase, the ribonuclear protein that functions to maintain telomeras 
length, has been associated with cellular ageing, immortalization, and 
cancer. Normal stomatic cells appear to lack telomerase activity and as a 
consequence, their chromosomes shorten with each cell division [49]. In 
contrast, germ-line cells, immortalized tissue culture cells, and most cancer 
cells show Telomerase expression [50,51], enabling them to overcome
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apoptosis [52,53]. With only a few exceptions, telomerase has been found in 
malignant, but not in benign tissues, and 70-95% of tumors have been found 
to Telomerase-positive [51,54,55]. Telomerase activity can be detected in a 
high percentage of TCC of the bladder using the telomeric repeat 
amplification protocol (TRAP) assay, based on the polymerase chain 
reaction (PCR) [55,56]. Telomerase activity can be demonstrated in tumor 
tissue from TCC, exfoliated cells obtained from either spontaneous urine or 
lavage fluid. Telomerase activity was demonstrated in 98% of TCC tissue, 
and in 89% of exfoliated cells obtained from either spontaneous urine or 
lavage fluid [56]. Telomerase activity was identified in voided urine from 
100% of patients with grade I, 92% with grade II, and 83% with grade III 
lesions [57]. Overall Telomerase expression was found 91% of the tumors 
versus 49% for cytology. The difference in detection of grade I and II 
lesions is even more striking (95% for telomerase vs 28% for cytology) 
[56,57]. The false positive rate of telomerase activity is 24%, and is seen in 
patients with benign proliferatif diseases of bladder like interstitial cystitis, 
inverted papilloma, and urothelial atypia [54] In conclusion, telomerase is 
detectable in nearly all cases of TCC, by means of an objective and non­
invasive method. Results are superior to cytology.
Microsatellite techniques have been used as a tool for detection of loss 
heterozygosity (LOH) and genomic instability in neoplasia. They are used to 
detection TCC by means of testing DNA from urine sediment. LOH was
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demonstrated in 95% in urine samples from patients with a pathologically 
confirmed bladder tumor. This novel molecular approach may provide a 
sensitive assay to detection of bladder cancer [58].
Conclusion
Since urinary cytology has poor sensitivity and specificity for the diagnosis 
and prognosis of superficial bladder tumors, other tests are needed. Several 
urinary tests are currently available or under investigation.
The Bard BTA test, a four-step office based test, has been shown to be 
superior to urinary cytology in papillary lesions. CIS, however, is missed 
frequently. Moreover, better and simpler BTA tests, BTA stat and BTA trak, 
are available, and will probably replace the BTA test in the very near future. 
The quantitative urinary NMP22 test is also superior to urinary cytology. 
Depending on the cut-off level chosen. It seems feasible to postpone 
uretroscopy based on NMP22 level below 10 U/ml. Both the BTA and the 
NMP22 test have to be interpreted with care in the case of infections, since 
in such patients the tests are likely to give false-positive results.
Quantitative bladder-wash cytology is objective and reproducible. Again, 
this test is superior to urinary cytology, but it is invasive test since a 
bladder-wash sample is necessary. An additional advantage of quantitative 
urinary cytology is the predictive value with regard to tumor recurrence and 
progression.
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Tumor specific-antigens have been introduced into daily practice. Their 
ability to detect low-grade tumors could be of particular help. The 
promising results of newer techniques, like Telomerase expression and 
microsatellite techniques, have yet to be confirmed in larger studies.
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CHAPTER 5
Comparison of the diagnostic value of the BTA 
Stat Test with voided urinary cytology for the 
detection of bladder cancer
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Introduction
Superficial bladder cancer (Ta, Tis, T1) has a high tendency to recur after 
transurethral resection of the tumor (TURT). In our own series the risk of 
recurrent disease in patients with primary superficial bladder tumors is over 
60% in 7 years [1]. In the literature, the recurrence rates after 5, 10 and 15 
years are reported to be 65%, 81% and 88% respectively [2]. Cytology 
suffers from low sensitivity in the presence of low-grade transitional cell 
carcinoma (TCC). Moreover, the results of urinary cytology vary depending 
on the training and expertise of the cytopathologist and usually take a few 
days to process [3]. Its use alone in the follow-up is not recommended [4]. 
Better noninvasive tests are necessary to diagnose and follow-up patients at 
risk for bladder cancer in order to avoid frequent cystoscopies.
The bladder tumor antigen stat (BTA® stat) test has been recently described 
to have significant advantages. However, false positive results can be 
determined in some benign conditions. Therefore, we compared the 
sensitivity and specificity of voided urine cytology (VUC) and the BTA® stat 
test for the diagnosis of TCC in our own series to evaluate diagnostic value 
of this test.
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Patients and Methods
In this study, fresh voided urine samples which were obtained from each 
patient with TCC or benign genitourinary disease (GUD), and healthy 
volunteers (HV), were used for cytology and the Bard® (Bard Diagnostic 
Sciences, C.R. Bard, Inc., Redmond, Wash., USA) BTA® stat test. All 
patients with TCC were investigated by detailed medical history, routine 
blood and urine analysis, intravenous pyelography, abdominal 
ultrasonography (USG) and computerized tomography. Each patient with 
TCC underwent cystoscopy with biopsy or TURT. In case of an invasive 
tumor radical cystectomy was performed. Patients with TCC plus another 
benign GUD were excluded from the study. The patients with benign GUD 
and HV whose samples were used in the specificity study were assumed not 
to have bladder cancer after careful investigation including abdominal USG, 
although cystoscopy was not performed.
The BTA® stat test was done by placing five drops of fresh voided urine 
into the sample well of the disposable test device. In the well, the urine 
mixes with a colloidal gold-conjugated antibody. In the presence of bladder 
tumor associated antigen, an antigen conjugate complex is formed that 
creates a visible red line after 5 minutes. Antibodies in the second control 
window adjacent to the specimen should create another visible red line each 
time to confirm proper function of the kit.
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Urinary specimens were stained according to Papanicolaou staining 
procedure for cytology. The pathologist performing the cytological 
examination was blinded for the results of cystoscopy and the BTA® stat 
test. A smear technique was performed twice for each urine specimen. A 
positive cytology result was defined if tumor cells were found. Acellular, 
suspicious or atypical results were considered as negative cytology.
Tumors were staged according to the TNM classification of the American 
Joint Committee on Cancer [5] and graded according to the World Health 
Organization classification system [6].
Statistical analysis was performed using the statistical package for social 
sciences (SPSS) computer software. The McNemar test was used to 
compare the sensitivity and specificity of the BTA® stat test and VUC. 
Pearson chi-square was used to analyze statistical differences of sensitivity 
and specificity for tumor grades and stages. A p value <0.05 was considered 
to be statistically significant.
Results
A total of 117 patients with histologically confirmed TCC were enrolled in 
this prospective study. Ninety-eight men (83.7%) and 19 women (16.3%) 
had a mean age of 61,3±9,2 (range 35-80) years. The control group 
consisted of 94 patients with benign GUD and 21 HV, 84 men (73%) and 31
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women (27%), mean age 41,2±12,8 (range 18-79) years. The patients in the 
benign GUD group had a cystocele (n=4), urethero-pelvic junction 
obstruction (n=3), renal cortical cyst (n=1), nephrolithiasis (n=24), benign 
prostatic hyperplasia (BPH) (n=14), urinary tract infection (UTI) (n=44), 3 
follow-up patients with augmentation cystoplasty operation and 1 patient 
was 18 days after a transvesical prostatectomy.
The BTA® stat test was positive in 94 of 117 patients with TCC. VUC was 
positive in only 33 of these patients. Thirty-six false positive results were 
found in the control group by the BTA® stat test. All of these had benign 
GUD: 19 patients with only UTI, 9 BPH patients with UTI, 1 cystocele, 6 
nephrolithiasis and 1 patient after transvesical prostatectomy. Antibiotic 
treatment was given to 21 false positive patients with UTI. Although, the 
BTA® stat test became negative in these 20 patients after treatment, the test 
remained as a positive in 1 BPH patient with UTI. In the control group, all 
VUC samples were reported negative. Only one patient with a T3 grade III 
TCC was positive by VUC while the BTA® stat test was negative. The 
overall sensitivity of the BTA® stat test and VUC was 80.3% and 28.2%, 
respectively. The difference was statistically significant (p<0.005). VUC 
was more specific than the BTA® stat test; 100% (95%CI=98.2-100%) 
versus 72.3% (95%CI=63.5-79.6%). The correlation of the BTA® stat test 
by tumor grade was statistically significant (p<0.005). However, no 
statistically significant correlation was found between the BTA® stat test
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and stage (p>0.05), although detection rates increased by stage. The 
correlation of VUC by stage and grade was also statistically significant 
(p<0.05). These results are detailed in Table I.
Table I. Sensitivity of the BTA® stat test and voided urinary 
cytology by stage and grade
Stage N
Voided Urine Cytology 
% 95% CI
The BTA Stat Test 
% 95% CI
Ta 33 3 1.7-6.4 52 42.8-61.2
T1 41 10 1.0-19.0 74 64.5-83.5
T2 10 33 24.4-41.6 89 83.3-94.7
T3-4 33 39 30.0-48.0 88 82.0-94.0
Grade
1 44 6 1.8-10.2 52 42.8-61.2
2 53 24 16.2-31.8 88 82.0-94.0
3 20 49 39.8-58.2 93 88.4-97.6
All 117 28.2 20.0-36.4 80.3 72.9-87.7
CI= Confidence Intervals
Discussion
Several attempts have been made to find the ideal tumor marker for the 
diagnosis and follow up of bladder cancer. The BTA® stat test is one of the 
promising markers that have been transferred to the clinical arena.
The BTA® stat test is an easy, single-step immunochromatographic assay to 
detect a bladder tumor associated antigen in voided urine with the result 
being available after 5 minutes. The antigen detected by the BTA® stat test
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is a human complement factor-H-related protein (hCFHrp), which is similar 
in structure and function to human complement factor H (hCFH) [7]. In a 
cell culture, hCFHrp is produced by several bladder cancer cell lines but not 
in normal tissue. By interaction with complement factor C3b, hCFH serves 
to inhibit the formation of a membrane attack complex, thereby preventing 
cell lysis. Like hCFH, bladder tumor antigens interrupt the complement 
cascade. In this manner, tumors producing hCFHrp related proteins could be 
protected from the immune system [8].
The overall sensitivity of the BTA® stat test was reported from 57 to 82.8% 
[10-15]. Sarosdy et al., investigated the sensitivity of the BTA® stat test and 
compared this with VUC in patients with recurrent bladder cancer using 
frozen urine [9]. The BTA® stat test was found to be positive in 147 (67%) 
of 220 samples. The overall sensitivity of the BTA® stat test and VUC in 
these patients was 58% and 23%, respectively (p<0.001). Sensitivity of the 
BTA® stat test was better than VUC for every grade and stage, except for 
Tis. A slight increase in detection of cancers was seen by combining the 
BTA® stat test and VUC, but this was not statistically significant. Leyh et al. 
reported that the overall sensitivity (65%) of the BTA® stat test was 
considerably higher than cytology (33%) (p<0.001) [10]. Although the 
BTA® stat test was significantly more sensitive than cytology for grade I 
and II tumors (p<0.005) and for stage Ta tumors (p<0.001), this was not the 
case for grade III and Tis, T1-4 tumors. In a multicenter study, the BTA stat
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test detected 90.1% of the primary and 73.7% of the recurrent tumors with a 
82.8% overall sensitivity [11]. All patients with CIS, high-grade tumors, 
muscle invasive cancer and tumors larger than 2 cm were diagnosed by the 
BTA® stat test. Patients under surveillance treated with intravesical BCG, 
however, had a significant increase in the number of false-positive results. 
In another study the sensitivity of VUC, BTA® stat, NMP22, 
fibrin/fibrinogen degradation products, telomerase, chemiluminicent 
hemoglobin and hemoglobin dipstick were compared to detect bladder 
cancer in 196 patients [12]. The BTA® stat test had the highest sensitivity of 
74%, but was less specific in this study. The overall sensitivity with VUC 
was only 44%. The urinary telomerase had the highest combination of 
sensitivity and specificity (70% and 99%, respectively) for TCC detection, 
but the combination of the BTA® stat test with telomerase revealed a 
statistically significant improvement (p=0.02). On the other hand, Wiener et 
al. reported almost equivalent overall sensitivity rates for different urinary 
diagnostic tests. The overall sensitivity was 48, 57, 58, 59 and 59 % for the 
NMP22 test, the BTA® stat test, bladder wash cytology, VUC and 
Quanticyt® [13]. Sensitivity of the cytological evaluation of voided urine 
and bladder wash material, and Quanticyt® increased as grade and stage 
increased, in contrast to the NMP22 and BTA® stat test. For grades 1 to 3, 
sensitivity was 17%, 61% and 90% for urinary cytology, as compared to 
48%, 58% and 63% for the BTA® stat test.
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In our study, the overall sensitivity of the BTA® stat test was significantly 
superior to VUC in detecting TCC of the bladder (p<0.005). Both tests 
performed better with increasing grade, with the BTA® stat test having the 
higher sensitivity for all grades and stages of TCC compared to VUC. The 
differences were highest in grade I (6% versus 52%), stage Ta (3% versus 
52%) and T1 (10% versus 74%) (p<0.001). The BTA® stat test appears to 
be especially useful in the detection of low risk tumors. Despite progression 
and recurrence rates of low and intermediate risk tumors are low, 
cystoscopy is performed at 3-month intervals for 2 years, 6-month for the 
next 2 years annually thereafter for the rest of the life in traditional follow- 
up protocol due to lower sensitivity of VUC to detect these low and 
intermediate risk tumors. However, many authors have suggested that the 
first cystoscopic control is one of the most important determinants of risk 
factor and should not be skipped [14-16]. With the negative first 3-month 
cystoscopic findings, the BTA® stat test could be helpful to the urologist in 
order to detect low and intermediate risk tumors owing to its higher 
sensitivity rates compared to VUC and, unnecessary cystoscopies could be 
avoided. The BTA® stat test and VUC were not combined to analyze 
detection rates because there was only one patient with TCC that was not 
detected by the BTA® stat test while VUC was positive.
A potential disadvantage of the BTA® stat test is the specificity. Specificity 
can be affected in some conditions. The BTA® stat test specificity was 95%
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in healthy volunteers and 93% in patients with nongenitourinary disease in a 
large multicenter study [9]. In this multicenter study, specificity was 88% in 
patients with BPH and decreased to 50% in patients with stones and 76% in 
those with inflammatory conditions, such as cystitis, urethritis and 
prostatisis. Invasive manipulation of the bladder or prostate decreased 
specificity to 33%. In another study, among 278 cases, 34 (12%) had 
histologically confirmed bladder cancer. [17]. A specificity of 82.4% and a 
PPV of 34.9% were found. The specificity and PPV of the BTA® stat test 
improved (91.5%, 69.7%) with exclusion of 6 clinical categories (infectious 
or benign inflammatory conditions, urolithiasis, recent history of a foreign 
body in the urinary tract, bowel segment interposition, another genitourinary 
cancer or an instrumented urinary sample). Our overall specificity (72.3%) 
for the BTA® stat test, which was lower than VUC, is comparable with this 
study. In the patients with exclusion criteria as defined by Sharma et al.
[14], the BTA® stat test gave some false (+) results and all HV were 
negative by the BTA® stat test in our study. In this study, especially UTI 
and nephrolithiasis cases were considerably affected the specificity of the 
BTA stat test. hCFH may enter the bladder as a result of different 
conditions and it can result in a false positive BTA® stat test. Although it is 
difficult to define exclusion criteria, the urologist should be aware of these 
conditions causing false positive tests.
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Conclusions
The BTA® stat test has significantly higher sensitivity than VUC in the 
detection of TCC, especially in low-grade tumors. Unfortunately, specificity 
can be affected by some benign conditions, especially UTI and 
nephrolithiasis. In the patients with low and intermediate risk tumors, the 
BTA® stat test may help to reduce the number of cystoscopies during follow 
up.
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The Urinary Bladder Cancer Test: can it be used 
as a new urinary tumor marker in the detection 
of carcinoma in-situ, pTa and pT1 bladder
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Introduction.
Researches in cell biology has provided new biological markers of bladder 
cancer in recent decades. The development of urothelial tumours causes 
exophytic growth of tumour into the bladder and urethelial cell damage. 
This can exfoliate lysed and alive malignant cells into bladder and a 
concomitant discharge of intracellular components into urine. One group of 
these intracellular components are cytokeratins (CKs). CK fragments are 
expressed in varying combinations and levels depending on the epithelial 
type, degree of differentiation, and existence of malignancy [1]. Malignant 
cells generally retain the intermediate flaments of their progenitor cell type. 
Moreover, CKs expression is retained throughout almost all stages of 
epithelial malignancy. For these reasons, CKs have been used to 
characterize neoplastic cells of epithelial origin [2]. It has also been 
suggested that CKs may be a specific biomarker for detecting bladder 
cancer. One such test is the Urinary Bladder Cancer (UBC) test (IDL 
Biotech, Sollentuna, Sweden), which detects the CK 8/18 pair in urine. 
However, the biological difference of CK variants between malignant 
urothelial cells and normal urothelial cells is small. The ability of a test to 
detect these differences will determine its clinical usefulness. Also, 
unsolved problems regarding CK testing in bladder cancer, such as the
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stratification of the antigen concentration in relation to the urinary creatinin 
concentration, still exist.
Although other bladder cancer tests and assays have been studied 
extensively, the experience with the UBC test is limited, since the test is 
relatively new. It is too early to make conclusions about the value of this 
marker in patients with bladder cancer. The aim of this study was to 
evaluate diagnostic performances of the UBC test in the patients in follow- 
up for superficial bladder cancer.
Material and Methods
Patients: The study population consisted of 101 consecutive patients seen in 
our outpatient department between October 1998 and March 1999 for 
follow-up superficial bladder cancer (pTa, pT1 and carcinoma in situ). 
Voided urinary specimens were collected from all patients, and all patients 
underwent cystoscopy. Transurethral resection was performed or biopsies 
were taken in the case of a bladder tumour or suspicion for CIS. Urine 
sediment and culture were performed for all patients because elevated UBC 
concentrations may be observed in the case of urinary tract infections (UTI). 
Patients who had undergone intravesical immunotherapy or chemotherapy 
less than 1 month before the test were excluded from the study. Tumours 
were staged and graded according to the TNM classification [3] and World 
Health Organisation classification [4] systems, respectively.
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Assay: The CK 8/18 fragments were determined in urine by using solid­
phase double determinant “sandwich” -type immunoenzmmometric assay. 
Frozen urine specimens were thawed and mixed before testing. Urine 
specimens, standards, and controls were incubated for 2 hours with 
monoclonal anti-UBC antibody coated to the wells of microtiter plates 
simultaneously with a horseradish peroxidase-labelled tracer antibody. 
During the incubation, both the immobilezed antibody and the horseradish 
peroxidase-labelled antibody bind to UBC antigen, forming a “sandwich” . 
The wells were washed and B substrate was added and incubated for 15 
minutes. Sulfuric acid was added to stop the reaction. The developed colour 
is directly proportional to the concentration of CKs. Because the results of 
assay can be affected by different urinary creatinine level, it is 
recommended that the UBC concentrations should be corrected by using 
urinary creatinine concentrations according to the following equation:
UBCcorrected (in g^ UBC/mg creatinin)- UBC measured (in g^ /L) / creatinin urinry (in mg/L) X
1000]. Non-corrected UBC antigen concentrations were also evaluated in 
the present study.
Statistical analysis: The diagnostic performance of the uncorrected and 
corrected UBC test was evaluated in three different ways. First, the median 
values of the (non-normal) distribution of test results were compared 
between patients with and without recurrent urothelial cell carcinoma. 
Possible differences in the distribution between both groups were tested for
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statistical significance using the non-parametric Mann-Whitney test. Second 
the sensitivity, specificity and positive predictive value (PPV), negative 
predictive value (NPV) of the uncorrected and corrected UBC test were 
assessed using a cut-off value 12 pg/L, as advised by IDL Biotech. Also, to 
summarize the diagnostic value of the test in a single measure, the odds 
ratio (OR) with corresponding 95% confidence interval (95%CI) was 
calculated. In a diagnostic setting, this OR reflects the ratio of the likelihood 
ratio of positive test result (LR+) and the likelihood ratio of negative test 
result (LR-). If a test does not have any diagnostic value, the OR (LH+/LH-) 
is close to 1.0. If a test has strong diagnostic value the OR will become 
extremely high.
Third, to avoid an arbitrary value for the test, we reanalysed the data using 
logistic regression analyses with the cystoscopic (plus histologic) results as 
a dependent variable and the UBC test as an independent variable. The 
result from this logistic regression analysis is the OR with 95% CI. 
However, because in this analysis the UBC test is a continuous variable 
instead of dichotomy variable, the OR cannot expected to be very high for a 
test with good diagnostic efficacy. To visualize the diagnostic efficacy of 
the test in the absence of an arbitrary cut-off value, we also summarized the 
data using a receiver operating characteristics (ROC) curve. The area under 
the curve (AUC) was calculated as a single measure for diagnostic efficacy 
of the continuos test result. If a test does not have any diagnostic value, the
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AUC is close to 0.5. If a test has strong diagnostic value the AUC will be 
close to 1.0. The Statistical Package for Social Sciences (SPSS), release 9.0, 
was used for analyses. ROC curves drawn according to Harley and Mc Neil 
[5].
Results
Eighty-three men and 18 women were enrolled this study. The patients had 
a mean age of 67.6years (range 40 to 86). In 29 (28.71%) of 101 patients, 
histologically proven recurrence of transitional cell carcinoma (TCC) was 
detected: 1 patient had CIS, 26 had stage pTa (19 low grade and 7 high 
grade), and 2 patients had a high-grade pT1 tumour. Among the patients 
with tumour, the median non-corrected and corrected UBC value was 3.40 
pg/L (range 0 to 54.5) and 2.50 pg/L (range 0 to 39.2), respectively. In 
patients with without signs of a tumour, the median non-corrected and 
corrected UBC value was 3.75 pg/L (range 0 to 60) and 3.21 pg/L (range 0 
to 45.7), respectively. The non-corrected UBC values were not significantly 
different between patients with and without a bladder tumour (p=0.75), nor 
were the corrected values (p=0.77). No differences were found between men 
and women. The test was not stratified according to stage and/or grade 
because of the limited number of patients.
The sensitivity, specificity, PPV, NPV and OR for the corrected and non­
corrected test, with and without a specific cut-off level, are listed in Table I.
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The diagnostic value of non-corrected and corrected test without an 
arbitrary cut-off level is detailed Figures 1 and 2, respectively.
Both ROC curves suggest that the UBC test has no diagnostic value in 
patients who are being followed up for recurrent superficial bladder cancer. 
The AUC was 0.519 and 0.517, respectively, for the non-corrected and 
corrected UBC test. The exclusion of patients with a urinary tract infection 
did not improve the results of test.
R O C  C u r v e
1 - Specificity
Diagonal segments are produced by ties.
Figure 1. ROC curve of the noncorrected UBC test (AUC 0.519; 
standart erro r 0.066)
The UBC test 120
R O C  C u rve
1 - Specificity
Diagonal segments are produced by ties.
Figure 2. ROC curve of the corrected (for creatinine) UBC test 
(AUC 0.517; standard error 0.065).
Table I. Sensitivity, specificity, positive and negative predictive 
values, and odds ratio for the UBC test with confidence 
interval
Non-corrected UBC test 
(Cutoff 12p,g/L)
Corrected UBC test 
(Cutoff 12p,g/L)
Sensitivity (%) 
Specificity (%) 
PPP (%)
NPV (%)
OR 
95% CI 
OR without cutoff 
95% CI
20.7
84.7 
35.3 
72.6 
1.44
0.43-3.86 
1.0149 (p=0.46) 
0.97-1.05
20.7
79.2 
28.6
71.3 
0.99
0.34-2.87 
1.01 (p=0.65) 
0.97-1.05
UBC=urinary bladder cancer, PPV=positive predictive value, NPV: negative predictive 
value, OR=odds ratio, CI=confidence interval
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Discussion
CKs are a multigene family of proteins forming water-insoluble 
intermediate filaments specific for cells of epithelial origin [6]. Twenty 
different CK has been analysed from different epithelial tissues. They can 
be further subdivided into type I (CK 9-20) and type II (CK 1-8) [7]. For 
normal formation of intermediate filaments different types of CKs are 
necessary (one type I and one type II) and two different CKs form a pair. 
The smallest CK pair, 8 and 18, is found in large quantities in simple, 
ductal, and glandular epithelium, pseudostratified epithelium, transitional 
epithelium and carcinomas arising therefrom [8]. Different CK fragments as 
a biomarker for bladder carcinoma has been studied in the serum, urine and 
exfoliated cells. In serum, for example, different tissue polypeptide antigens 
have been studied. These polypeptide antigens measure CK 8,18 and 19, 
and they have been used as a serologic markers for the follow-up and 
diagnosis of bladder cancer [9-12]. The reported results indicated a low 
sensitivity, particularly in low-grade tumours, and the tests were not 
considered useful for the early detection of bladder cancer [10-12]. On the 
other hand, urinary CKs could be useful because of the direct contact of 
urine with the tumour. For example, because of the overall low sensitivity of 
serum CYFR 21-1 (CK 19 fragments), this marker was not useful marker 
for diagnosing TCC [13]. Expression of CK-20 was also found to be a
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potential biomarker for non-invasive detection of bladder carcinoma by 
assaying uroepithelial cells from the voided urine specimens [14].
Urinary CK fragments can be measured quantitatively by their 
immunochemical reactivity with the help of both polyvalent and monoclonal 
antibodies in blocking enzyme-linked immunoabsorbent assay (ELISA)
[15]. An example of such a test is the UBC test, which detects the CK 8/18 
pair in the urine.
Sanchez-Carboya et al. studied the diagnostic performance of the UBC test 
as a tumour marker for TCC of the bladder [16]. In their first report, the 
urinary UBC antigen was measured in 5 different groups: 86 patients with 
active TCC (pTa-pT4, group 1), 76 tumour-free patients in follow-up after 
resection of TCC (group 2), 25 patients with benign urologic diseases 
(group 3), 25 patients with other malignant conditions (group 4) and 30 
healthy volunteers (group 5). The mean urinary UBC antigen concentration 
was significantly different between the five groups, except for groups 1 and 
4 (p=0.19). For patients, in group 1; no correlation with stage was found 
(p=0.26), although significant differences were seen between pT1 and pT2 
(p=0.001) and between pT2 and pT3 (p<0.0005). No significant difference 
was evident between grades I and II (p=0.29), but a significant difference 
between grade II and III (p=0.0006) was found. In their study, the overall 
sensitivity and specificity for the UBC test was 87% (95% CI 79.2 to 92.7)
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and 86.8% (95% CI 77.1 to 93.5), respectively, with an optimised threshold 
of 9.74|ig/L.
In their second report, group 1 (active TCC) was extended to 111 patients 
[17]. In that report, the overall sensitivity and specificity was 79.3% and 
88.5%, respectively. The sensitivities in group 1 was 78.4%. For pTa 
tumours, this was 66.7% (16 of 24) and for pT1, 88.7% (47 of 53). The 
specificity in group 2 was 97.4%. The positive and negative predictive 
values in group 1 and 2 together was 97.4% and 79.0%, respectively. The 
false positive rate in group 4 was 44.0%. In this second analysis, no 
significant correlation was found with regard to tumour stage, grade, size, 
growth pattern, multifocality, or previous recurrences.
Mian et al. compared the UBC test and nuclear matrix protein 22 (NMP22) 
test using frozen urine for the detection of TCC in 81 patients having 
symptoms suggestive of TCC and 159 patients under follow-up after 
transurethral resection [18]. With cutoff levels for bladder cancer of 12 
U/ml for NMP22 and 12^g/L for the UBC test, the overall sensitivity in 54 
patients with histologically proved TCC was 55.5% and 64.8% for NMP22 
and the UBC test, respectively. The sensitivity of UBC test was higher than 
that of NMP22 for each stage and grade, although not significantly. Thus, 
low-grade and low-stage tumours especially were better detected with the 
UBC test. The specificity was 79% for the NMP22 test and 93% for the 
UBC test.
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In the previous studies, the results of the UBC test were promising. 
However, we could not confirm these results. In our patient population, the 
OR was very close to 1.0 and the AUC in the ROC curves was very close to
0.5, suggesting no diagnostic value for the UBC test. With a cutoff value of 
9.74^/L, for example, which was the optimal value in the studies of 
Sanchez-Carboya et al., the sensitivity in our population improved to 38.7%, 
but the specificity decreased to 60%. Specimen collecting and storage, 
specimen preparation, and the technical performance of the test were well 
defined and repeatedly discussed with the manufacturer, so these factors 
were excluded as possible causes for the discrepancy with previous reports. 
The most important reason for the discrepancy is probably the different 
selection criteria for the patients in these studies. Our patient population 
consisted of patients with superficial bladder cancer in follow-up. The 
reason we chose to test this population was to evaluate the diagnostic 
performance of the UBC test in a group of patients in follow-up for 
recurrence, because we consider this to be the primary indication of a 
urinary marker such as the UBC test. In the diagnosis of patients with 
invasive bladder tumours, such as were included in the other two studies 
urinary marker tests have limited value. Still, Sanchez-Carboya et al. also 
found a good sensitivity in patients with superficial bladder TCC [17]. 
Theoretically, antigenic expression may be detected in the urine some time 
before a recurrent tumour becomes apparent, resulting in a “false-positive”
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UBC test. This would imply a prognostic value for this test, as has been 
seen with other tests. However, we could not test for a prognostic value, 
because this marker is not suitable for the detection of recurrent bladder 
cancer. Sanchez-Carboya et al. also found high UBC concentrations in 
patients without tumour recurrence during their follow-up [16]. This finding 
questions any prognostic value of the test, although they suggested that 
residual tumour or mucosal abnormalities owing to the field detect could 
cause a CK level below the cutoff level differentiates active tumour from 
tumour-free disease. Most of our group had low stage and low grade 
tumours. Although this also could be an explanation for the lack of 
sensitivity in our study, Mian et al. [18] indicated that, especially in these 
low-grade and low-stage tumours, the UBC test performs well. Moreover, in 
the study of Sanchez-Carboya et al., the UBC levels in some cancers other 
than bladder cancer overlapped with those of the bladder cancer cases, 
although this overlap remained after exclusion of patients with renal and 
prostate cancer from the analysis. We did not check our patient population 
for the other malignancies; however, none of our patients had such a history. 
Therefore, it is not unlikely that the presence of other malignancies 
influenced the test result in our patient population. There is also potential 
overlap between patients with benign conditions and bladder cancer. This 
has been shown for CYFRA 21-1 [19], particularly in patients with low-
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grade tumours. Since this compromises specificity, it is another undesirable 
condition for a good tumour marker.
In conclusion, from the results of our study, it appears that the UBC test, a 
new urinary marker, is not useful in the diagnosis of recurrent tumours in 
the follow-up patients with superficial bladder cancer.
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Bacillus Calmette-Guérin in superficial 
transitional cell carcinoma
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I- BACILLUS CALMETTE-GUERIN IN SUPERFICIAL 
TRANSITIONAL CELL CARCINOMA. 
Introduction
The antitumor effect of tuberculosis has been known since 1929, when Pearl 
reported an autopsy study in which patients with tuberculosis had 
significantly fewer malignant tumors than a control group [1]. In 1966, Coe 
and Feldman showed a strong delayed hypersensitivity reaction in the 
guinea pigs, indicating an immunological response to BCG [2]. In 1976, 
Morales et al. [3] were the first to use intravesical installations of BCG for 
superficial bladder cancer. Now, after 22 years, BCG is widely used in the 
treatment of carcinoma in-situ (CIS) and residual tumor after endoscopic 
resection (therapeutic use), and after complete endoscopic resection to 
prevent tumor recurrences and/or progression (prophylactic use) [4].
Effector mechanisms of BCG in cancer
Although the clinical use of BCG has gained wide spread acceptance, the 
mechanism of action has not been completely understood. Studies in 
animals have suggested that BCG activates the host’s immunologic system 
and immunocompetence may be necessary for therapeutic effect to be 
achieved [5,6]. Attachment of BCG to the bladder wall via fibronectin (FN) 
has been shown to be an important step in initiating its antitumorigenic 
activity [7].A major 30-32 kDa. protein antigen from Mycobacterium Bovis
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BCG, the so-called antigen 85 complex, is known to bind specifically to the 
collagen binding region of FN [8]. Antigen 85 is an immunodominant 
protein complex, associated with protective T cells in tuberculosis and 
leprosy, and a powerful IL-2 and IFN-y inducer [9]. Hudson et al. found that 
inhibitors of fibrin clot formation decreased the efficiency of intravesical 
BCG therapy in patients with superficial bladder cancer. They indicated 
that the attachment to FN could be decreased by fibrin clot inhibitors. Two 
possible explanations for these results were proposed. Firstly, fibrin clot 
inhibitors might have an adverse effect on binding of BCG to FN and 
thereby inhibit the effect of BCG; second, aspirin-like drugs have anti­
inflammatory effects [10]. However, in another study these adverse effects 
of fibrin clot inhibitors could not be confirmed [11].
The mechanism(s) by which BCG mediates the immunological system 
require lymphokine-activeted killer cells, BCG activated killer cells, T 
lymphocytes (CD4 helper cells and CD8 suppresser/cytotoxic cells) and 
monocytes [12,13]. Several immunological effects of BCG have been 
described: a significant increase in T cell infiltration of the lamina propria 
has been reported and shown to persist for at least 3 months following 
treatment [14]. This T cell infiltrate contains immunologically active CD4 
and CD8 cells. This effect may result in increased tumor cell-killing activity 
by cytotoxic T cells and various macrophages [14,15]. Ratliff et al. also 
showed that both CD4 and CD8 T cells are necessary for the anti-tumor
Intravesical BCG 132
effect of BCG [16]. BCG induces the expression of the MHC class II 
antigen by normal and malignant cells [17]. This antigen interacts with the 
CD4 T cell and is mandatory for the process of antigen presentation. It has 
been proposed that, following the induction of the MHC class II antigen, the 
bladder cancer cells perform an antigen-presenting function and presents the 
BCG antigen to the CD4 T cells [15,17]. CD4 cells activated in this way 
produce IL-2, IFN-y and TNF. In a prospective study, the urine of patients 
receiving BCG therapy for superficial bladder cancer was examined before 
and after treatment [18]; there was a significant increase in the levels of IL-
1, IL-2 and TNF. These findings suggest that LAK cells may be involved in 
BCG-mediated antitumor effects. IFN-y appears to have a pivotal role as a 
powerful immunomodilatory and macrophage-activating cytokine and 
inhibits the in vitro growth of human bladder cancer cells [19-21]. The role 
of IFN-y in the overexpression of MHC II molecules on the urethelial cells 
has been confirmed again by Jackson et al. [22], who showed that the 
increased expression of these molecules induced by urine after BCG 
treatment was neutralised by polyclonal antibodies to IFN-y. Moreover 
several studies suggest that IFN-y is strongly linked to the T-cell mediated 
response to BCG. In humans, Thanshauser et al. [23] showed that 
monoclonal antibodies neutralising IFN-y can inhibit the BCG-mediated 
activation of LAK cells.
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Different parameters of immune response can be monitored during 
intravesical BCG therapy; when treating superficial bladder cancer with 
BCG, urethelial cells are exposed to BCG mycobacteria. In vitro, this 
situation has been shown to up-regulate cytokines synthesis by human 
bladder tumor cells [24,25]; some of these in vitro observations seem to be 
analogous to observations in vivo [25-27], supporting the therapy that 
urethelial cells may contribute to the modulation of BCG induced 
immunoreaction that is important for antitumor activity [28]. Urinary 
cytokine induction is an additional aspect of the BCG-induced 
immunological cascade. IFN-y can only be detected in urine dialysed 
immediately, TNF-a is unstable at 40 C and 200 C, and IL-1ß and TNF-a 
determinations are influenced by the presence of cellular material in the 
urine collection, IL-2 and IL-6 could be the cytokines of choice for routine 
monitoring during intravesical BCG installations [29,30]
Viability, dose, appropriate strain
The efficacy of a BCG vaccine depends on several factors, of which the two 
most important are the ability of the organisms to multiply in vivo, i.e. 
viability, which is different in the available strains, and the number of bacilli 
used in each vial, i.e. the dose. Different strains of BCG and different 
samples of BCG of the same strain have different numbers of colony 
forming units (c.f.u.). For example, in the Pasteur BCG strain (Institute
Intravesical BCG 134
Armand Frappier, Quebec, Canada) for example the number of c.f.u. varied 
from 6X106-8 till 1X1012 per ampule. There is a relation between viability 
and treatment results: patient treated with 6X106-8 per ampule had recurrent 
tumors in 71%, while patients treated with 3X1011 CFU per ampule showed 
recurrences in 25% [31]. Storage of BCG at the correct temperature is 
critical for the survival of mycobacteria. Generous use of lubricants to assist 
catheterization during intravesical BCG therapy will result in a clinically 
significant decrease in the number of intravesically instilled viable 
mycobacteria. Thus, during intravesical immunotherapy with BCG only 
small amounts of lubricants should be used for urethral catheterization, and 
use of catheters not requiring lubricants should be considered [32]. The 
effect of distilled water on exfoliated cells from transitional bladder 
carcinoma was compared to the effect of BCG dissolved in either saline or 
distilled water. Distilled water proved to be as effective as BCG in distilled 
water and much more destructive on cells than BCG in saline within 2 hour 
[33].
Until now 12 strains of BCG have been used in immunotherapy of 
superficial bladder cancer Pasteur (Quebec, Canada), Tice (Chicago, USA), 
Connaught (Toronto, Canada), Pasteur (Paris, France), Glaxo (Greenford, 
England), Moreu (San Paulo, Brazil), RIVM (Bilthoven, The Netherlands), 
Tokyo 172 (Tokyo,Japan), Evans (Glaxo, Danish strain), Berna (Italy), 
Taipei-NIMP (Taiwan, China) and a Russian strain. Studies to compare
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different strains have been done. A prospective randomised multicentre 
study showed that there is no difference in side effects or efficiency between 
BCG-TICE and BCG-RIVM [34,35]. Mujkhere et al. studied the Glaxo and 
Pasteur strain of BCG and also found no difference in efficiency [36]. In 
another study, Evans BCG and Pasteur BCG were compared to investigate 
the complete regression of lesions in 97 patients with multiple recurrent Ta, 
T1 tumors and again no significant statistically difference was found [37]. 
The culturing methods also differ, resulting in variable ratio of viable 
organisms on one hand and subcelluler debris and dead bacilli on the other 
hand. Since we do not know which parts of bacilli are responsible for the 
immunologic effects, this ratio might also be important, although Hanna 
demonstrated that BCG components were not effective substitutes for whole 
viable BCG cells to achieve systemic tumor immunity [38]. In another 
study, the antitumor effect of intravesical mycobacterium cell wall (MCW) 
therapy on orthotopic and heterotopic bladder tumors in the mouse was 
assessed with MRI [39]. Treatment with MCW resulted in significant 
inhibition of tumor growth compared with untreated animals (p<0.005) 
although the antitumor effect was less pronounced than that of live BCG. 
Flow cytometric analysis of bladder washings with phenotype-specific 
monoclonal antibodies revealed predominantly a CD3 T cell infiltrate in the 
control and BCG-treated as well as the subset in both the BCG- and MCW- 
treated animals, and the CD4/CD8 ratio in both of the treated groups
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differed significantly from that of the control untreated groups. Intravesical 
MCW appears to invoke a similar inflammatory response in the mouse 
bladder mucosa as the live BCG organism and retains an antitumor action. 
Zolatta et al. pointed out that the antigen 85 complex secreted in BCG 
culture filtrate binds specifically to fibronectin and is a powerful T cell 
stimulus [40]. A major increase in the lymphoproliferative response against 
purified protein derivative, antigen 85, BCG culture filtrate, whole BCG and 
pokeweed mitogen was observed in 69.0, 65.5, 79.3, 48.3 and 65.3% of the 
patients, respectively, analysed after BCG therapy. No correlation could be 
found between the immunological response against any of the BCG antigens 
and the clinical evolution of the response. Intravesical BCG installations 
induce a transient (less than 6 months) peripheral immune activation against 
several purified BCG antigens and among them the fibronectin binding 
antigen 85 complex.
2)The number of colony forming units in the preparation of a BCG strain is 
more important than the dry weight of the preparation. Although the 
antitumor activity increases with the dose, there seems to be an optimal dose 
of 5X108-5X109 CFU. A higher dose results in decreasing antitumor 
activity.
Several studies with lower dose BCG therapy have been carried out 
recently. The results of the first large trail using a low dose regimen (BCG 
Pasteur, 75 mg) in the prophylaxis of tumor recurrences after transurethral
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resection (TUR) of papillary tumors and in the therapy of CIS were 
published in 1991 by Pagano et al [41]. Overall, 70 patients were 
completely treated with a TUR and BCG, 63 were in the control group and 
56 in the therapy group (CIS). In the prophylaxis, control and therapy 
groups, 74, 17, and 57% of patients, respectively, achieved complete 
responses (CR), all with a mean follow-up of 21 months. Tumor progression 
subsequently occurred in 4% of patients in prophylaxis group, 17% of the 
control group (p<0.001) and 12.5% of therapy group. The patients who 
underwent an additional course, 69% of the prophylaxis group and 50% of 
the therapy group achieved a CR. They concluded that the 75 mg regimen 
was as effective as the 150 mg regimen in preventing recurrent superficial 
transitional cell carcinoma (TCC) of the bladder and in treating CIS. In a 
subsequent phase III trial, Pagano et al. randomised patients with multiple 
papillary tumors (Ta-T1 stages) and CIS to receive 75 or 150 mg Pasteur 
BCG during 6 weeks [42]. The time-to-failure curves showed a disease-free 
interval significantly higher in the low dose group compared with the 
standard-dose group. Similar tumor progression rates were reported in both 
groups (9%). Morales et al reported on small number patients with Tis and 
T1 plus Tis, and concluded that these tumors can only be treated effectively 
with a higher dose BCG-Pasteur (120 mg) [43]. Mack and Frick pointed out 
that the low dose (27 mg) BCG-Connaught Canada regimen was effective in 
the treatment of high risk superficial TCC of the bladder in a phase II study
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[44]. Complete responses were similar to those achieved with higher doses 
of BCG. In a study by the CUETO group, 27 mg and 81 mg BCG 
Connaught were compared in a schedule contemplating 6 weekly 
installations followed by 6 fortnightly installations. The primary results 
showed that there is no significance difference in overall reccurence rates 
(22.3 vs. 19.6 %) and progression (4.7 vs. 2.9 %) between the two groups. 
Moreover, when making distinction between the different T categories, a 
trend towards poorer efficacy (although not statistically significant) of the 
low dose was observed in CIS (replacing rate 11.7 % vs. 31.2 % for low 
dose), in the overall progression rate (1.5 % in the standard-dose arm vs. 
4.3% in the low-dose arm) and in particular in T1 G3 tumor progression rate 
(4 vs. 18%) [45,46]. In all these dose reduction studies, the toxicity was 
significantly reduced in the low dose group.
Route of administration
There are 5 routes of administration which have been used for BCG in the 
treatment of superficial bladder cancer: i) Percutaneus administration: Many 
variables in patient selection and treatment program made it impossible to 
estimate the value of this route of administration, although antitumor effect 
was observed [47,48]; ii) Intralesional administration: This has been 
abolished due to serious hypersensitivity reactions and allergic shock 
[47,48]; iii) Oral administration: It was studied by Netto and Lemos in 1984.
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They found a complete response of 70% [49]. Others could not confirm 
these results. Lamm found no measurable antitumor effect of oral BCG in 
the treatment of superficial tumors comparing oral versus intravesical and 
percutaneus administration [50]; iv) Intravesical installations plus 
percutaneus inoculation: With this regime Morales found complete response 
in 50% of the patients using BCG as a prophylactic therapy, in 58% of the 
patients with residual disease, and in 77% of the patients with CIS [51]. 
Other investigators found similar results; v) currently, intravesical 
administration of BCG alone is accepted in most centres to be the best route 
of administration, as percutaneous administration does not increase 
treatment efficacy in three prospective randomised studies [52-54]. The 
significance of the PPD test is borderline, and should not be used as a 
prognostic marker in individual patients [55].
Clinical schedules
The BCG treatment schedule is initially arbitrary and controversy exists 
with regard to the optimal treatment protocol. A variety of different BCG 
treatment regimens have been used that vary in intensity from one weekly 
instillations for 6 consecutive weeks to 24 weekly installations followed by 
instillations bimonthly for 3 months and than monthly for 18 months 
[56,57]. Most urologists use at least an induction course of 6 consecutive 
weekly BCG instillations, as first proposed by Morales [57]. The efficacy of
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the 6-week course of BCG has been widely reported in the literature. The 6- 
week course resulted in tumor-free rates of 63 to 100% after one year and 
55 to 75% after two years, and in an average time to recurrence of 10 to 
22.5 months [58-62]. One course of 6 instillations, however, might not be 
optimal. When patients fail this course two different schemes can be 
followed.
Brosman advocated maintenance therapy [63]; this regimen consisted of 
intravesical instillations once weekly for 6 weeks, biweekly for 3 months, 
and than monthly until recurrence or a maximum of two years. He found 
better response rates than in a 6 week course. On the other hand Badalament 
and Hudson found no significant difference in the reduction of recurrent 
tumors between a 6-week course and maintenance therapy [64,65]. The 
SWOG compared a 6-week induction course to maintenance therapy 
consisting of 3 weekly BCG instillations at 3 months, 6 months and every 6 
months up to 3 years [66]. They demonstrated a significant superiority of 
maintenance therapy, not only in patients with rapidly recurring Ta/T1 
lesions (p=0.000001) but also in patients with CIS (p=0.04). More 
importantly, the maintenance therapy has significantly improved the 
patients’ survival compared to induction only (92 vs. 86% at 4 years, 
p<0.04). In another study, a 6 and 12-week course with 120 mg Pasteur 
were compared for the treatment of high-risk superficial bladder cancer 
[67]. A 70% tumor-free rate and mean interval of 12.9 months to recurrence
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were achieved in the 12 week course compared to 55% and 12.3 months, 
respectively, in the 6 week course with the 12 week course patients had an 
overall longer disease-free survival, although not statistically significant. 
The results showed that the longer BCG course had better overall results. A 
prospective study by a Chilean group reported the same efficacy of 5 
different dose and treatment schedules; 6 weekly instillation with 120 mg 
BCG, 100 mg weekly during 2 months, 50 mg monthly during 12 months, 
20 mg during 12 months, or 1 mg monthly during 12 months [68]. The local 
and systemic toxicity of the maintenance therapy, however, is more severe 
and significantly worse than in other protocols [69].
The second possibility for additional treatment is a second 6-week course in 
patients failing the first course. The response rates could be improved from 
approximately 60% after one 6 week course to approximately 80% after a 
second course without the severe toxicity of the maintenance therapy 
[70,71]. Khana also found that therapy beyond an initial course of 6 weekly 
instillations increased the percentage of complete responses [72]. He 
reviewed 13 other studies and found that the greatest improvement in 
percentage of complete responses occurred with the second course of 
treatment. Therefore, a second course of BCG seems most useful in patients 
who have sustained response to the initial treatment. The value of an 
additional 6-week course in patients who recur after this first course was 
also demonstrated by Sarosdy and Lamm, who studied the long term results
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of BCG therapy [73]. With retreatment of some of the early failures the 
initial success rate of 78% was increased to 89%, with a median follow up 5 
years, suggesting a durable beneficial response after BCG therapy rather 
than a simple delay of tumor recurrence. The re-treatment consisted of a 
second course, followed by maintenance therapy. Coplen et al. reported 
their long term follow up and concluded that one 6-week course may be 
ineffective for some patients, and a second 6-week course provided long 
term tumor free survival for many patients failing the initial course [74]. 
However, in CIS patients failing both courses a significantly higher risk for 
muscle invasion was found. This potential danger of repeated BCG courses 
was also found by Catalona et al., who performed a risk to benefit analysis 
of repeated courses of intravesical BCG [70]. They found that the risk of 
developing invasive cancer or metastasis in patients who failed 2 courses of 
intravesical BCG (respectively 30% and 50%) exceeded the prospects of 
eradicating the superficial tumor with further BCG treatment. In conclusion, 
more than 2 courses might be dangerous with regard to disease progression. 
Some studies have tried to tailor BCG therapy by means of cytokine 
measurement or p53 determination during therapy.de Reijke et al. showed 
evidence for a correlation between urinary cytokine induction and clinical 
response following intravesical BCG therapy for superficial bladder cancer 
[30]. BCG induced cytokine levels were generally highest after instillation 
week 5 or 6. During the first 24 hours after BCG instillation the highest
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concentrations were most frequently observed at 4 or 6 hours after 
instillation. A significant correlation between urinary IL-2 level and tumor 
recurrence was found (p=0.003) at six months. If the threshold for 
recurrence was set at 9 or 12 months instead of 6 months the significance of 
correlation for IL-2 was lost (p=0.090 and p=0.089 respectively). They 
pointed out that especially, monitoring of IL-2 may potentially be of 
prognostic value provided that strict precautions regarding urine collection, 
such as maximal 2-hour sampling and immediate cooling are taken. p53 
overexpression is predictive of TCC progression and survival. The detection 
nuclear p53 over-expression before BCG therapy does not predict response 
to BCG therapy. Pre-BCG p53 protein overexpression, response to BCG 
therapy, and pre BCG tumor stage are all independent markers of disease 
progression. In patients with residual disease after BCG therapy 
(nonresponders), studies confirmed that posttherapy p53 overexpression was 
the only independent marker of disease progression [75,76].
Toxicity
Side effects after intravesical installations with BCG can be divided in local 
side effects, allergic reactions and systemic side effects. In a review 1278 
patients treated with BCG, cystitis-like complaints were found in over 90% 
of the patients [77]. These complications increase with the number of 
installations, but are easily treated with non-steroidal anti-inflammatory
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drugs. Hematuria is seen in 43% of the patients but is seldom severe. 
Systemic side effects such as fever (28%), malaise (24%), and nausea (8%) 
generally subside spontaneously. Severe side effects are seen in about 5% of 
all patients with fever >39.5 C (2.9%), genital infections (1.3%) and 
hematuria (1.0%) as main problems. However, also serious BCG induced 
infections were seen such as BCG pneumonia/hepatitis in 0.7% and BCG 
sepsis in 0.4% [78].
In case of severe irritative bladder symptoms, fever, chills, or malaise, the 
dose should be lowered to half the initial dose, and patients should be 
treated with isoniazid 300 mg daily starting on the day before instillation 
and continue for 3 days or until symptoms resolve [78,79]. In case of severe 
systemic side effects the treatment with BCG should not be continued, and 
antituberculosis combination therapy should be given for 3 months 
(isoniazid 300 mg orally per day, rifampicin 600 mg orally per day, 
ethambutol 1200 mg orally per day). Prednisolone 40 mg per day can be 
added to triple tuberculostatics in case of life-threatening BCG reactions 
[80,81]. In case of acute problems cycloserine (250-500 mg orally twice a 
day) could be given for the first 3-5 days, because it is effective several days 
before the classical combination therapy is [81]. Sparks indicated that 
antituberculous drugs do not seem to interfere with anti-tumor effect of 
BCG in animal studies [82]. van der Meijden et al. showed that there is a 
possible inhibition of antitumor efficacy by antibiotics in general, and
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tuberculostatic agents in particular [83]. They reported the sensitivity of 
different BCG strains for all known antituberculosis drugs. No difference 
between strains was found, and all were very sensitive to these drugs. In a 
prospective randomised multicenter study the side effects of intravesical 
BCG instillations with or without isoniazid were compared in patients with 
stage pTa and pT1 bladder tumors [84]. Isoniazid was given orally in a dose 
of 300 mg daily at every instillation in an attempt to decrease the side 
effects of BCG. No differences in local or systemic adverse reactions after 
intravesical BCG instillations could be observed between patients treated 
with or without prophylactic isoniazid therapy. However, analysis of liver 
function tests after BCG with isoniazid showed slightly more liver toxicity 
compared to BCG alone. They concluded that prophylactic administration 
of isoniazid during BCG instillations provides no decrease in any known 
side effect of BCG. Therefore, the use of prophylactic isoniazid in patients 
treated with BCG is not recommended. Traumatic catherization seems to 
play a role in most of the fatal complications. Therefore, it is strongly 
recommended that if trauma during catheterization occurs, the treatment is 
postponed for one week [85]. A study to analyse quality of life in patients 
undergoing BCG therapy showed that in general, the quality of life of these 
patients is characterised by the disruption of their lifestyle and marked by 
change in their circumstances [86]. It was pointed out that it is the
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responsibility of the urologist to take the necessary time to educate, comfort 
and motivate these patients.
Clinical results
Three different applications have been described in the treatment of TCC of 
the bladder with BCG; prophylaxis after a complete TUR, treatment of CIS 
and treatment of residual tumor. Endoscopic resection remains the first 
choice therapy for bladder tumors. Approximately 60% of endoscopically 
resected superficial bladder tumors, however, recur, usually within the first 
years [69].
In prophylaxis BCG is used to post-pone or prevent recurrences and/or 
progression. The success rate of BCG treatment is between 58% and 100%, 
with a minimal follow-up of one year [69,87,88]. BCG is generally accepted 
as the drug with higher efficacy than chemotherapy when used 
intravesically for therapy in superficial bladder tumors. For thiotepa and 
doxorubicin this seems obvious, because all direct comparisons showed an 
advantage of BCG [89]. Since intravesical chemotherapy, however, has less 
and less severe side effects, this remains a possible interesting approach. 
Moreover, direct comparison of BCG and mitomycin C (MMC) did not 
show a clear advantage of BCG in all studies. Some studies indeed show an 
advantage of BCG over MMC, while others could not confirm these 
differences.
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Lundholm et al. studied intravesical therapy with MMC and BCG in 261 
high risk patients [90]. Both MMC (40 mg) or BCG Pasteur were given for 
up to 3 years. After a median follow up of 39 months 49% in the BCG 
group were free disease, as compared to 34% in the MMC group. In Tis 
patients this difference was even larger (54% versus 33%). The progression 
rate (13%) was similar in both groups. Side effects were, as expected, more 
severe and more frequent in BCG group. In a study of the Finnbladder 
group BCG also appeared to be superior to MMC [91]. In this randomised 
prospective multicentric study frequently recurrent Ta-T1 tumors were 
treated. CR rate, disease free interval and recurrence rate were in favour of 
BCG. In CIS, however, MMC was more effective (58% CR versus 40% 
with BCG). Side effects were more severe in the BCG group.
A third study indicating superiority of BCG was SWOG study 8795, which 
was closed early because of a highly significant difference [92]. In all, 469 
patients were selected with an increased risk for recurrent disease. BCG 
Tice or MMC (20 mg) were given 6 times weekly and monthly thereafter 
for 1 year. In 377 evaluable patients the number of recurrences was 
significantly better in the BCG group (37/190 versus 61/187, p:0.0052), as 
was the time to treatment failure (p=0.006). Grade 1 and 2 toxicity was 
significant higher in the BCG group (74% versus 57%, p<0.001). Grade 3 
and 4 toxicity was similar in both treatment arms.
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Other studies, however, failed to confirm a higher efficacy of BCG, for 
example, in a large German multricentre trail adjuvant MMC or BCG were 
compared with TUR only [93]. Patients pTa grade 1 were excluded. MMC 
(20 mg) was given two-weekly for 1 year, and monthly during the second 
year. BCG (120 mg) was given 6 times weekly and 4 times monthly. At a 
median follow up of 20 months in 337 evaluable patients the relative risk for 
recurrences in the BCG group was 0.618 and 0.508 in the MMC group (not 
statistically significant). The progression rate was estimated at 4.2% per 
year, and comparable in all three groups. Side effects were common in the 
BCG group. Witjes et al evaluated 437 patients with primary or recurrent 
pTa and pT1 bladder tumors, including carcinoma in situ [34]. The number 
of low risk patients (e.g. primary solitary pTa grade 1) was less than 10%. 
The median follow up was 36 months. MMC (30 mg) was given 4 times 
weekly and 5 times monthly, BCG (5X108 CFU Tice BCG or RIVM-BCG) 
was given 6 times weekly. Again toxicity was significantly more frequent 
and more severe in the BCG treated patients. Efficacy with regard to 
recurrence in papillary tumors was the same for MMC and RIVM-BCG 
(p=0.53), but MMC was more effective than BCG-Tice therapy (p=0.01). 
There was no significant difference in efficacy when both BCG strains were 
compared. Results in CIS patients and the progression rate in all patients 
was similar for the three treatment arms, but numbers are small. In another 
study the long term follow up of intravesical BCG-RIVM and MMC was
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compared in a randomised prospective trial in 344 patients [35]. This study 
showed similar efficacy of BCG and MMC. Although MMC seems more 
effective in the prevention of progression in non CIS patients (5/157 versus 
17/147, p=0.006) these numbers are again small.
BCG also has been compared with other immunomodulators. Jimenez Cruz 
et al. enrolled 122 patients with recurrent T1G3 tumors in prospective 
multicentric trial who were randomised to receive either 150 mg Pasteur 
BCG or 54 million units a-2a-IFN intravesically [94]. The incidence of 
recurrences was 39.3% for BCG and 69.3% for IFN with a disease free 
interval of 19.3 and 15.2 months respectively. The recurrence index was 2.2 
for BCG and 5.5 for IFN (p=0.001). In another study the combination of 
BCG and a-2b-IFN showed that this combination therapy is safe and well 
tolerated [95]. Early results in a limited patient group showed high response 
rate. In a randomised comparison of BCG and keyhole-limpet haemocyanin 
(KLH), tumor recurrence was 41% in KLH treated patients versus 14% in 
BCG treated patients [96].
CIS, a preinvasive highly aggressive malignancy, is a difficult disease to 
control. Patients can either have CIS as a primary disease, or have a 
papillary tumor with concomitant CIS. The efficacy of three 
chemotherapeutic agents has been defined in clinical trails: Thiotepa has an 
overall complete response rate of 29%, doxorubicin of 38% and MMC of 
48% [97]. With BCG encouraging results have been described with success
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rates between 42% and 83% after minimal follow up of one year. De Jager 
et al. published long term results in CIS patients from 6 phase II trails [98]. 
119 patients were treated with 6 weekly Tice BCG instillations, followed by 
12 monthly instillations. In all, 90 (75.6%) patients achieved a CR, 
including 45 of 63 patients who failed prior intravesical chemotherapy. 45 
of the responding patients remained free of disease after a median follow up 
of>48 months. Cystectomy rate in the non-responders was significantly 
higher, time to cystectomy significantly shorter. However, there was no 
difference in survival between BCG responders and non responders. They 
concluded that Tice BCG is effective for CIS, with or without prior 
chemotherapy. Harland et al also found “impressive” responses in 53 CIS 
patients after BCG therapy (53% CR after median follow up of 32 months) 
[99]. In the group of responders disease progression occurred in 10% of 
patients, whereas in non responding patients progression was seen in 48%. 
They also concluded that CIS could be successfully treated with intravesical 
BCG, but it remains a dangerous disease. Akaza et al. treated 157 patients 
with papillary bladder tumor and CIS with Tokyo 172 BCG strain, 80 mg 
weekly for eight times [100]. The efficacy was a CR rate of 84.4% and 
partial response (PR) of 6.3% for 32 patients with CIS. In another study a 
total of 115 patients with CIS of the bladder were treated with BCG Pasteur 
F. 25 patients had primary CIS and 90 had secondary CIS with synchronous 
or prior superficial papillary tumors [101]. 22 of the 25 patients (88%) with
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primary CIS responded completely, with negative cytology and cystoscopy 
findings after a median follow up period of 44 months. 3 of the 25 (12%) 
had cytological evidence of disease within 9 months of therapy and were 
considered to be early treatment failures. 70 of 90 patients (78%) with 
secondary CIS had a CR after treatment with BCG, with repeated negative 
cytology and cystoscopy examinations after a median follow up of 40 
months. 20 of the 90 (22%) with secondary CIS had a positive cytology 
within 9 months after BCG therapy and were considered early treatment 
failures. 15 of the 20 failures received a second course of BCG. 4 of these 
patients responded and the remaining 11 also failed the second course. 
Including two patients with T1G3 bladder cancers, four with invasive 
bladder cancer, two with solid urothelial carcinomas of the prostatic urethra, 
and three with Tis of upper urinary tract. According to these data, early 
treatment failure after 6 weekly instillations is an alarming signal which 
requires immediate re-assessment of the patient to exclude a muscle 
invasive bladder cancer or extravesical CIS, either in upper the urinary tract 
or in the prostatic urethra. The presence of CIS in the prostatic urethra can 
be managed with endovesical BCG as initial treatment with fairly good 
success (70-100%) [102-104]. There is no need for TUR, even though a 
loop biopsy may have to be obtained at the first control examination to 
make sure there is no stromal invasion [102].
Intravesical BCG 152
BCG also can be used to eliminate residual tumor after an incomplete 
endoscopic resection or in patients who are unfit for surgery. The number of 
tumors seems of no consequence as long as they are small and accessible to 
the action of BCG. Success rates of approximately 60-70% were found 
[105,106]. Intravesical BCG therapy for the treatment of muscle invasive 
transitional cell carcinoma of the bladder is ineffective [107].
BCG is not indicated for low and intermediate risk patients, in whom 
chemotherapy is the first choice because of less frequent and less severe 
side effects. BCG is also contraindicated in patients with invasive bladder 
carcinoma =T2, in immunocompromised subjects such as HIV-positive 
patients, those with congenital immunodeficiency syndromes or patients 
undergoing immunosuppresive treatment, in patients harbouring other 
progressive malignancies, leukaemia or Hodgkin’s disease, in patients with 
active tuberculosis and in pregnant and/or lactating women [108].
Based on several trails reported by the EORTC Genitourinary Group, the 
following conclusions can be drawn [109]; 1) in patients with a low and 
intermediate risk for recurrence MMC and BCG are equieffective in 
preventing recurrence [110,111], whereas in patients with high risk for 
recurrence (concomitant CIS, T1 lesion, =3 recurrence/year) BCG is 
superior to either MMC or doxorubicin [92,112]; 2) primary treatment of 
CIS is best performed with BCG [113]; a maintenance schedule is superior 
to a single week course [114]; BCG can be successful as second line
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treatment after intravesical chemotherapy has failed to achieve complete 
tumor response [109].
Summary and conclusions
The mechanisms by which BCG exerts its antitumor activity remain unclear. 
Attachment of BCG to the bladder via FN has been demonstrated as an 
important step in initiating its antitumorigenic activity. The mechanism(s) 
by which BCG operates require LAK cells, BCG activated killer cells, T 
lymphocytes (CD4 helper cells and CD8 suppresser/cytotoxic cells) and 
monocytes. The optimal route of administration is the intravesical. The 
efficacy of a BCG vaccine depends on the viability, dose and strain. 
Differences in efficacy and side effects have not been shown between 
different strains. Low-dose regimens give successfully protect from 
recurrences, with fewer side effects. The initial schedule of BCG is a course 
of 6 instillations in 6 weeks; when the patients fail this course, two 
possibilities arise. The first is maintenance therapy; response rates improve 
but there is more local and systemic toxicity. The second is a further 6-week 
course, and this seems most useful in those with a sustained response to the 
initial treatment. The clinical response to BCG therapy can be monitored 
using cytokine measurement or p53 determination. Toxicity remains a major 
problem in BCG treatment and triple antituberculosis combination therapy 
should be given for 3 months in those with severe systemic side effects. The
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use of prophylactic isoniazid is not recommend to decrease side effects. The 
clinical results of BCG have been good, with success rates of 58-100%, with 
a minimal follow-up of one year in prophylaxis. BCG seems superior to 
intravesical therapy, but at the cost of inducing more adverse effects. BCG 
is not indicated for low- and intermediate-risk patients, in whom 
chemotherapy is the first choice. BCG can also be used to eliminate tumor 
after an incomplete TUR, or in patients who are unfit for surgery with a 60­
70% success rate. The primary and best treatment for CIS is intravesical 
BCG; encouraging results have been reported, with success rates of 42- 83% 
after a minimal follow up of one year. Although currently BCG seems to be 
the choice for high risk superficial TCC, many questions remain 
unanswered, especially about the mechanism(s) of action, the optimal dose 
and clinical schedule.
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II- RESULTS OF A RANDOMIZED PHASE III TRIAL OF 
SEQUENTIAL INTRAVESICAL THERAPY WITH 
MITOMYCIN-C AND BACILLUS CALMETTE-GUERIN 
VERSUS MITOMYCIN-C ALONE IN PATIENTS WITH 
SUPERFICIAL BLADDER CANCER.
Introduction
There is a high recurrence rate of superficial transitional cell carcinoma (TCC) 
of the bladder after transurethral resection (TUR) of the initial tumour. In an 
attempt to reduce the number of recurrences adjuvant therapy after TUR has 
become common practice in subgroups of patients at an intermediate or high 
risk of tumour recurrence. For this purpose, several dosages and schedules of 
intravesical chemotherapy have been used. There is a clear initial effect on the 
recurrence rate, but this positive effect seems to disappear after 5 years of 
follow up [1], although a recent metanalysis indicated that even after a median 
survival follow up of 7.8 years there was an ongoing reduction in the 
recurrence rate after intravesical chemotherapy as compared to no additional 
therapy [2]. Another possibility is the use of intravesical bacillus Calmette- 
Guerin (BCG). BCG is considered to be the most effective drug to reduce the 
number of recurrences, especially if more than one course of 6 instillations or 
maintenance therapy is used. BCG, however, has more frequent and more 
severe side effects, often increasing with the number of instillations. 
Therefore, BCG is generally reserved for intermediate and high risk patients.
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In an attempt to improve the efficacy of intravesical therapy, recently 
intravesical chemotherapy and BCG have been combined [3-6]. These so 
called sequential or alternating therapies have several rationales. Since 
intravesical chemotherapy and BCG have different working mechanisms, there 
might be a potentiation of antitumour effect from these two modalities. 
Increased efficacy with chemotherapy preceding immunotherapy has been 
demonstrated in animal experiments in various tumours [7-9]. Secondly, 
intravesical chemotherapy causes a chemical cystitis which might have a 
positive effect on the adherence of BCG particles to the bladder wall, a 
necesarry first step in the working mechanism of BCG [10,11]. On the other 
hand, however, a combination of a chemotherapeutic drug and BCG might 
also enhance the toxicity. Therefore, we studied the incidence and severity of 
side effects as well as the treatment efficacy of a sequential treatment of 
Mitomycin-C (MMC) and BCG as compared to the use of MMC alone in a 
multicentre prospective randomized phase III trial with intermediate and high 
risk superficial bladder cancer patients.
Material and Methods
Patients with histologically proven primary multiple (> 2 tumours) or recurrent 
multiple (> 2 tumours) stage pTa or pT1 TCC, patients with solitary or 
multiple GIII tumours and patients with primary or concomitant CIS of the 
bladder were included in the study. These patients are considered to be at an 
intermediate or high risk for recurrence and/or progression. Patients were 
ineligible in case of previous radiotherapy and intravesical or systemic
Intravesical BCG 168
chemotherapy within 3 months of registration. The presence of a second 
primary malignancy or TCC of the upper urinary tract or in the prostatic 
urethra were also exclusion criteria. In case of TCC of the prostatic urethra 
patients were eligible after fractionated TUR of the prostate.
After complete TUR of all visible lesions and random biopsies of normal 
appearing mucosa, patients were randomized in 1 of the 2 treatment groups. In 
group 1, intravesical chemotherapy with MMC (MutamycinR Kyowa, 40 mg 
in 50 mL saline) was administered once a week for 4 consecutive weeks, 
followed by intravesical immunotherapy with BCG-Tice (OncoticeR Organon 
Teknika, 5x108 bacilli in 50 mL saline), once a week for 6 weeks. In group 2, 
40 mg MMC in 50 mL saline was given once a week during 10 consecutive 
weeks. Instillations were started between 7 and 15 days after the TUR. After 
completion of the instillation therapy, patients were followed every three 
months by urine cytology and cystoscopy until recurrence occurred.
Side effects were divided in local, allergic and systemic side effects. Local 
toxicity was defined as the occurrence of culture proven bacterial cystitis, 
chemical or drug induced cystitis or other local side effects such as 
haematuria, prostatitis or epididymitis. In case of bacterial cystitis the patient 
was treated with antibiotics and the instillations were postponed until the urine 
culture was negative. The severity of side effects was classified in three 
categories: requiring no delay of treatment, requiring delay or requiring 
cessation of instillation therapy. Side effects were investigated by complaints 
registration, physical examination and blood and urine analysis.
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Tumour recurrence had to be proven by biopsy. In case of positive cytology 
without appearance of a papillary tumour, random biopsies were done, to 
diagnose or exclude CIS. In case of a recurrence, the patient went off study 
and further therapy was left to the discretion of the individual urologist. After 
going off study, patients were followed for survival.
For evaluation of the "test" results the chi-square test was used. For evaluation 
of the follow up data the log rank method was used in combination with the 
Kaplan Meier representation.
Results
From January 1991 till November 1993 182 patients from 17 centres of the 
Dutch South East Cooperative Urological Group entered the study. A total of 
90 patients were allocated to group 1 (sequential therapy, MMC plus BCG) 
and 92 to group 2 (MMC alone). Toxicity data of all patients are available. 
Patients' characteristics and tumour characteristics (Table I and II) are similar 
in both treatment arms.
For bacterial cystitis, chemical cystitis and other local side effects the 
difference between the two groups was not significant. Allergic reactions, 
including skin rash, were more frequent in group2 (p=0.08), whereas other 
systemic side effects were more frequent in group 1 (p=0.07) (Table III). 
There were 29 occurences of other systemic side effects in 16 patients in group 
1 compared to 30 occurences in 8 patients in group 2 (Table IV).
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Table I. Tum or characteristics of evaluable patients per treatm ent group.
Group 1 Group 2 Totals
No. Pts 90 92 182
pTa
G1 18 13 31
G2 23 16 39
G3 2 7 9
+CIS 3 4 7
pT1
G1 1 3 4
G2 19 28 47
G3 16 16 32
+CIS 8 17 25
primary 62 67 129
recurrent 28 25 53
primary CIS 18 15 33
Total CIS 29 36 65
Table II: Tum or characteristics of evaluable patients with prim ary 
tumors per treatm ent group
Group1 Group 2 Totals
No. Pts. 62 67 129
pTa
G1 6 6 12
G2 15 13 28
G3 1 3 4
+CIS 3 3 6
pT1
G1 1 1 2
G2 17 26 43
G3 14 11 25
+CIS 7 13 20
Side effects. Local and systemic side effects are shown in Table III.
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Table III: Local and systemic toxicity during instillation period.
Group 1 Group 2 p-
value
No. pts. 90 92
No. Instillations 860 876
No. pts.
without side effects
29
(32%, 95% CI 22-42)
38
(41%, 95% CI 31-51)
0.20
Bacterial cystitis
23
(26%, 95% CI 17-35)
15
(16%, 95% CI 9-23)
0.13
Chemical cystitis
37
(41%, 95% CI 31-51)
29
(32%, 95% CI 22-42)
0.18
Other local side 12 9 0.45
effects (13%, 95% CI 6-20) (10%, 95% CI 4-16)
Allergic reactions
5
(6%, 95% CI 1-11)
12
(13%, 95% CI 6-20)
0.08
Other systemic side 16 8 0.07
effects (18%, 95% CI 11-25) (9%, 95% CI 3-15)
CI = 95% confidence interval
Table IV: O ther systemic side effects
Group 1 (16 pts.) Group 2 (8pts.)
temperature rise >38.5oC 11 Tired 9
general malaise 11 not specified 7
hot flushes 2 back ache 6
headache 2 pain not specified 4
dizziness 1 temperature rise 3
>38.5oC
tired 1 fear 1
nausea 1
Total 29 Total 30
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The severity of side effects is shown in table 5, and is not significantly 
different for either group (Table V).
Table V: Severity of side effects.
Group 1 Group 2
Bacterial cystitis 23 15
Therapy delay 7 8
Therapy cessation 2 3
Chemical cystitis 37 29
Therapy delay 3 6
Therapy cessation 1 0
Allergic reactions 5 12
Therapy delay 0 1
Therapy cessation 1 5
Systemic side effects 16 8
Therapy delay 2 3
Therapy cessation 1 1
Efficacy. The median follow up is 32 months (range 2 to 65). Recurrences 
were seen in 77 of 182 patients (42.3%, 95% confidence interval [CI] 35% to 
49%), including 35 (39%, 95%CI 29% to 49%) in group 1 and 42 (46%, 95% 
CI 36% to 56%) in group 2 (p=0.36, chi-square test, see figure 1).
At the end of this analysis 39 patients were still at risk for recurrent disease in 
group 1 and 43 in group 2. Median time to the first recurrence did not 
differ.significantly (43.7 months in group 1, not reached yet in group 2).
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Figure 1. Kaplan Meier curves for recurrent free survival (p=0.53 Log 
R ank test).
Progression to an invasive TCC of the bladder was seen in 9 patients (4.9%, 
95% CI 2% to 8%) of the total group, including 5 in group 1 (6%, 95% CI 1% 
to 11%) and 4 in group 2 (4%, 95%CI 0% to 8%) (p=0.70, chi-square test). In 
group1, 21 (23%, 95% CI 14% to 32%) and in group 2, 14 (15%, 95% CI 7% 
to 22%) patients died (p=0.16, chi-square test). Causes of death in group 1 
(n=21) were disease related in 5 (2 malignancies, 3 cause not specified), not 
disease related in 13 (2 other malignancies, 1 pulmonary, 4 cardiovascular and
6 cause not specified), and cause unknown in 3. Causes of death in group 2
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(n=14) were disease related in 8 (1 malignancy, 7 cause not specified), not 
disease related in 5 (cause not specified) and cause inknown in 1.
Discussion
The sequential use of chemotherapy and immunotherapy has some theoretical 
advantages and disadvantages. The advantages might be the combination of 
different working mechanisms with possible potentiation of antitumour effect 
or synergism from two drugs. Increased efficacy with chemotherapy preceding 
immunotherapy has been demonstrated in various (animal) tumour models [7­
9]. In the clinical situation promising effects were achieved in several tumours. 
In patients with metastatic renal cell carcinoma treatment with interferon 
alpha-2a and vinblastine resulted in a objective clinical response in 27.7%, 
although toxicity was considerable [12]. In patients with advanced cervical 
cancer interferon-alpha and doxorubicin was shown to have increased efficacy 
[13]. A combination of interleukin-2 and dacarbazine in 25 metastatic 
melanoma patients showed clear activity, but not more than could be expected 
of interleukin-2 alone [14].
In superficial bladder cancer the intravesical route of administration might 
have a second advantage. A chemotherapeutic drug causes a chemical cystitis 
with an increase in the fibronectin (FN) activity [15] which can have a positive 
effect on the adherence of BCG particles to the bladder wall. Kavoussi et al., 
for example, found that chemical disruption of the urothelium caused by the
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use of adriamycin prior to BCG, increased the FN mediated BCG attachment 
to the murine bladder mucosa [16]. It is known that BCG attachment to FN is 
an important first step for the development of an immune response and 
antitumour activity [10].
A disadvantage could be that intravesical combination of a chemotherapeutic 
drug and BCG might also enhance the toxicity, since attempts to improve the 
efficacy of intravesical BCG with more courses or maintenance intravesical 
therapy cause more frequent and more severe side effects. Intravesical BCG in 
case of a cystitis is generally not advised, because the likelihood of increased 
adverse effects.
In an animal model the combination of intravesical MMC and intravesical 
BCG was studied for the immunological effects [17]. Four weekly instillations 
with MMC were followed by 6 instillations with BCG. Several immunological 
parameters (PPD skin reaction, local inflammatory reaction of the bladder 
wall, BCG granulomas in the iliac lymph nodes, adherence of BCG to the 
bladder wall) appeared to be similar in the MMC/BCG treated guinea pigs as 
compared to those treated with 4 instillations of saline followed by BCG. 
These authors concluded that MMC did not potentiate the immune response of 
BCG, but that a possible increased antitumour activity was more due to the 
separate activity of both drugs.
The clinical experience with sequential intravesical chemo-immunotherapy in 
patients with bladder tumours is limited.
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Serretta et al. performed a pilot study on the use of intravesical sequential 
combination therapy of epirubicin and interferon alpha-2b in high risk patients 
[3]. Four treatment groups were compared. After a mean follow up of 12 
months 32 patients (51.6%) showed a recurrence. The recurrence rate was 
higher in the low dose groups (NS). No serious side effects were seen. In 12 
patients (19.3%) mild to moderate chemical cystitis was seen. This 
combination appears to be safe, efficacy cannot be judged.
A combination of intravesical IFN alpha-2b and epirubicin was compared to 
IFN alpha-2b monotherapy in 85 patients with superficial bladder cancer [18]. 
50 MU of IFN was given weekly for 8 weeks, biweekly for 4 months, and 
finally monthly for another 4 months. In the combination group 80 mg 
epirubicin was given 0, 24 and 48 hours after TUR, whereafter the patients 
received the same schedule of IFN. The efficacy of IFN-alpha 2b was 
confirmed and the combination with early epirubicin instillations further 
reduced the percentage of recurrences and improved the disease free interval. 
The Finnbladder group conducted 2 studies comparing MMC alone with an 
alternating MMC/BCG schedule in patients with CIS [4] or rapidly recurring 
papillary tumours [5]. After TUR (papillary lesions) or biopsy (CIS) 5 MMC 
(20-40 mg) instillations were given: the first within 48 hours, followed by 4 
weekly instillations. After these 5 instillations 11 monthly and 4 tri-monthly 
instillations were given. In group 1 only MMC was given, in group 2 MMC 
and BCG (75 mg Pasteur strain) were alternated. In both studies the side
Intravesical BCG 177
effects in the MMC/BCG group were similar to those in the MMC group, but 
side effects of the alternating schedule were fewer compared to BCG 
monotherapy. In CIS patients the alternating schedule was significantly more 
effective than MMC alone with regard to the CR rate (74% versus 47% at 24 
months, p=0.041), disease free interval (p=0.043) and recurrence rate (0.922 
versus 1.834, p=0.013) [4]. Efficacy results in papillary tumours, however, 
were equal in both arms [5].
A similar approach as in our study was used to study the effect of sequential 
therapy in patients on a marker lesion [6]. Here 35 patients were treated on a 
weekly basis with 4 instillations MMC follow by 6 instillations with BCG- 
RIVM. In these patients all tumours except one were resected before the 
instillation therapy was started. Side effects during the treatment period were 
similar to those reported earlier with MMC and BCG alone. Complete 
response to therapy, determined 2 weeks after the last instillation, was found in 
19 patients (confirmed histologically in 16). Only 1 patient showed 
progression. It was concluded that the sequential treatment appeared to be safe 
with regard to toxicity and efficious as an ablative therapy.
Results from this study show that the combination of 4 instillations with MMC 
and 6 with BCG has comparable toxicity as 10 instillations of MMC alone 
with regard to bacterial cystitis, chemical cystitis and other local side effects. 
Allergic reactions, a well known side effect of MMC [19], were more frequent 
(p=0.08) in group 2 than in group 1. Since the number of MMC instillations in
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group 2 was lower (4 versus 10), this seems logical since the skin rash caused 
by MMC is a type IV hypersensitivity reaction which needs several challenges 
with MMC to develop. Other systemic side effects, that can be expected with 
BCG, were seen more often in group 2 (p=0.07).
We also compared the 6 week BCG instillation period of group 2 with a 6- 
week BCG therapy from one of our previous trials [20], in which no 
pretreatment was done (Table VI).
Table VI: Side effects during 6 weeks of BCG-Tice with (this study) and 
without (previous study) MMC pretreatm ent.
No. Pts (%)
Present Study Previous Study 20
Total 90 140
bacterial cystitis 23 (26%) 38 (27%)
chemical cystitis 37 (41%) 42 (30%)
other local side effects 12 (13%) 23 (16%)
allergic reactions 5 (6%) 3 (2%)
systemic side effects 16 (18%) 38 (27%)
The number and severity of side effects caused by BCG were not significantly 
different, indicating that BCG related toxicity does not seem to increase when 
BCG instillations are started directly after a period of intravesical 
chemotherapy. With regard to treatment efficacy, the results did not reveal any 
differences for the number of recurrences (p=0.36), the time to first recurrence 
(p=0.53), progression (p=0.70) or survival (p=0.16). Follow up in the current 
trial, however, is relatively short.
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Conclusion
The sequential use of intravesical BCG and MMC has no advantage over the 
use of intravesical MMC alone in intermediate and high risk superficial 
bladder cancer patients with regard to tumour recurrence and progression. 
There was also showed no major differences between the 2 treatment groups in 
regard to toxicity, although allergic reactions were more frequent in the MMC 
treated patients, whereas other systemic side effects were more frequent in the 
sequential arm.
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Introduction
Superficial bladder tumours have a high tendency to recur after transurethral 
resection (TUR). Since superficial bladder cancer is a heterogeneous disease, it 
may be difficult to predict which patient will develop a recurrence and which 
one will not. With the help of prognostic factors, such as stage, grade, 
multifocality, tumour size, previous bladder tumours and positive biopsies, it is 
possible to identify three groups of patients. A minority of patients has a 
relatively benign type of superficial transitional cell carcinoma (TCC), with 
low recurrence rate. These low risk tumours are the primary, small, solitary, 
well to moderately differentiated pTa tumours. In such a patient adjuvant 
treatment seems to be unnecessary or one immediate instillation with a 
chemotherapeutic agent can be given [1,2]. However, recently community 
practice in the US was studied, and it appeared that the use of BCG for low 
grade TCC is rather common with significant side effects on a repeated course 
[3]. The largest group consists of patients who develop a superficial 
recurrence, but seldom progression. Adjuvant treatment, such as intravesical 
chemotherapy, may be given to decrease the recurrence rate, with the hope to 
prevent or delay tumour progression. A small group of patients, finally, has 
already a relatively malignant superficial tumour at presentation and will 
develop invasive cancer despite maximal intravesical treatment (BCG). It is 
important to select these high-risk patients as early as possible.
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Principles of intravesical prophylaxis and therapy
The mechanism of action for prophylactic intravesical chemotherapy remains 
unclear [4]. For example, regular instillations might be practical, but probably 
not ideal from a molecular biologic (cell cycle) point of view.
The drug is dissolved in sterile water, that provides better results as a diluent 
than saline [5]. The effect of the pH of the solution is not well known. 
Theoretically the pH can influence the stability and efficacy of the drug. The 
colony forming ability of the cell line, for example, was lowest at a pH of 5.5 
for thiotepa and at a pH of 7.0 for ADM and MMC [6]. Cell line sensitivity 
under different acidic conditions was specifically studied for MMC [7]. 
Although these results also indicated a clear relation between acidity and 
cytotoxicity of MMC, in this study MMC was most effective under acidic 
conditions (pH5.8-6.0). Wientjes and Badalament used known 
pharmacokinetic data to develop a computer model to predict the antitumour 
effect of MMC [8]. The therapeutic outcome of MMC was influenced by: dose 
> residual volume > urine production > dosing volume > urine pH > dwell 
time. They hypothesized that under optimal conditions the efficacy of MMC 
could be improved by 20%, increasing the average recurrence free rate from 
56 to 76%.
Although cytotoxicity is proportional to drug concentration and exposure time, 
longer instillation time might increase toxicity and it is unpractical [9]. This is 
also true for continuous low dose intravesical infusion, which in animal
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experiments was shown to be significantly more effective than intermittent 
instillation [10]. An advantage of the intravesical route of administration is that 
there is no or little systemic uptake of the drug (only in case of a molecular 
weight of less than 400) and that there is an optimal contact between the 
tumour or tissue at risk and the drug. Disadvantages are the local side effects 
in the bladder because of the high local drug concentration and the need for 
transurethral manipulation.
In conclusion, although chemotherapeutic drugs have been used 
intravesically for decades, pharmacokinetics can probably still be improved.
Thiotepa
Usually 30 to 60 mg is used, although 30 mg in 30 ml seems to be as effective 
as 60 mg in 60 ml [11]. The use of 60 mg in 30 ml, however, seems to increase 
the dose rate to the tumour without increasing systemic toxicity [12]. After 6 
weekly instillations generally treatment is continued for 1 year with monthly 
instillations.
Although the moleculer weight as low (189), thiotepa induced 
myelosuppression is considered to be rare, usually mild and transient [13]. 
White blood cell count (>4000/mm3) and platelet count (>100,000/mm3) 
should be controlled before and during treatment and treatment should be 
delayed if necessary. Chemical cystits is another side effect and is seen in 
approximately 14% [14].
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Combining the results of thiotepa as definite therapy from two reviews, the 
success rate is approximately 38% (109/285) in 10 small series [15,16]. 
Single adjuvant instillations with thiotepa have been used after a complete 
TUR. The Medical Research Councel (MRC) conducted a large randomized 
trial with 379 eligible patients, comparing immediate thiotepa instillations 
(30 mg) versus immediate followed by 4 three-monthly instillations versus 
controls [17]. They found no advantage in either of the treatment groups 
(p=0.4 and p=0.7). These findings were confirmed with long-term follow-up 
[18].
When thiotepa as used as adjuvant (non) maintenance therapy after TUR, 
complete response rates between 35% and 45% [19]. The National Bladder 
Cancer Group found success rates of 66% and 54% after 12 and 20 months 
respectively, versus 40% and 28% for controls [11]. With longer follow up of 
48 months, however, only 16 of 45 patients treated with thiotepa remained 
disease free, compared to 11 of 45 controls [20]. Disease progression was seen 
in 8 and 5 patients respectively.
Lamm compared the recurrence rate of thiotepa (45%) to the recurrence rate in 
control groups (62%) in a series of 10 controlled studies with 1009 patients 
[21]. Apart from the fact that, these results depended on the follow up period,
5 of the 10 series failed to reach statistical significance, including the three 
largest series, such as the MRC study, described above. Another large series, 
EORTC study (30751), also failed to show a statistical difference in disease
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free interval between thiotepa, controls and the third study arm 
epipodophyllotoxin (intravesical VM 26) [22]. However, the recurrence rate of 
the treated patients was significantly better than the control group.
Novak et al. treated 409 patients with TUR alone, TUR and thiotepa (6 
instillations) or TUR and BCG [23]. Although the recurrence (41.9% versus 
56,7%) and progression (16.9% versus 19.8%) rate in the thiotepa group was 
better than in the TUR group, the difference was not significant.
In two controlled studies thiotepa was compared to ADM. The first used a 
schedule of 15 instillations in 1 year with thiotepa, ADM and BCG in 176 
patients [14]. After a median follow up of approximately 3 years, 
chemotherapy was significantly less effective than BCG, but both 
chemotherapeutic drugs were equally effective. The success rates for BCG, 
ADM and thiotepa were 86.6%, 56.6% and 64.3% respectively. In the second 
study a similar instillation schedule with thiotepa, ADM and cisplatin was 
used in 184 patients [24]. No significant difference in efficacy between the 
three groups was found.
In conclusion of thiotepa is better than no additional therapy, although not 
always statistically significant. Thiotepa is not used frequently anymore due to 
its toxicity and limited efficacy.
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Doxorubicin hydrochloride (Adriamycin, ADM)
The dose of ADM ranges from 30 to 100 mg in several instillation schedules. 
ADM has a relatively high molecular weight of 580, thus absorption and 
systemic toxicity are extremely rare.
The main side effect of ADM is chemical cystitis in 25-30% of the patients 
[25,26]. Rare side effects are allergic reactions (0.3%), gastrointestinal side 
effects (1.7%) and fever (0.8%). Most side effects, however, are mild and 
disappear after cessation of therapy.
The response rates of ADM used as definite treatment for papillary tumours, 
varies between 28 and 56%, with an average of 38% (273/712), depending on 
the dose used [16]. For CIS the complete response is only 34% and the median 
time to treatment failure is reported as only 5 months [27].
In four large controlled studies where ADM was used as prophylactic, the 
percentage of patients with a recurrence in the ADM groups was 38%, versus 
56% in the control groups, indicating an advantage for ADM of 18% [21]. 
However, the three largest series showed no significant advantage for ADM. 
For example, in a study in which 268 patients after TUR were randomized for 
no further treatment, 12 bi-weekly instillations and 1 year of ADM treatment, 
there was no significant difference for the recurrence rate, progression and 
survival between the three groups [28].
Garnick et al. used an escalating dose schedule, with 60 to 90 mg ADM with 
12 instillations and increasing intervals between the treatments [29]. After a
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median follow up of 18 months, 53% of the patients remained free of 
recurrence. Flamm compared a course of 6 weekly instillations of 50 mg ADM 
with maintenance therapy (additional monthly instillations for 2 years) [30]. 
Both treatment arms were equally effective, indicating that ADM maintenance 
therapy is of no additional value. In another study the efficacy results of long 
term ADM treatment (42 instillations of 50 mg in 3 years) were the same as 
treatment with MMC in different long-term schedules [31].
The Japanese urological cancer research group conducted a series of large 
randomized trials on prophylactic intravesical therapy. In the first study only 
short-term schedules were used, with two different doses of ADM, MMC and 
controls [32]. In all, 575 patients were evaluated. The disease free rates were 
significantly better in the 20 mg/40 ml ADM group and in the MMC group 
(p<0.05). In a second study, the same drugs and the same dosages were used, 
but now a 2 year maintenance schedule was used with 18 instillations [32]. In 
all, 607 patients were evaluable. In all treatment groups a significant reduction 
in recurrence rate was observed (p<0.05). The results of both studies were 
comparable, suggesting no advantage of the maintenance therapy. In another 
Japanese study, patients receiving long-term (21 instillations in 2 years) 
therapy were compared to a group receiving 6 instillations with ADM in the 2 
weeks prior to TUR [33]. The results in 284 evaluable patients showed no 
prophylactic effect of the preoperative instillations as compared to controls.
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Adjuvant instillations were significantly more effective than no treatment 
(p<0.01) or pre-TUR treatment (p<0.05).
In conclusion, ADM is a safe drug with almost no systemic side effects. ADM 
is more effective than no adjuvant treatment, but again these figures often are 
not significant. ADM maintenance is clearly of no additional value.
Epirubicin (EPI)
The dose of EPI varies from 20 to 80 in several instillation schedules. The 
antitumour effect of EPI is similar to ADM. Toxicity is mild and not causing 
discontinuation of therapy. The relative absence of side effects, even when the 
intravesical instillation is given immediately after the TUR, can be explained 
by the finding that even under those circumstances the absorption of EPI is 
very limited due to moleculer weight [34]. Chemical cystitis was reported in 
14% patients in a large series by Burk et al [35]. In the EORTC study (30863) 
with a single instillation of 80 mg of EPI, the frequency of drug induced 
cystitis was also only 6.8% [2]. In the same study the recurrence rate was 
significantly less in the EPI group (p<0.0001) as compared to an instillation 
with sterile water. For patients with solitary pTa grade 1 tumours EPI was of 
no benefit. The efficacy of one early (<24 hours after TUR) instillation was 
also studied with 40 mg/40 ml in 119 patients [36]. Again, the yearly 
recurrence rate was significantly less in the treated group (0.13 versus 0.29) 
with mild toxicity (13.8% bladder irritation).
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One of the early large randomized clinical trials compared EPI to doxorubicin 
[37]. Thirty mg/30 ml of both drugs was used during 1 year (19 instillations) in 
114 evaluable Ta/T1 patients. The tumour free rates at 1 and 2 year were 
92.8% and 88.6% for EPI, and 86.4% and 81.7% for ADM respectively (not 
significant).
Recently an instillation scheme of 6 instillations in 10 days was given with a 
new EPI formulation (epirubicin-RTU, 60 mg/30 ml) in 20 patients with 
superficial bladder tumours [38]. Of the 18 patients that completed this course 
12 complete responders were seen. Side effects were frequent (pollakysuria in 
17/20; pain in 17/20; hematuria in 16/20), but all reversible and tolerable.
In another study, 45 patients with primary superficial bladder cancer were 
treated with EPI 20 mg every second week for 4 months and then once a 
month or every 2 weeks for the next 8 months after TUR. The overall 
recurrence free rate was 76.1% and 52.3% at 2 and 5 years and these results 
were better than patients treated with TUR alone [39]. In a randomized UK 
study, the difference in response to high and standard doses of intravesical EPI 
of a marker tumor was determined [40]. No difference in the marker response 
rate was found.
The additional value of EPI (40 mg) maintenance was also studied in 138 
patients [41]. Six initial instillations in 4 weeks were followed by 11 additional 
monthly instillations in half of the patients. Maintenance therapy did not 
improve the efficacy.
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In a conclusion, the efficacy of EPI and results of maintenance therapy with 
EPI seems similar to other chemotherapeutic drugs, however, with less drug 
induced cystitis.
Valrubicin (AD32).
AD32 is a derivative of the anthracycline doxorubicin [42]. In patients with 
BCG-refractory CIS or recurrent papillary tumours of the bladder that have 
failed other intravesical therapies and refuse cystectomy, AD32 has been used. 
In a dose ranging trial, 29% complete response during twelve months was 
reported in patients with CIS [43]. Disease free rates were 32% and 15% 
respectively, at 6 and 15 months in 170 patients with BCG refractory CIS [44]. 
As the studies are limited in number, it is not yet possible to make definitive 
statements about AD32.
Pirarubicin
Another anthracycline under investigation is piraribucin. An initial study 
comparing 20 mg of ADM, EPI, pirarubicin and a control group, showed no 
significant difference in efficacy for the three drugs used, although pirarubicin 
failed to show a significant advantage over the control group [45]. Another 
study also showed no significant advantage of pirarubicin (20 mg/40 ml) over 
no treatment [46]. However, the optimal dose and instillation time recently 
were found to be 30 mg/30 ml during 30 minutes [47].
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Mitomycin C (MMC)
The dose varies between 20 and 60 mg per instillation. MMC has a molecular 
weight of 329 and it is hardly absorbed. Myelosuppression is rare (0.7%). For 
the intravesical route of administration, the most frequent side effects are 
chemical cystitis and allergic reactions. The incidence of chemical cystitis 
ranges between 6 and 41%, with a mean of 15.8% (97/613) [25]. In case only a 
single or 4 three-monthly instillations are used, drug induced cystitis seems 
much less frequent [48]. Allergic reactions are mainly skin symptoms, which 
are seen up to 9.8% of patients treated with intravesical MMC instillations 
[25]. Most skin reactions are due to a delayed type hypersensitivity reaction, 
usually occurring after the second instillation [49]. Most side effects disappear 
after cessation of therapy. Although reports of bladder wall calcifications are 
rare in literature [35], we have seen several patients with calcifications at the 
site of the TUR after MMC, usually without apparent symptoms.
The overall success rates for MMC in the treatment of papillary lesions is 43% 
(270/627) and for CIS 58% (51/88) [50]. With MMC also marker lesions 
studies have been done. In an EORTC study (30864), the complete response 
rate for the marker lesion after 8 instillations with 80 mg of MMC was 50% 
(48/96) [16]. In one patient progression in stage was seen. In a subsequent 
EORTC marker lesion study (30897) with sequential MMC and BCG, 4 
weekly MMC instillations prior to TUR for low stage, low-grade recurrent 
bladder tumours gave a complete response of 69% [51].
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For prophylactic use, after complete TUR, Lamm reviewed five controlled 
trials with 859 patients [21]. The advantage of MMC was 15% (52% 
recurrences in the control groups versus 37% in the MMC group). This 
advantage of MMC was mainly due to a large MRC series, because in three of 
the remaining four series the difference was not significant. In this MRC series 
patients were randomized after complete TUR between no adjuvant treatment, 
one immediate instillation with 40 mg of MMC and one immediate and 4 
subsequent three-monthly MMC instillations [48]. With a median follow up of
7 years and 397 evaluable patients 1 and 5 instillations with MMC resulted in 
a decreased recurrence rate in all risk categories. Five instillations seemed to 
offer a slight advantage to 1 instillation. The effectiviness of a single 
immediate MMC instillation in patients with low risk superficial bladder 
cancer with short and long term followup was studied by Solsona et al. [52]. In 
this prospective controlled trial, 131 patients received no or one immediate 
instillation of 30 mg MMC after complete TUR. Recurrences developed 
during the first 12 months in 59% of the control group but only 22.2% of the 
MMC group (p=0.005). However, at long-term follow-up these differences 
were not statistically significant and the recurrence-free interval curves were 
parallel. From our first study with 344 eligible patients recently long-term 
follow-up (median 7.2 years) was reported [53]. The efficacy with regard to 
tumour recurrence was similar for MMC and BCG-RIVM. Progression, 
however, was seen more frequently in patients without CIS treated with BCG.
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In the second study, after a median follow up of 5 years, 57% of MMC treated 
patients remained tumour free [54] Soloway treated 80 patients with persistent 
superficial bladder cancer [55]. Most tumours were recurrent before MMC 
was given. His initial response rate at twelve weeks was 37% for pTa, 44% for 
pT1 and 33% for CIS. Failure at twelve weeks was considered to be an 
important negative prognostic sign.
The advantage of MMC maintenance therapy is controversial. Some studies 
showed an advantage of maintenance therapy. Soloway, for example, used a 
monthly instillation scheme for 1 year and prevented recurrences in most of 
the patients that had a complete response after the initial course of instillations 
[56]. Huland compared 3-year MMC instillation therapy (42 instillations of 20 
mg) to no intravesical therapy in a randomized trial after complete TUR [57]. 
The percentage of recurrences was 10.4% in the MMC group compared to 
51% in the control group. A later prospective multicentre trial confirmed these 
results with the same method of long-term prophylaxis [31]. With a mean 
follow up of 62.5 months the recurrence rate was higher (20.7%), the overall 
progression rate 9.3%. However, the majority of these patients were at low risk 
for recurrence (low grade tumours, low previous recurrence rate). The results 
of the Japanese group showed no advantage for maintenance MMC therapy 
over short-term therapy [32]. In another Japanese study, instillations of MMC 
were combined with ADM [58]. In this study complete responders on an 
induction course of 5 weekly instillations were randomized between no
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adjuvant therapy and 12 monthly instillations of MMC and ADM. Even in this 
group of complete responders no beneficial effect of maintenance therapy was 
seen in patients with papillary tumours. For CIS patients the 2-year recurrence 
rate after maintenance therapy was significantly better (p<0.05), but the curves 
suggest that with a longer follow up this difference will disappear.
Two studies compared maintenance MMC with maintenance BCG [59,60]. In 
one study, the relative risk of recurrence of MMC (0.508) and BCG (0.618) 
were similar [59]. In a recent study, BCG was superior to MMC for recurrence 
prophylaxis but no difference was found for progression and survival [60].
In conclusion, although, the frequency of drug-induced cystitis is comparable 
to other chemotherapeutic drugs and systemic side effects are rare, up to 10% 
of the patients can experience reversible allergic reactions. The response rates 
of MMC seem higher than other chemotherapeutic drugs, however again not 
all studies show a significant advantage of MMC over no additional treatment. 
The advantage of MMC maintenance therapy is not clear.
Other intravesical chemotherapeutics
Ethoglucid (epodyl).
The mechanism of action of epodyl is poorly understood. With a molecular 
weight of 262 it is poorly absorbed and systemic side effects are rare. Drug 
induced cystitis (13-59%), small capacity bladder and bone marrow
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suppression have been reported [61,62]. The EORTC-GU group found 
exactly the same yearly recurrence rate for intravesical ADM and epodyl 
which was significantly better in the control group (EORTC 30790) [63]. 
Flamm et al. treated 85 patients with primary tumours with 50 ml 1% epodyl 
during 1 year and compared this with intravesical keyhole-limpet hemacyanin 
(KLH) immunotherapy (n=76) [62]. After a mean follow-up of 27.5 months 
no significant difference in recurrence or progression rate (6.5% KLH versus 
9.4% etoglucid) were found. Long-term follow up data were reported after 
complete TUR and 12 weekly instillations (n=43) [64]. After the initial 12- 
week course 72 patients (65%) had a complete response. However, only 33% 
remained free of tumour for 5 years.
Cisplatin
Intravesical cisplatin has been used in a randomized EORTC trial (30782), 
where it was compared with thiotepa and ADM [65]. Final results showed no 
significant difference between the three treatment groups with regard to 
recurrence and progression. However, in 7 of 68 patients on cisplatin an 
anaphylactic reaction occurred, which resulted in closure of this treatment arm 
for accrual. Another series reported the use of 50-150 mg intravesical cisplatin 
in 24 "high risk" superficial bladder cancer patients [66]. Only 3 patients 
(13%) achieved a complete remission and also one patient was reported with
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an acute anaphylaxis. Cisplatin was concluded to be ineffective in this dose 
and in these patients.
Additional measurements or to improve the efficacy of 
intravesical chemotherapy
Several drugs have been combined with intravesical chemotherapy to improve 
its efficacy. Efficacy has been found in vitro such as for peroxide, dimethyl 
sulfoxide (DMSO), tween 80, 5-Fluorouracil (5-FU) and quinolones, but 
clinical data are not yet available.
Intravesical hypertherm ia has been used to improve the efficacy of 
intravesical MMC. In the patients receiving MMC only pathological complete 
response was seen in 5 cases (22%), while complete response was seen in 19 
patients (66%) in the MMC/hyperthermia group (p<0.01), indicating that this 
combination is safe and effective [67].
Some cells have been shown to display a multi-drug resistance (MDR) to 
several natural products and drugs, including chemotherapeutic drugs. One 
possibility to overcome MDR is to select drugs that retain their efficacy in 
MDR expressing cells. A second possibility is the use of MDR reversers such 
as Verapamil, a calcium channel blocker. The mechanism of action remains 
unclear, but verapamil is not exhibit cytotoxic in itself. In a cell line study, 
verapamil increased the cytotoxicity of ADM with a factor 2.5 [68]. This 
increased sensitivity for ADM by verapamil was confirmed by others [69].
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Recently a large randomized controlled trial was published, comparing ADM 
and ADM plus verapamil [70]. After a median follow up of 38.5 months the 
combined group showed a significantly lower recurrence rate with a similar 
incidence of side effects. In conclusion, verapamil has potentially additional 
value.
Photodynamic therapy (PDT) combines a photosensitizer such as Photofrin 
with red laser light to destroy tumour cells [71]. One of the problems with this 
form of PDT, however, is cutaneous photosensitivity. Therefore, recently also 
the intravesical route of administration has been tested in rats and might be 
feasible [72].
Two recent studies addressed the possibility of intravesical electromotive 
drug administration (EMDA). Some preliminary results and side effects 
were reported by Riedl et al. [73] and Brausi et al. [74].
In conclusion, these methods and drugs are still under investigation to 
improve the efficacy of intravesical chemotherapy with promising results. 
Further studies are necessary for clinical use.
Sequential chemo/immunotherapy
The sequential use of chemotherapy and immunotherapy has some theoretical 
advantages and disadvantages. The advantages might be the combination of 
different working mechanisms with possible potentiation of antitumour effect 
or synergism from two drugs. In superficial bladder cancer the intravesical
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route of administration might have a second advantage. A chemotherapeutic 
drug causes a chemical cystitis with an increase in the fibronectin (FN) activity 
[75] which can have a positive effect on the adherence of BCG particles to the 
bladder wall [76]. A disadvantage could be that intravesical combination of a 
chemotherapeutic drug and BCG might also enhance the toxicity.
The Finnbladder group conducted 2 studies comparing MMC alone with an 
alternating MMC/BCG schedule in patients with CIS [77] or rapidly recurring 
papillary tumours [78]. In both studies the side effects in the MMC/BCG 
group were similar to those in the MMC group, but side effects of the 
alternating schedule were fewer compared to BCG monotherapy. In CIS 
patients the alternating schedule was significantly more effective than MMC 
alone with regard to the CR rate (74% versus 47% at 24 months, p=0.041), 
disease free interval (p=0.043) and recurrence rate (0.922 versus 1.834, 
p=0.013) [77]. Efficacy results in papillary tumours, however, were equal in 
both arms [78].
In an EORTC marker lesion study (30897), 4 instillations of MMC were 
followed by 6 instillations with BCG-RIVM [79]. The results showed that the 
sequential treatment was safe with regard to toxicity and efficious as an 
ablative therapy.
Results from a recent study from our department show that the combination of 
4 instillations with MMC and 6 with BCG has comparable toxicity as 10 
instillations of MMC alone [80]. Allergic reactions were more frequent in the
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MMC arm. With regard to treatment efficacy, the results did not reveal any 
differences for recurrences or progression.
In conclusion, the sequential use of intravesical chemo and immunotherapy 
does not seem to increase toxicity, but efficacy also does not seem to be 
improved significantly.
Conclusions
Intravesical chemotherapy can be used in the majority of patients with 
superficial bladder tumours. One can choose between several 
chemotherapeutic drugs and schedules. Drug induced cystitis is seen in 20­
30% of patients on intravesical chemotherapy. However, there are differences 
in other side effects. There does not seem to be significant difference in 
efficacy between these drugs. All are able to improve the recurrence rates with 
15 to 20% with a follow up of 5 years. In contrast to another report [81], a 
recent EORTC/MRC meta-analyses showed that this reduction in recurrence 
rate also remains significant after longer follow up [82]. For all drugs the 
advantage of maintenance treatment is doubtful. Intravesical chemotherapy, 
however, has no impact on progression and disease specific survival [21,82].
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Discussion For Chapter 2
In this part of the thesis, we analyzed gender differences in bladder cancer 
stage and survival. Women appeared to have a less favorable stage 
distribution at first presentation compared with men. The differences were 
clearer among patients with non-TCC bladder cancer than among patients 
with TCC bladder cancer but even in the latter group the gender differences 
were statistically significant because of the large numbers. It appeared that 
these differences in stage distribution are responsible for part but not all of 
the observed gender difference in prognosis. Even after stratification by 
stage category, the relative survival of bladder cancer was found to be worse 
among women.
Some methodological factors need to be taken into consideration before 
adopting the conclusions of these studies. First, comparing gender-specific 
stage frequency distributions may be misleading. A higher percentage of 
high stage cancers in females may be due to a delayed diagnosis but it may 
also be caused by a higher risk of low stage cancers in males which shifts 
the distribution towards low stage disease in males. For example, if  smoking 
causes relatively many low-stage cancers, men (who smoke more) will have 
a favorable stage distribution. Therefore, it is unknown whether the focus 
should lie on etiologic research in low stage and high stage disease, or on 
diagnostic delay in women or anatomical gender differences.
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Second, the data on survival of patients with bladder cancer were obtained 
from large population-based cancer registries. The advantage of using such 
population-based cancer registries is the complete coverage of the 
population, i.e. a systematic collection of data on all malignant neoplasms 
occurring in a geographically defined population. The disadvantage, 
however, is that cancer registries strictly adhere to the TNM or AJCC 
staging rules. These rules were originally designed for research, not for 
everyday practice. In everyday practice, it is common that not all required 
diagnostic tests are performed for the formal staging of patients. It may also 
be possible that all required diagnostic tests were performed but specific 
information is lacking in the medical record. Consequently, when cancer 
registrars use the formal staging rules before assigning a specific stage 
category to each registered patient, a large number of patients will have an 
“unknown” or “blank” disease stage. These patients will be left out of any 
stage-stratified analyses. In the analyses of the SEER data, more than two 
thirds of all patients appeared to have an unknown disease stage.
Third, because data on bladder cancer specific survival are not available 
from population-based cancer registries, we analyzed gender differences in 
relative survival. The relative survival represents the percentage of patients 
alive after a certain period of follow-up in the hypothetical situation where 
the cancer in question is the only possible cause of death. It is calculated by 
dividing the observed  survival in the patient group by the expected  survival
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based on general population mortality rates. Therefore, the validity of the 
relative survival estimate is dependent of the accuracy of the expected 
survival and the assumption that non-cancer mortality is independent of 
cancer mortality. This latter assumption may not hold. For example, 
smoking is one of the most important bladder cancer risk factors. But it is 
also closely related to the risk of dying from, e.g., cardiovascular disease 
and chronic obstructive pulmonary disease. Consequently, the expected 
survival of bladder cancer patients is probably worse than estimated from 
population rates resulting in an underestimate of the relative survival. This 
phenomenon combined with the possibility that the etiologic fraction of 
smoking on the risk of bladder cancer is higher among males than among 
females (as is claimed by several epidemiological studies) suggests that the 
relative survival is underestimated to a larger extent among males. This 
would mean that the favorable prognosis that we found for males may even 
be more favorable. On the other hand, the clearest differences in prognosis 
were found in the analyses of the SEER data from the US. It was striking to 
see, however, that the relative survival rates from the US were much better 
than those from the Netherlands (and other European countries). Similar 
differences can be seen for other tumor sites. The most likely explanation 
for this is that the follow-up of cancer patients in the US is incomplete. This 
would lead to underestimates of observed survival and consequently to
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underestimates of relative survival. It is not clear how all this affects 
relatively small differences in gender-specific prognosis.
Fourth, we should be careful in not over interpreting statistical significance. 
The findings in our studies were highly statistically significant. However, 
the data were so abundant that almost any (small) difference would be 
statistically significant.
Leads for future research (Chapter 2)
It is important to note that gender differences in bladder cancer stage 
distribution and survival are relatively small and that the absolute risk 
(incidence) of high stage bladder cancer is still higher among men than 
among women. Therefore, future studies on these gender differences will be 
more based on scientific curiosity than on anticipated clinical utility.
It is probably not worthwhile to study differences in diagnostic delay 
between men and women. Such differences may be responsible for 
differences in stage distribution but cannot explain stage-adjusted 
differences in prognosis.
Apparently, women do not experience a worse prognosis for other tumors. 
On the contrary, for many cancer sites the 5-year relative survival rates are 
better for women than for men [1]. This suggests that it is not likely that 
genetic or hormonal factors are responsible for a worse survival of female 
bladder cancer patients and the study of such factors should therefore not
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have priority. However, anatomical differences between men and women 
may be important and deserve attention in future research.
The worse prognosis in female patients with bladder cancer may also be 
related to a relatively high incidence of squamous cell carcinoma (SCC). 
SCC is an aggressive tumor, which is usually invasive and treated by radical 
cystectomy. Among women, 30% of all cystectomies were performed for 
SCC compared with 6% in men (a ratio of 5:1) [2]. It was not possible to 
stratify our data on the prognosis of bladder cancer by morphology. 
Possibly, a relatively higher frequency of non-TCC among women may 
have caused a worse prognosis. It would be interesting to obtain 
morphology specific survival data from the SEER cancer registries.
It is not clear yet why SCC is relatively more common among women. This 
may be related to its association with inflammatory processes. Females 
more frequently have inflammatory bladder disease compared with males. 
Bladder cancer is related to the absorption of carcinogens like nitrosamines 
from the urine as a result of increased permeability or damage to the 
urethelium, which may occur in humans with urinary tract infection. 
Furthermore, inflammatory disease affects the Glycosaminoglycan (GAG) 
layer and Laminin levels in the bladder. These are bladder barriers for 
cancer. The GAG layer and Laminin levels may be compared between men 
and women with (different types of) bladder cancer.
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Discussion for Chapters 3 - 6
The likelihood that superficial cancer will recur is 50% to 75% in 5 years. 
Approximately 15% of all superficial bladder cancers progress to invasive 
bladder cancer. Even after a large number of years, recurrences and 
progression can occur. This strongly indicates the need for follow-up of 
superficial bladder cancer. At present, follow-up of patients with superficial 
bladder cancer includes periodic examinations based on cystoscopy and 
cytology. Cytology provides a convenient noninvasive means for evaluating 
patients with hematuria or irritative symptoms and for screening of high-risk 
populations such as persons exposed to known carcinogens, in addition to 
bladder tumor follow-up. Its specificity is excellent. Cytology, however, has 
certain drawbacks, including its subjectivity, its reliance on the skills of the 
pathologist, and its relative insensitivity for low-grade tumors. In addition, 
any kind of therapy for bladder cancer (e.g., surgery, radiotherapy, or 
intravesical therapy) reduces the accuracy of cytology. Attempts to improve 
the sensitivity of cytology have been made by applying new techniques such 
as thin membrane filtration, cytocentrifugation, monolayer technology, 
fluorescence in-situ hybridization (FISH) combined with flow cytometry or 
computerized image analysis techniques (quanticyt). However, these new 
techniques require a high level of expertise, must be performed in a 
specialized laboratory and are not widely available. Furthermore, cell bound 
diagnostic tools depend on the quality and quantity of cells in the
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specimens. Therefore, several methods have also been used to obtain a high 
quality and quantity of cells for cytology such as better storage of urine, 
bladder wash, and modification of sampling technique. Urine obtained with 
catheterization and/or bladder wash provides more and better preserved cells 
and less contamination with normal urothelial cells compared with voided 
urine cytology. However, it requires instrumentation and is an invasive 
procedure that may introduce instrumentation artifact. In our study, 
described in C hap ter 3, which aimed at increasing the amount of cells for 
cytology by modification of the sampling technique fractioned voided 
urinary cytology (VUC) and bladder wash cytology (BWC), did not affect 
detection rates especially in grade I and II tumors. This results indicated us 
that only higher quantity of cells for cytology is not enough to improve 
sensitivity of urine cytology without any improvement on identification of 
objective diagnostic criteria for malignant cells, particularly in well- 
differentiated.
Although urine cytology is not sensitive to detect most low-grade tumors, 
these tumors are at low risk for disease recurrence or progression. The 
sensitivity of cytology is relatively high for CIS and grade III tumors which 
are exactly the tumors that should not be missed, although one might argue 
that detection of new low-grade lesions is of secondary importance for the 
early detection of disease progression. Our study offered promising results
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in grade III tumors. Therefore, it deserves a place as a basis for further and 
larger scale studies.
C hapter 4, in recent years much attention has been directed towards the 
possible use of various urinary markers in screening and monitoring because 
cytology and cystoscopy have certain drawbacks. Analysis of urinary 
specimens for the presence of substances that may reflect the activities of 
tumor cells in disrupting the basement membrane and extra cellular matrix 
in the infiltrating bladder wall, or assessment of these specimens for cells 
and cell products are being evaluated for their specific applicability. 
However, the past years have showed us that these tests also have their 
limitations, besides various advantages.
The BTA stat test is easy to perform in a diagnostic setting. In our study, 
C hapter 5, this test presented significantly higher sensitivity than VUC in 
detection of TCC, particularly in low grade tumors. However, it can easily 
be affected by benign conditions and yield false positive result. Therefore, 
we recruited patients with benign urological conditions to determine 
possible false-positive results. Unfortunately, the possible confounding 
effect of benign urological conditions could not be evaluated completely in 
the present study due to the small number of subjects. These conditions 
should be evaluated in larger scale studies. On the other hand, if  for every 
test all kinds of exclusion criteria have to be defined, one could raise 
questions about the clinical usefulness of such a test, since “confounding”
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benign urological conditions are seen regularly in normal day practice. In 
the present study, the performance of the urine cytology was low, since we 
selected a relatively high number of low-grade tumors in our study group. 
However, in these low grade patients the relative influence of confounding 
factors on the test result should be highest, giving us the best opportunity to 
study the performance of the test in these patients.
In our hands, C hapter 6, the UBC marker appeared not as good as it was 
claimed in previous studies. Possible explanations for this are: problems 
with the technical performance, limited biological differences of antigens 
between normal and malignant urothelial cells, and different patient 
selection. As in previous studies, the technical procedure was performed 
according to the manufacturer. Therefore, this factor was excluded as a 
possible cause for discrepancy. The cut-off differences between normal and 
malignant urothelial CK 8/18 antigens are too small. This could be a reason 
for clinical usefulness of this test, but, could not explain differences with 
previous studies. The most obvious differences between our study and 
others was the “appropriate” patient selection. Only superficial bladder 
cancer patients in follow-up were recruited for this study. The reason we 
chose this population was to evaluate the diagnostic performance of the 
UBC test in a group of patients during follow-up for recurrence, because we 
consider this to be the primary indication of a urinary marker such as the 
UBC test. The previous studies included invasive bladder cancer patients in
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their patient groups as well. Results from studies including invasive TCC 
(higher sensitivity) should not be used to predict test performance in 
superficial bladder cancer. In our patient population, the diagnostic OR was 
very close to 1.0 and the AUC of the ROC curve was very close to 0.5, 
suggesting no diagnostic value for the UBC test in this patient population. 
Thus, we concluded that the UBC test does not seem to be suitable for use 
in superficial bladder cancer patients.
The early detection of (superficial) bladder cancer in patients at risk for 
newly diagnosed or recurrent cancers may significantly impact the options 
and effectiveness of therapies. This is relevant with sensitivity of diagnostic 
test. The sensitivity indicates percentage of patients with disease who have 
an abnormal test. The sensitivity is most important because high sensitivity 
leads to high negative predictive value (NPV). NPV of one diagnostic test 
shows that there is indeed no disease. Specificity is percentage of patients 
without disease who have normal test. A relatively high false positive rate 
(low specificity) is not dramatic because these patients only undergo 
cystoscopy. Therefore, high NPV for a diagnostic test for bladder cancer is 
one of the most desirable criteria, particularly in follow-up of disease. 
However, the major shortcoming of new diagnostic tests is the low NPV. To 
date, the Food and Drug Administration (FDA) has approved the 
commercial use of new diagnostic tests only as adjuncts to cystoscopy.
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The patient’s opinion and preference are also very important parameters in 
the evaluation of the diagnostic methods because long-term follow-up is 
required. The experience of our department showed that if  the sensitivity of 
a urinary test is lower than 90%, 89% of patients will prefer flexible video­
controlled cystoscopy as the diagnostic method in the follow-up of 
superficial bladder cancer instead of a urinary test [3].
In conclusion, several diagnostic tests and methods have been developed in 
recent years, but cytology still maintains its important place in the 
diagnostic spectrum. While recent reports on the new urinary tumor markers 
show markedly improved sensitivity versus urinary cytology particularly in 
low-grade tumors, their sensitivity is not yet good enough. Therefore, these 
new markers are ancillary techniques. They should be used in a panel with 
cytology and cystoscopy. Combining these new markers could optimize 
their performance, allowing the advantages of one test to correct the 
shortcomings of another. The current view is that some of these tests could 
influence the frequency of cystoscopic controls, but these tests cannot 
completely replace cystoscopy and cytology.
Leads for future research (Chapters 3 -  6)
Overall sensitivity of cytology is poor. Perhaps, the greatest determinant of 
the quality of cytology is the level of cytopathological expertise. Currently, 
modern communication tools are essential in the transfer of educational
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information. CD-roms, interactive computers, and mobile interaction are 
just some examples of modern ways to inform and instruct people. These 
tools can be used in a direct educational format to improve cytopathological 
expertise. Low sensitivity of cytology is also explained by poor criteria for 
identifying well-differentiated, low-grade TCC. Further studies should focus 
on identifying features to aid in the distinction between normal urothelial 
cells and well-differentiated malignant cells by using objective diagnostic 
criteria. For example; some useful objective criteria such as cytoplasmic 
homogeneity, increased nuclear-to-cytoplasmic ratio and irregular nuclear 
borders increased the sensitivity to 85% and specificity to 96% when 
applied retrospectively. When examined prospectively, the sensitivity 
decreased to 33% [4]. Nevertheless, we need better criteria to improve the 
diagnostic accuracy of cytology. Furthermore, urine is an inhospitable 
medium for desquamated urothelial cells, which leads to difficulties in 
assessing cytology specimens. Further studies should focus on obtaining 
more and/or better preserved cells by using different methods such as 
creating an optimal pH for cells or decreased osmolality of urine. A 
phosphate buffer medium with balanced electrolytes may be added to the 
urine specimen to minimize harmful effects of contents of urine to cells 
before submitting the specimen to the laboratory.
The application of immunocytochemistry to urine samples using various 
monoclonal antibodies against tumor-associated antigens, e.g., Lewis X
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antigen, a relative of the ABO blood group antigens, significantly increases 
the sensitivity of urine cytology. However, these antigens also suffer from 
the common problem of low specificity. Furthermore, spectral imaging of 
different cytochemical dyes such as 5-aminolevulinic acid (5-ALA) 
fluorescent dye may be used for staining of neoplastic transferred urothelial 
cells in urine samples. In vivo application of 5-ALA induces an 
accumulation of fluorescent prophyrins in malignant tissues of epithelial 
origin. Possible malignant areas reflect fluorescent light. Its combination 
with certain light sources has shown to improve the diagnostic sensitivity 
and specificity of cystoscopy significantly [5]. Nevertheless, it should be 
investigated initially whether desquamated cells can take up these 
fluorescent dyes.
Another major drawback of cytology is the low cellular yield in voided 
urinary samples. Cell cultures could be used to cope with this disadvantage. 
Currently, cell cultures have been used in various fields of medicine such as 
immunology for white blood cells, infectious disease for bacteria and 
viruses, and oncology for vaccine. However, it has not been tried for 
cytology yet. Cell cultures of urine specimens are made by inoculating 
appropriate media with a certain amount of urine and activating the cells 
with external stimuli. The percentage of dead and damaged cells can be 
decreased significantly by external proliferative stimuli and an increased 
amount of cells can be obtained for cytological investigation of urine within
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an acceptable time. An uncontrolled rapid proliferation of neoplastic 
transformed urothelial cells makes them ideal for cell culture. On the other 
hand, cultured cells may show different differentiation stages for 
interpretation of urine cytology because large amounts of cells are used. 
Moreover, cell proliferation in response to external stimuli is a complex 
process. It involves delivery of a signal or set of signals to the cell 
membrane, activating intracellular pathways that are not well understood, 
like activation and transcription of multiple genes, DNA and protein 
synthesis, and finally cell division.
The clinical usefulness of a diagnostic test depends on procedure time, 
costs, personnel and material needed in addition to its sensitivity and 
specificity. The ideal test besides accurately predicting the presence of 
tumor, should also indicate tumor extent and correlate with the severity of 
the disease. High sensitivity and specificity are critically important 
measures of the test’s utility. However, for a test to be clinically applicable 
and useful for routine practice, the test should be reproducible with minimal 
intraobserver and interobserver variability. The method of collection should 
be simple and practical. The assay should provide a rapid result at 
affordable costs, should be simple to run, and, ideally, should be performed 
at the point of care. At last, all data regarding new diagnostic tests must be 
confirmed by large multicenter studies with an appropriate patient selection, 
before clinical practice can be altered.
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Discussion and Leads for future research (Chapters 7 and 8)
Because leads for future and discussion of intravesical therapy were closely 
related, these were handled together in this part of the thesis. Despite 
intensive laboratory research we still have not elucidated the working 
mechanism of BCG, C hapter 7. It is known that a complex cascade of 
immunological events takes place. It is agreed that the induction course 
should exist of 6 instillations. However, long-term results have 
demonstrated that the immune protection is not life long and six weekly 
instillations is a sub optimal protocol. To evoke the necessary immune 
response in the host, repeated instillations are recommended. Lower disease 
recurrence rates have been reported after BCG maintenance therapy of up to 
3 years. Boosters of BCG were given at 3,6,12,18,24,30 and 36 months [6]. 
Nevertheless, a maintenance schedule is practically limited by its toxicity. 
The majority of patients were not able to complete such intensive protocols. 
Several studies suggest that side effects might be less when decreasing the 
dose of BCG in patients with an intermediate risk [7,8]. In papillary T1-Ta, 
G1-G2 lesions, the dose can be reduced to 25% with the same effectiveness 
as the full dose and fewer general side effects. However, in patients with 
high-risk superficial bladder cancer, caution should be exercised in selecting 
dose. Isoniazid (INH) has also been given prophylactically in an attempt to 
reduce side effects, but a reduction of adverse effects was not observed in 
clinical studies. EORTC protocol 30911 (phase III study) has shown that
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prophylactic INH does not influence the efficacy or toxicity of BCG [9], but 
induces some toxicity itself such as temporary liver function disturbances. 
We need some objective markers to detect tumor and bladder wall response 
after intravesical BCG therapy to prevent unnecessary courses. After 
binding of BCG to the bladder wall, BCG antigens, likely processed by 
monocytes and possibly urothelial (tumor) cells preferentially activate T 
helper type 1 (Th1) lymphocytes, which generate a Th1 milieu (such as IL-
2, IL-8, IL-12, interferon-a) at the site of the tumor. Urinary cytokine 
production is associated with anti-tumor activity and may be a possible 
predictor of the reaction of the bladder wall and subsequent tumor response 
during intravesical BCG maintenance therapy. There is a polymorphism in 
the capacity of each individual to mount an effective Th1 anti-tumor 
response following intravesical BCG instillations. Therefore, monitoring the 
expression of these cytokines in urine may lead to a more rational basis for 
the originally arbitrary BCG treatment schedule, designing a more 
individualized and possibly more efficacious instillation schedule [10]. At 
present, however, a complex and expensive methodology is necessary for 
cytokine determinations in urine. This makes the determination of urinary 
cytokines not practical for daily clinical use. Development of test reagent 
strips and technology will facilitate urinary cytokine determinations 
considerably. Some conflicting results are also present in the literature [11] 
which indicate the necessity of a consensus with regard to sampling (time
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and period), pre-analytical workup, assay method and inter-laboratory 
standards.
Since BCG probably exerts its anti-tumor activity in superficial bladder 
cancer management in part or in total by stimulating the host’s immune 
response and by polarizing this response toward a Th1 state, several other 
biological responses should be evaluated in this field; such as: antibody 
response against native heat shock protein (P64) of BCG.
Other immunotherapeutic drugs such as interferons, interleukins and 
Keyhole Limpet Hemocyanin (KLH) may have a place in the adjuvant 
treatment of superficial bladder cancer.
KLH is a non-specific immunomodulator such as interferons and 
interleukins. When recognized by macrophages, KLH initiates the 
stimulation of a cell-mediated, delayed hypersensitivity reaction and 
primary humoral response. KLH also induces secretion of IL-1a in the 
urine. Despite some promising results were observed in selected patients, 
the data presented in literature are certainly limited and need to be supported 
by additional studies.
Intravesical cytokine gene transfer is a novel modality for potential 
enhancement of immune response. Vectors bearing the gene to be 
transferred can be instilled into the bladder transurethrally. Expression of 
the gene may lead to inhibition of tumor development and growth or to a 
novel form of immunotherapy (IL-2 gene transfer) [12].
Discussion 229
Three major parameters are involved in optimal anti-tumor response: the 
host, the immunomodulating agent, and the tumor. Despite incomplete 
understanding of the bladder tumor, immunomodulating agents and host 
immune system, the rapid progress in immunology and urology will provide 
a framework for more effective and safe interventions. Non-specific and 
broad stimulation of immunomodulating agents will be replaced by the 
highly specific stimulation of immune reactions targeting precisely defined 
tumor antigens in the near future. Another important issue is the immune 
status of the patient. There is increasing evidence that bladder cancer is able 
to induce an immune-suppression or to counteract the anti-tumor response. 
We do not know whether the immune status of the patient, before starting 
BCG, is important. This issue deserves further research.
A variety of intravesical chemotherapeutic agents are now available for the 
treatment of superficial bladder cancer, C hapter 8. The most frequently 
used chemotherapeutic agents for bladder instillations are mitomycin C, 
epirubicin and doxorubicin. No clear evidence suggests that any intravesical 
chemotherapeutic drug is superior to the other in terms of tumor recurrence, 
progression, and survival. However, the toxicity profile associated with 
these agents may make one more appealing than the other. Future studies 
should, for example, focus on obtaining higher drug concentrations in the 
urine and bladder cancer tissue instead of a higher total dose to increase the 
efficacy and to decrease the toxicity of intravesical chemotherapy.
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Absorption enhancers such as dimethyl sulfoxide (DMSO) may provide 
rationale for future clinical trials involving intravesical chemotherapy for 
superficial bladder cancers. The concomitant use of DMSO with intravesical 
chemotherapeutic agents enhances the absorption of the agent into the entire 
bladder wall. In this way, cytotoxicity and antitumor activity could be 
enhanced.
Although BCG seems to be the best available prophylactic treatment for 
superficial bladder cancer, chemotherapy can provide similar results in 
selected patients. The EORTC-GU group designed a randomized 
prospective trial comparing intravesical BCG and mytomycin C in 
superficial bladder cancer [13]. After a median follow up of 7.2 years, 
toxicity and efficacy of the two treatment groups was found to be similar. In 
terms of progression to invasive disease, mytomycin C was more effective 
than BCG in patients without CIS. However, the difference is rather small 
(p=0.06). Because one or two BCG courses of 6 weeks were used in this 
study, whether maintenance BCG therapy would have made a difference 
remains question. Moreover, the patient selection, dose and treatment 
schedules were different in this study. Difference of definition of CIS is a 
possible bias.
Based on prognostic factors, superficial bladder cancer patients can be 
divided into low, intermediate and high-risk groups. One single instillation 
with epirubicin or mytomycin C is advocated in all low-risk patients. In
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intermediate risk-group, efficacy of BCG is similar to intravesical 
chemotherapy, but BCG has more severe side effects. It is agreed that BCG 
is the state-of-art treatment for high-risk tumors, such as T1GIII and CIS. 
Controversy exists whether BCG is able to prevent progression to muscle 
invasive disease. It is suggested by some that BCG decreases the chance of 
disease progression [14,15]. Others, however, have not been able to confirm 
these results [16]. The same question of a decreased chance of disease 
progression after intravesical chemotherapy is less controversial. A large 
meta-analysis (3,899 patients in 22 randomized prospective controlled 
studies) on the long term (5-year) effect of intravesical chemotherapy on 
recurrence and progression was performed by Lamm et al. [17]. 
Maintenance chemotherapy has failed to decrease tumor progression on the 
long-term. Among randomized patients progression occurred in 7.5% of 
those receiving intravesical chemotherapy and 6.9% of those treated by 
surgery alone. The EORTC-GU group has also performed a meta-analysis 
on combined data of Ta and T1 bladder cancer that compared transurethral 
resection alone or with adjuvant prophylactic intravesical chemotherapy 
from four randomized, phase III trials trails carried out by the EORTC-GU 
group and two by the Medical Research Council (MRC) studies carried out 
in the UK [18]. The results of this meta-analysis suggest that no clear 
advantage exists was found with regard to muscle invasive disease 
progression, time to appearance of distant metastases or duration of survival
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and progression-free survival as well. Adjuvant therapy had only a favorable 
impact on the disease-free interval of patients with superficial bladder 
cancer. This meta-analysis demonstrated a significant 7% reduction in 
tumor recurrence after 5-year follow-up but found no evidence of reduction 
in disease progression. Paradoxically, reduction in tumor recurrence does 
not necessarily correspond with a reduction in tumor progression, and 
freedom from recurrence is not a guarantee against developing muscle 
invasive tumours. How can this be explained? A first explanation can be a 
statistical one. The incidence of tumor progression is much less than that of 
recurrence. Thus, even with effective treatment a very large sample size 
would be required to demonstrate statistically significant differences. 
Patients with a lower risk for recurrence and progression were included in 
this study. Differences in progression are more difficult to demonstrate in a 
low-risk population. Secondly, the most predictive factor for recurrence is 
multifocality, whereas high stage, and to a lesser extent, high grade are 
correlated with tumor progression. It is likely that recurrence and 
progression may be biologically different phenomena. In the third place, 
chemotherapy kills cells by direct contact, and cell kill is proportional to the 
concentration and duration of exposure to the agent. Tumor cell contact with 
intravesical chemotherapy occurs as a result of diffusion down a 
concentration gradient. Cells that are most likely to extend into muscle 
receive the least effective treatment. In the last place, chemotherapy is
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mutagenic, and previous investigations have shown that repeated instillation 
of chemotherapy into normal rodent bladders can induce invasive TCC. 
These data raise the concern that intravesical chemotherapy might possibly 
be carcinogenic in humans. Therefore, these treatment options should be 
addressed in terms of toxicity, cost effectiviness affectivity and patients’ 
preferences as well. Future studies are necessary to evaluate preferences of 
patients who have experience with intravesical chemo or immune therapy. 
Because no single drug available for intravesical chemo and immune 
therapy is entirely effective in eradicating bladder tumors or in preventing 
tumor recurrences and progression, a combination of two or more drugs has 
been investigated. The exact mechanism by which combination therapy 
exerts an antitumor effect on bladder cancer, is not known. Combined 
chemotherapy and immunotherapy protocols aim to have synergistic 
anti tumor effect. Combined protocols of immunomodulating agents for 
prophylactic treatment of superficial bladder cancer aim to enhance the cell- 
mediated immune function or to induce apoptosis of tumor cells by cytolitic 
cytokines. The use of recombinant BCG strains producing immune 
enhancing cytokines, such as IL-2 or IL-12, seems to be an exciting future 
prospect in immunotherapy for superficial bladder cancer. Although results 
are encouraging, combination treatment protocols are scarcely investigated 
and the results are not yet conclusive. Therefore, combination modalities of
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promising agents should be investigated more intensively to tailor better 
treatment options for superficial bladder cancer.
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Bladder cancer is an important public health problem, not in the least place 
because of the high recurrence rate (and hence prevalence) of so called 
superficial bladder tumours. Several aspects of these superficial tumors have 
been studied in this thesis. We studied the impact of gender at first 
presentation to get more insight in the consequences of gender on the 
prognosis of (superficial) bladder cancer. In an attempt to improve and/or 
facilitate the diagnosis of superficial bladder cancer we tried to improve the 
performance of urinary cytology and looked at several urinary markers. 
Finally, the therapy of superficial bladder cancer is critically discussed.
In C hapter 2, we described stage properties at first presentation and 
prognostic discrepancies of (superficial) bladder cancer in men and women. 
In our first study, it appears that women with bladder cancer have a higher 
chance to be diagnosed at first presentation with invasive disease than men. 
It has been suggested that the worse prognosis is caused by a worse stage 
distribution at diagnosis among women. The purpose of the second study 
was to evaluate whether women with bladder cancer have a worse prognosis 
even after adjustment for disease stage at first presentation by using U.S and 
Dutch cancer registries. In each stage category, female patients had still a 
worse prognosis compared to males in both the U.S. and the Dutch 
databases after stage adjustment. The higher stages showed a worse 5-year 
survival for females compared to males in the same stage, with the largest 
difference for pT4 tumors. It is unlikely that the difference can be explained
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entirely by the more frequent diagnosis of higher stages at first presentation 
among women. In the last study, anatomical and other differences between 
men and women are discussed which may explain the differences in 
prognosis.
In the study presented in C hapter 3, the ultimate goal was to improve the 
insufficient sensitivity of urine cytology by using various urinary samples 
under different pressure profiles of the detrusor activity. For this purpose, 
voided urine specimens and bladder wash materials were divided into three 
portions as first, mid and last. No statistically significant differences were 
found in the sensitivities of voided urine and bladder wash cytology 
between either grades or portions in this study. However, malignant cells 
and particularly grade III tumors have been detected with highest sensitivity 
in the last portion of the voided urine when detrusor activity was maximal.
In C hapter 4, the clinical utility of the BTA test, the BTA stat test, the BTA 
track test, NMP22, quanticyt, monoclonal antibodies (surface antigen 
19A211 and mucinous antigen M344), telomerase and microsatellite 
techniques for the diagnosis and prognosis of superficial bladder cancers 
were reviewed. The sensitivities of all these new tests in overall terms and 
according to stage and grade were better than those of urine cytology, their 
specificities were lower when compared to those of cytology. Although 
these new tests have some advantages as compared to cytology, none of 
these seems to have ideal diagnostic properties.
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In C hapter 5, we prospectively evaluated and compared the diagnostic 
values of the BTA stat test and voided urinary cytology in patients with 
histologically confirmed TCC, benign genitourinary disease and healthy 
volunteers. The BTA stat test was significantly more sensitive than urine 
cytology for all grades and stages of the tumor, but was less specific. False 
positive results were found in patients with benign genitourinary disease 
such as urinary tract infection, BPH, cystocele, nephrolithiasis and previous 
prostate operations. Our results suggested that this simple test could 
improve the detection of TCC, particularly in low-grade tumors. However, 
the urologist should be aware of the fact that this test may be affected by 
some benign conditions.
In C hapter 6, the diagnostic value of the UBC test was evaluated in patients 
who were under follow-up after transurethral tumor resection for superficial 
bladder cancer. There were no significant differences in UBC values (non­
corrected and corrected) between patients with or without superficial 
bladder cancer. Exclusion of urinary tract infection did not improve the 
results. The overall sensitivity, specificity, positive predictive value and 
negative predictive value of this new urinary marker were far from 
qualifying it as an ideal diagnostic test.
In C hapter 7 and 8, practical guidelines of intravesical BCG and 
intravesical chemotherapy in the management of superficial bladder cancer 
are presented. Much work has been done to investigate several aspects of
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the use of intravesical BCG or intravesical chemotherapy in the treatment of 
superficial bladder cancer. However, many questions still remain. In the 
second part of chapter 7, we presented the results of a randomized phase III 
protocol, comparing MMC alone with subsequent administrations of the 
MMC and BCG, in patients with moderate and high-risk superficial bladder 
cancer. No significant differences were found between the groups in terms 
of tumor recurrence, tumor progression, or systemic toxicity.
In conclusion, gender at first presentation appears to have a significant, 
although clinically limited, influence on the prognosis of bladder cancer 
patients. There is no clear explanation for this finding. Urinary cytology 
remains the golden standard in the diagnosis of superficial bladder cancer. 
Although urinary cytology is not very sensitive in case of low grade tumors, 
it is very specific. Current, commercially available urinary markers seem to 
have some additional value over cytology, but cannot replace cytology and 
certainly not cystoscopy. Therapy of superficial bladder cancer remains a 
choice between intravesical chemotherapy and the more toxic but also more 
effective use of BCG.
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Blaascarcinoom is een belangrijk probleem voor de volksgezondheid, niet in 
de laatste plaats door de hoge recidief frequentie (en dus hoge prevalentie) 
van de zogenaamde oppervlakkige tumoren. Verschillende aspecten van 
deze oppervlakkige blaastumoren zijn in dit proefschrift bestudeerd. Zo is 
gekeken naar de invloed van het geslacht van de patiënt bij primaire 
diagnose van (oppervlakkig) blaascarcinoom, om een indruk te krijgen van 
de invloed van het geslacht op de prognose. In een poging de diagnose van 
het oppervlakkige blaascarcinoom te verbeteren of te vergemakkelijken 
hebben we geprobeerd de waarde van urine cytologie te verbeteren, en 
hebben we diverse urine makers bestudeerd. Ten slotte is de behandeling 
van oppervlakkig blaascarcinoom kritisch bekeken.
In hoofdstuk 2 wordt beschreven dat er verschillen zijn tussen mannen en 
vrouwen in het stadium van het (oppervlakkige) blaascarcinoom bij primaire 
presentatie. De eerste studie laat zien dat vrouwen een hogere kans hebben 
bij primaire presentatie te worden gediagnosticeerd met een invasieve 
blaastumor dan mannen. De indruk bestond dat dit kwam door een slechtere 
stadium verdeling bij vrouwen vergeleken met mannen. Daarom werd in 
een tweede studie gekeken of vrouwen nog steeds een slechtere prognose 
hadden indien eerst werd gecorrigeerd voor stadium, door gebruik te maken 
van de Amerikaanse en Nederlandse kanker registratie. Ook na correctie 
bleken vrouwen in elk stadium een slechtere prognose te hebben vergeleken 
met mannen, zowel met de Amerikaanse als Nederlandse gegevens. Zo
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werd een slechtere 5 jaars overleving voor vrouwen gevonden bij hogere 
tumor stadia, met een grootste verschil voor pT4 tumoren. Het is 
onwaarschijnlijk dat dit verschil alleen kan worden verklaard door 
overdiagnostiek van meer invasieve tumoren bij vrouwen. In de laatste 
studie, beschreven in dit hoofdstuk, worden meerdere aspecten van 
blaascarcinoom bij vrouwen besproken. Behalve verschillen in incidentie en 
prognose, verschillen blaastumoren bij vrouwen op nog meer punten van 
blaastumoren bij mannen.
In hoofdstuk 3 wordt een studie beschreven waarbij het uiteindelijke doel 
was om de (onvoldoende) sensitiviteit van urine cytologie te verbeteren 
door verschillende porties urine te verzamelen tijdens verschillende fase van 
de mictie en dus verschillende druk profielen van de musculus detrusor. 
Porties urine van het begin, midden en eind van de mictie werden 
vergeleken. Er werd geen significant verschil gevonden voor de sensitiviteit 
van urine cytologie, noch van blaas spoelings cytologie tussen de 
verschillende porties. Wel was de sensitiviteit van cytologie van de laatste 
geplast portie urine, wanneer de activiteit van de musculus detrusor 
maximaal is, het hoogst.
Hoofdstuk 4 geeft een overzicht van de klinische waarde van verschillende 
urinetesten. De sensitiviteit van al deze testen is in het algemeen, maar ook 
voor de diverse stadia en differentiatie graden van tumor, beter dan van 
normale urine cytologie. Aan de andere kant is de specificiteit van deze
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testen lager dan die van urine cytologie. Dus, ondanks het feit dat dergelijke 
testen enkele praktische voordelen boven urine cytologie hebben, geen van 
de huidige testen is ideaal.
In hoofdstuk 5 is de diagnostische waarde van de BTA stat test prospectief 
vergeleken met die normale urine cytologie bij patiënten met een 
histologisch bewezen urotheelcel carcinoom van de blaas, goedaardige 
urologische afwijkingen en gezonde vrijwilligers. De BTA stat test was 
significant sensitiever voor alle graden en stadia van tumoren, maar minder 
specifiek vergeleken met urine cytologie. Fout positieve resultaten werden 
bij patiënten met infecties, BPH, cystocele, stenen en eerdere prostaat 
operaties. Deze studie suggereert dat de simpele BTA stat test de detectie 
van blaastumoren kan verbeteren, met name in laaggradige tumoren. Aan de 
andere kant more de uroloog zich bewust zijn van de invloed van 
verschillende goedaardige urologische afwijkingen op de uitslag van deze 
test.
In hoofdstuk 6 wordt de diagnostische waarde van de UBC test beschreven 
bij patiënten die vervolgd worden na behandeling van een oppervlakkige 
blaastumor. De UBC test (al dan niet gecorrigeerd), bleek niet te kunnen 
discrimineren tussen patiënten met en zonder een recidief van hun 
oppervlakkig blaascarcinoom. Uitsluiten van urineweg infecties en corrctie 
voor geslacht verbeterde de studieresultaten niet. De sensitiviteit,
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specificiteit en positief voorspellende waarde van deze nieuwe urine test 
waren verre van ideaal.
Hoofdstukken 7 en 8 geven praktische richtlijnen voor de behandeling van 
patiënten met oppervlakkige blaastumoren met intravesicale BCG of 
chemotherapie. Ondanks het vele werk in dit gebied blijven vele vragen 
onbeantwoord. In het tweede deel van hoofdstuk 7 wordt een 
gerandomiseerde fase III studie beschreven, waarin Mitomycine wordt 
vergeleken met een combinatie van Mitomycine en BCG, bij patiënten met 
gemiddeld en hoog risico oppervlakkige blaastumoren. In deze studie werdt 
geen significant verschil gevonden tussen beide behandelings armen met 
betrekking tot tumor recidief, tumor progressie en systemische 
bijwerkingen.
In conclusie blijkt geslacht een klinisch beperkte maar wel significante 
invloed te hebben op de prognose van patiënten met blaascarcinoom, waar 
vooralsnog geen duidelijke verklaring voor bestaat. De diagnose van het 
oppervlakkige blaascarcinoom gebeurt nog steeds met urinecytologie. 
Hoewel weinig sensitief voor laaggradige tumoren is het zeer specifiek, en 
de huidige commercieel verkrijgbare urinetests lijken in de dagelijkse 
praktijk hooguit een aanvulling op urinecytologie, geen vervanging, zeker 
niet van een cystoscopie. Therapie van het oppervlakkige blaascarcinoom 
blijft vooralsnog een keuze tussen intravesicale chemotherapie en het meer 
toxische maar ook effectievere BCG.
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